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ABSTRACT 
 
ESSAYS ON AGING-RELATED DISEASE IN THE U.S. POPULATION 
Ezra Fishman 
Dissertation supervised by Samuel H. Preston and Irma T. Elo 
I research three topics in adult morbidity in the United States, focusing on two 
increasingly prevalent chronic diseases, diabetes and dementia. In the first essay, I 
investigate changes in age-specific diabetes prevalence across cohorts born in the 20th 
century and use the cross-cohort comparisons to generate model age patterns of diabetes 
prevalence and incidence. I show that most of the increase in diabetes prevalence over 
time is attributable to increases in age-specific prevalence from one cohort to the next. 
Because the risk of diabetes is embodied in cohorts, diabetes prevalence is likely to 
increase in the future even if the prevalence of risk factors such as obesity plateau.  
In the second essay, I use multiple-decrement life tables to estimate age-specific 
lifetime risks of dementia for a dementia-free person. I estimate that about a quarter of 
dementia-free 70-year-old males and a third of females will develop dementia in their 
lifetimes. Although interventions that delay dementia onset could substantially reduce 
dementia risk, the results indicate a widespread need to prepare for a life stage with 
dementia.  
In the third essay, I use recent advances in propensity-score matching techniques 
to estimate the association between incidence diabetes and subsequent accumulation of 
mobility limitations. Among observationally similar pairs of individuals, those who 
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developed diabetes reported an average of 25% more mobility limitations at study exit 
than those who did not develop diabetes. My estimates of this association are smaller 
than those found in most of the existing literature, but they are likely less biased. 
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Introduction 
As adult mortality continues its long-run decline in industrialized countries, 
demographers have paid increasing attention to morbidity (Crimmins & Beltrán-Sánchez 
2010; Vaupel 2010). In the following chapters, I research three topics in adult morbidity 
in the United States, focusing on two increasingly prevalent chronic diseases, diabetes 
and dementia. Increases in diabetes prevalence are associated with changes in the risk 
profile of the population, especially the prevalence and duration of obesity (Abdullah et 
al. 2011; Gregg, Boyle, et al. 2013; Reis et al. 2013). Increases in dementia prevalence 
are largely attributable to the declining risk of death at “younger old” ages, allowing a 
larger fraction individuals to live long enough to develop dementia (Deckers et al. 2014; 
Hurd, Martorell, Delavande, Mullen, & Langa 2013; Plassman et al. 2011). 
A life-course perspective on chronic disease in the United States unites the three 
chapters that follow. In Chapter 1, I consider the life course of cohorts, using the fact that 
young-age characteristics of a cohort stay with the cohort as it ages, predicting later-life 
cohort characteristics. This perspective enables the estimation of model age patterns of 
diabetes prevalence and incidence that reflect what cohorts actually experience as they 
age. In Chapter 2, I investigate the life-cycle implications of dementia incidence and 
mortality for an average older adult. The life table methods used in Chapter 2 synthesize 
population rates back to the level of the individual life course. In Chapter 3, I isolate the 
role of incident diabetes in the subsequent accumulation of mobility limitations, reducing 
biases found in studies that use diabetes presence as the exposure.  
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Another unifying theme is the distinction – and interaction – between disease 
incidence and prevalence. Incidence is a classic demographic rate: the ratio of new cases 
to person-time at risk. Prevalence is the proportion of the population with the disease at a 
given time. Chapter 1 uses an innovative cohort-based method to infer incidence from 
prevalence and differential mortality. Chapter 2 uses incidence and prevalence to refine 
estimates of differential mortality, and synthesizes the different rates to develop the 
lifetime risk estimate. Lifetime risk would be equivalent to prevalence in a stationary 
population if there were no differential mortality; the large mortality differentials 
between people with dementia and their age-contemporaries without it necessitate a life 
table based estimate (Preston, Heuveline, & Guillot 2001). Finally, Chapter 3 shows that 
examining incident disease as a risk factor for subsequent outcomes, in this case mobility 
limitations, can generate somewhat different results than examining prevalent disease as a 
risk factor.   
 
The cohort dynamics of diabetes in the United States 
(Note: This chapter was co-authored with Prof. Samuel H. Preston and Andrew Stokes.) 
Diabetes is a leading cause of mortality, disability, and health care costs in the 
United States (Murray 2013). Few national studies provide detail on age patterns of 
diabetes prevalence above age 65 (Y. J. Cheng et al. 2013; Menke, Casagrande, Geiss, & 
Cowie 2015). Since future gains in life expectancy are likely to be concentrated at old 
ages (Li, Lee, & Gerland 2013), such age-detail is valuable. Furthermore, data limitations 
reduce our ability to get good estimates of age-specific disease incidence, and of trends 
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over time, especially since changes in diagnostic criteria for diabetes and awareness of 
the disease among the public make self-reported data of questionable quality (e.g. Gregg 
et al. 2014). Most generally, there is insufficient understanding in chronic disease 
epidemiology of the importance of birth cohorts as embodiments of lifetimes of risk 
factors that presage future trends in prevalence and incidence. 
Chapter 1 addresses these gaps in the literature by examining age patterns of 
diabetes prevalence across birth cohorts, using a stable measure of blood glucose 
collected from population-representative samples in the National Health and Nutrition 
Examination Surveys (NHANES), 1988 to 2010. In the cross-section, prevalence appears 
to decline after age 75, a result that could arise if people with diabetes at those ages die 
more quickly than new cases occur. However, Chapter 1 will show that this result appears 
in the cross-section because older cohorts had lower diabetes prevalence throughout their 
lives than younger cohorts had.  
The value of the cohort-based approach is demonstrated in an age/period/cohort 
model of diabetes prevalence. To avoid the classic identification problem in such models, 
where any one of age, period, and cohort is a linear combination of the other two (Mason 
& Fienberg 1985), the chapter uses a single continuous measure to capture cohort-based 
risks of diabetes: the prevalence of obesity in the cohort at age 25. In addition to avoiding 
the classic identification problem, this approach also identifies cohort effects with an 
intuitively appealing risk factor, rather than with complex mathematical transformations 
(e.g. Reither et al. 2009). I find that including this single continuous variable reduces all 
period coefficients to nearly zero. In other words, increases in diabetes prevalence over 
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time are almost entirely explained by increases in the age-25 obesity prevalence of 
successively younger cohorts. 
In a cohort closed to migration, increases in diabetes prevalence from one age to 
the next result only from incidence and mortality differentials between the diabetic and 
non-diabetic populations. Using the cohort perspective, I develop a model age pattern of 
diabetes incidence by measuring within-cohort changes in prevalence and adjusting for 
differential mortality. The results show that diabetes incidence peaks in late middle age 
(55 to 64) and declines at older ages. To my knowledge, these are the first estimates of 
diabetes incidence using nationally representative data with a stable, objective measure of 
blood glucose. 
The main insight of Chapter 1 is that the risk of diabetes is embodied in cohorts. 
One implication is that the possible plateauing of obesity prevalence recently observed 
(Flegal, Carroll, Kit, & Ogden 2012) does not imply that diabetes prevalence will soon 
plateau as well. As current young-adult cohorts age, they are likely to experience higher 
levels diabetes prevalence at any given age than past cohorts. More generally, a 
perspective that integrates the life course of a cohort into the measurement of disease 
occurrence can provide deeper understandings of past trends and perhaps better ability to 
predict future trends. 
 
Lifetime risk of dementia in the United States 
Dementia imposes a financial cost of over $40,000 per affected person per year, 
comparable to the financial costs of heart disease and cancer (Hurd et al. 2013). 
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Americans over 60 reported fearing dementia more than any other disease, including 
cancer (Alzheimer’s Association 2014). As the U.S. population ages, the number of 
Americans with dementia is very likely to increase in the coming decades (He & Larsen 
2014; Kasper, Freedman, Spillman, & Wolff 2015). Using nationally representative, 
longitudinal data from the Aging, Demographics, and Memory Study (ADAMS), fielded 
2001 to 2009, Chapter 2 estimates the probability that an average dementia-free person 
will develop dementia in the course of life. 
An approach that incorporates the competing risks of death and dementia 
incidence in a prospective cohort allows one to estimate the risk that the average 
dementia-free individual will develop dementia in the future. It can also provide an 
estimate of the related measures of dementia-free life expectancy and life expectancy 
with dementia. These quantities are important for individuals, businesses, and 
governments as they plan for retirement, save and contribute to pensions, and assess 
future health care costs and caregiving needs. For demographers and epidemiologists, 
these quantities provide meaningful insight into the question of whether long-run gains in 
survivorship are being experienced in healthy or unhealthy states (Crimmins & Beltrán-
Sánchez 2010; Crimmins, Hayward, & Hagedorn 2009). 
To my knowledge, this is the first study of the life cycle implications of dementia 
that uses data representative of the U.S. old-age population and explicitly accounts for the 
competing risk of death. The study will also utilize stationary population relations to 
refine estimates of a difficult-to-estimate quantity, the age-specific relative risk of death 
with dementia (versus without dementia). Finally, I will use the competing-risks model to 
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simulate the effects of interventions that delay onset of dementia or reduce its risk 
throughout old age. 
My findings suggest that the lifetime risk of dementia for an average adult are 
considerably higher than estimates extrapolated from non-national samples (Seshadri & 
Wolf 2007; Seshadri et al. 1997). Furthermore, my simulations suggest that, even in a 
population subject to interventions that substantially delay or reduce the risk of dementia, 
more than 20% of dementia-free 70-year-olds are likely to develop the disease before 
they die.  The results suggest a widespread and underappreciated need to prepare for a 
life stage with dementia. 
 
Incident diabetes and mobility limitations: reducing bias using risk-set matching 
 Although diabetes is an increasingly important cause of death in the U.S. (Murray 
2013), its consequences in terms of morbidity are also important. In Chapter 3, I 
investigate the relation between incident diabetes and the accumulation of mobility 
limitations using the Health and Retirement Study (HRS), a longitudinal survey 
representative of the U.S. population above age 50, covering 1992 to 2010. There is no 
agreed-upon method for estimating functional limitations associated with chronic 
conditions in the presence of comorbidities. Although diabetes prevalence and physical 
functional limitations are strongly correlated, the level of rigor of the studies showing this 
correlation is fairly low (Wong & Gregg 2013). Most studies, for example, ignore the 
possibility of reverse causality: mobility limitations can increase the risk of diabetes by 
making persons more sedentary (Bardenheier, Gregg, Zhuo, Cheng, & Geiss 2014). 
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Studies looking at diabetes presence as a risk factor for mobility limitation also cannot 
control for the time-ordering of covariates, even though many personal characteristics can 
both cause and result from diabetes (Narayan et al. 2011). Recent advances in propensity-
score matching techniques have not been applied to the study of chronic diseases.  
Chapter 3 addresses these gaps in the literature by investigating the role of 
diabetes incidence, rather than prevalence, in subsequent mobility decline. The long 
duration and time-invariance of questions about diabetes presence and functional 
limitations in the HRS allows the investigator to observe both incident diabetes cases and 
a long subsequent accumulation of mobility limitations. The rich data on socioeconomic 
and health backgrounds of subjects also allow for more robust controls for confounding 
variables compared to most prior literature. The innovative method of risk-set matching 
non-parametrically controls for time-varying onset of diabetes and of time-varying and 
time-invariant covariates. Cases and controls not only look similar in the cross-section; 
they have similar pre-exposure trajectories. This procedure generates a stronger, less-
biased control group than the extant literature. The chapter illustrates one approach that 
can be used to study the contribution of a specific disease to physical functioning 
limitations in the presence of multiple comorbidities. 
 The results show that individuals who developed diabetes subsequently 
accumulated more mobility limitations than matched controls. In each pair of case and 
control, subjects were followed for the same length of time both before and after diabetes 
onset. The magnitude of the association between diabetes and mobility limitations is 
smaller than that presented in most of the prior literature; however, there is reason to 
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believe my estimate is less biased. More practically, there is a great deal of room for 
better diabetes management to reduce the burden of physical functioning limitations 
associated with diabetes. 
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1 The Cohort Dynamics of Diabetes in the United States 
1.1 INTRODUCTION 
Diabetes is a leading cause of death in the United States (Murphy, Xu, & 
Kochanek 2013). A recent meta-analysis estimates that people with diabetes have a 50-
80% increased risk of disability, including impaired mobility, activities of daily living, 
and instrumental activities of daily living, compared to people without diabetes (Wong et 
al. 2013). The prevalence of diabetes among adults is approximately 12%, corresponding 
to approximately 26.1 million adults with diabetes in 2005-10 (Y. J. Cheng et al. 2013).  
 The incidence and prevalence of type 2 diabetes, which accounts for over 90% of 
diabetes cases (American Diabetes Association 2012), are clearly related to factors in an 
individual’s past.  In particular, individuals’ own histories of obesity and smoking (Luo et 
al. 2013; Yeh, Duncan, Schmidt, Wang, & Brancati 2010) have been shown to affect the 
risk of developing diabetes. Of these risk factors, the relationship between obesity history 
and diabetes incidence has been studied more extensively. One study found a steep 
gradient in the lifetime risk of diabetes based on body mass index (BMI, measured in 
kilograms per meters squared) at age 18. Males in the optimal BMI range of 18.5 to 25 
kg/m2 at age 18 had a 19.8% lifetime risk of diabetes, while males with BMI in the obese 
range of 30 to 35 kg/m2 at age 18 had a 57.0% lifetime risk of diabetes (Narayan et al. 
2007). A European cohort study  found that the earlier in life that subjects gained weight, 
the more likely they were to develop diabetes (Schienkiewitz, Schulze, Hoffmann, Kroke, 
& Boeing 2006). Among subjects in the Framingham Heart Study, each additional two 
years of obesity were associated with about a 12% increased odds of developing diabetes 
10 
 
(Abdullah et al. 2011). In the National Longitudinal Study of Adolescent Health, 
persistent obesity was associated with twice the risk of diabetes prevalence compared to 
adult-onset obesity (The, Richardson, & Gordon-Larsen 2013). In the CARDIA study, 
each additional year a person was obese increased their odds of developing diabetes by 
4% (Reis et al. 2013). These and other studies indicate that obesity over the life course is 
an important predictor of diabetes incidence. 
 In this paper, we investigate the rise in diabetes in the United States through the 
lens of birth cohorts.  Previous studies examining changes in diabetes prevalence over 
time have compared one calendar-year period to another (Bullard et al. 2013; Y. J. Cheng 
et al. 2013). However, like other chronic diseases, type 2 diabetes is the result of 
cumulative processes that develop over a lifetime. A full understanding of the prevalence 
of diabetes at a moment in time requires reference to the past, a past that is embodied in 
the birth cohorts alive during that period. Because histories in a birth cohort are persistent 
– characteristics of a birth cohort established at age 25 remain the age-25 characteristics 
of that cohort as it ages – we expect to find “cohort effects” that differentiate one birth 
cohort from another as they age. 
 Birth cohorts not only embody a history of exposures, they are also the 
appropriate vehicle for calculating disease incidence. We take advantage of this 
opportunity to present new estimates of the age-pattern of diabetes incidence in the 
United States. These are the first estimates of incidence that use measured data in a 
nationally representative sample. Previous national estimates of diabetes incidence used 
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retrospective reports of individuals rather than biological indicators and provided little 
age detail (Geiss et al. 2006; Narayan et al. 2003).  
 
1.2 METHODS 
Population and data collection 
 In order to investigate the dynamics of diabetes in the United States, we use data 
from the National Health and Nutrition Examination Surveys (NHANES). We employ 
data from NHANES III, conducted in two phases, 1988 to 1991 and 1991 to 1994; and 
from the Continuous NHANES that began in 1999, for which data are released in two-
year cycles. We pool adjacent data-release cycles of Continuous NHANES to obtain 
three observation periods from Continuous NHANES: 1999 to 2002, 2003 to 2006, and 
2007 to 2010. NHANES is a complex, multi-stage probability sample of the U.S. civilian 
non-institutionalized population. Participants complete a home interview and are then 
examined in a mobile examination center, which includes sampling participants’ blood 
for laboratory tests. Participants are randomized into morning or afternoon examinations, 
and the morning examinees are asked to fast for at least nine hours prior to the 
examination. Whenever possible, NHANES uses consistent laboratory procedures over 
time to facilitate analysis of trends in population health. The National Center for Health 
Statistics (NCHS) provides extensive documentation of NHANES survey, examination, 
and laboratory procedures on its website (National Health and Nutrition Examination 
Survey 2012). The characteristics of the NHANES study sample are reported elsewhere 
(Bullard et al. 2013; Y. J. Cheng et al. 2013). 
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 There were 88,224 individuals examined during our study periods. We exclude 
individuals below age 20 (n=40,899), above age 80 (n=3,558), or who were pregnant 
(n=1,510). We also exclude individuals who were exactly 20 years old when surveyed in 
2010 (n=105) because these individuals would not comprise a complete birth cohort, as 
described below. We also exclude subjects with missing HbA1c values (n=2,022). The 
final analytic sample for HbA1c-based measures consists of 40,130 observations, with 
7,011 observations from Phase 1 of NHANES III, 7,427 from Phase 2 of NHANES III, 
7,778 from NHANES 1999-2002, 7,755 from NHANES 2003-2006, and 10,159 from 
NHANES 2007-2010.  
 
Definition of diabetes 
 We rely on laboratory results, rather than self-reported diagnoses, because the 
latter fails to capture the considerable number of individuals in the US population with 
undiagnosed diabetes. A 2010 study estimated that 3.9 million individuals above age 20 
had undiagnosed diabetes, representing 19% of the diabetic population (Cowie et al. 
2010). Furthermore, intertemporal comparisons based on self-reported diagnosis are 
complicated by the fact that criteria for diagnosing diabetes in the clinical setting have 
changed (Gregg et al. 2004; Stokes & Mehta 2013).  
 Our primary definition of diabetes is based on HbA1C, which was first measured 
in NHANES III. This measure reflects average glycemia over a prolonged period and 
thus has more intra-subject stability than the leading alternative,  a measure of fasting 
plasma glucose (FPG) (Bonora & Tuomilehto 2011). Furthermore, HbA1c-based 
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measures of diabetes are more strongly associated with cardiovascular disease and death 
than are FPG-based measures (Selvin et al. 2010). Finally, only 54% as many 
observations of diabetes status are available in NHANES using FPG as using HbA1c. A 
sensitivity analysis defined diabetes presence as FPG ≥ 126 mg/dL.  
 Several changes in laboratory measurement of HbA1C occurred over the course 
of Continuous NHANES (detailed elsewhere (Bullard et al. 2013)), but we follow the 
NCHS recommendation and the methods of recent studies and used HbA1C data without 
any corrections or adjustments (Bullard et al. 2013; Y. J. Cheng et al. 2013). Individuals 
are considered diabetic if they had HbA1c ≥ 6.5% (48 mmol/mol) (American Diabetes 
Association 2012). Because diabetes medication is expected to reduce glycemia, the 
HbA1c values of medicated persons might not capture their diabetes status correctly; 
therefore, all individuals who reported taking diabetes medication are considered 
diabetic. In our sample, there were 4,678 individuals who met our definition of having 
diabetes. There were 896 individuals, or 19.2% of the group with diabetes, who reported 
taking diabetes medication and who had HbA1c < 6.5%.  
 
Cohort assignment 
 Birth cohorts must be constructed from repeated cross-sections because NHANES 
does not repeatedly sample the same individuals over time. We calculate each 
individual’s birth year using the equation Birth cohort = Period - Age. For the purpose of 
calculating birth cohorts, Period is defined as the midpoint of the NHANES wave or 
phase: April 21, 1990 for Phase 1 of NHANES III, April 23, 1992 for Phase 2 of 
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NHANES III, and January 1 of the second year of each data release cycle of Continuous 
NHANES. In a recent study of cohort obesity patterns that used NHANES data and the 
same procedure for calculating birth years, results were robust to alternative 
specifications of period (J. M. Lee et al. 2010). Age is the age of the individual, in 
completed years, at the time of the survey. To ensure large enough age-cohort cells, we 
analyze cohorts born in ten-year-wide intervals (1910 to 1919, 1920 to 1929, etc.). Using 
this approach, we obtain a total of 8 ten-year birth cohorts between 1910-1919 and 1980-
1989. This method involves assuming that upon reaching age 20, diabetes prevalence is 
not affected by migration. We test the sensitivity of our results to this assumption by 
excluding foreign-born individuals from the sample. 
 
Statistical methods 
 Prevalence is calculated as the proportion of individuals in the given age-period or 
age-cohort cell with diabetes as defined above. Calculations are adjusted for complex 
survey design using strata and primary sampling units provided by the National Center 
for Health Statistics (NCHS), along with survey weights. For HbA1c, we use the final 
examination weight provided by NCHS; because we pool adjacent data release cycles of 
Continuous NHANES, we divide the examination weights in Continuous NHANES by 2, 
as recommended by NCHS (National Health and Nutrition Examination Survey 2006).  
 We use least squares to model the age-, cohort- and period-patterns of diabetes 
prevalence in the U.S. population, using the following regression models: 
Age/Cohort model: ln(Yia) = α +βaXa + βiXi [1] 
15 
 
In this equation, Yia is the proportion of the population in cohort i at age a with diabetes, 
Xa is a dummy variable indicating that the observation pertains to age a, and Xi is a 
dummy variable indicating that the observation pertains to cohort i. 
Age/Period model: ln(Yia) = α +βaXa + βpXp [2] 
Here, Yia and Xa are defined as in Equation 1 and Xp is a dummy variable indicating that 
the observation pertains to period p. 
Age/Period/Cohort model: ln(Yia) = α +βaXa + βpXp + γCoh_ob [3] 
Yia, Xa, and Xp are defined as in Equation 2 and Coh_ob is a continuous variable 
representing the prevalence of obesity at age 25 in the cohort corresponding to the given 
age and period. We use age 25 because NHANES inquired about weight at that specific 
age. Obesity at age 25 serves as a measure of a cohort’s history of obesity. The use of a 
continuous variable to represent birth cohort influences avoids the identification problem 
that any two of age, cohort, and period indicators can be linearly combined to produce the 
third (Mason & Fienberg 1985).  
Each prevalence estimate is weighted by the number of observations that gave rise 
to it in order to give more weight to values estimated with greater precision. The log 
specification implies that cohort membership affects an age-pattern of prevalence 
multiplicatively; a simple additive specification would suggest implausibly that the age-
pattern of prevalence is shifted up or down by the same amount at each age, with no 
cohort effect on prevalence beyond the earliest age. 
 Birth-cohort obesity prevalence is estimated using age-25 weight and height recall 
data in Continuous NHANES waves 1999-2008. Height recall was only asked of 
16 
 
participants aged 50 and over; for younger individuals we used self-reported current 
height. We identify birth cohorts by subtracting age from survey year, using the 
beginning of the second year of each of the waves (e.g., 2000.0 for 1999-2000) and 
aggregate them into five-year wide intervals. The earliest and most recent birth cohorts 
for whom cohort obesity is calculated are the 1920-1924 and 1975-1979 birth cohorts, 
respectively. Thus, the age-period-cohort model excludes prevalence estimates that drew 
exclusively from the oldest or youngest birth cohorts (born 1910-1919 and 1980-1989). 
Appendix A.1.1 shows a table of the cohort-obesity prevalence values used in this study.  
 The examination of diabetes prevalence within birth cohorts allows us to estimate 
the age-specific incidence of diabetes. In essence, this estimate is made by dividing the 
prevalence of non-diabetes in a birth cohort at one age interval (e.g. 50 to 54) by the 
prevalence of non-diabetes in the same birth cohort in the adjacent, younger age interval 
(e.g. 45 to 49) and adjusting for the fact that people without diabetes die at lower rates 
than the general population. The prevalence estimates used in this calculation are based 
upon the age coefficients estimated from the age/cohort model, presented in Figure 3B. 
These summarize the age-pattern of prevalence revealed within eight birth cohorts, 
adjusting for cohort-specific effects. Life tables for individuals without diabetes and for 
the general population are estimated using pooled data from NHANES III and 
Continuous NHANES (1999-2004 waves) cohorts linked to deaths in the National Death 
Index through 2006 (National Health Interview Survey (1986-2004) 2009). A discrete 
hazards model on a person-month file is employed to generate the underlying risks for 
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predicting mortality rates. The model is implemented on baseline ages 20-74. There were 
2,903 deaths among 25,971 respondents.  
 
Derivation of formula for diabetes incidence in a cohort 
 Suppose that 20% of a cohort has diabetes at age 30 and 25% of that cohort has 
diabetes at age 35. Then the incidence of diabetes (number of new cases per diabetes-free 
member of the population) between ages 30 and 35 is approximately .05/.80=.0625. That 
figure refers to incidence over a five-year period, whereas incidence is normally 
measured annually. An annualized rate would be .0625/5=.0125. This figure is based on 
the number who are free of diabetes at the beginning of the interval, whereas incidence is 
typically measured using a denominator measured at the middle of the interval. So the 
corrected figure is (.05/.775)/5=.0129. 
 This calculation makes three basic assumptions: (1) Migration does not affect 
birth cohort prevalence; (2) Those with diabetes at age 30 do not become diabetes-free by 
age 35, and (3) Those with diabetes at age 30 have the same probability of dying by age 
35 as those who were diabetes-free at age 30. In constructing our estimates of the 
incidence of diabetes, we retain assumption 1 and 2, that migration does not affect 
prevalence and that those who enter the diabetic state leave it only by death (see 
Discussion section for analysis of remission). To check the sensitivity of our results to 
Assumption 1, we excluded foreign-born individuals from our sample, and results were 
not substantially altered (see Appendix A.1.6). We address Assumption 2 in the 
Discussion section below. However, Assumption 3 is demonstrably untenable (Stokes & 
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Mehta 2013). Accordingly, our estimates of diabetes incidence adjust for the higher 
mortality of those with diabetes. 
 We develop the estimation formula first by referring to the population at exact 
ages and then substituting equivalent formulas for the population at discrete age intervals. 
Under our assumptions, the diabetes-free population is subject to two sources of 
decrement, incident diabetes and death (Preston et al. 2001). 
 𝑝𝑥
0 = exp(−5(𝜇𝑥
0 + 𝛿𝑥
0)) ,5  [4] 
where 
O
xp5  = probability of surviving in the disease-free state from age x to age x+5 for a 
person free of diabetes at age x, 
O
x =  death rate at age x for a person free of diabetes, 
O
x =  rate of acquiring diabetes (incidence rate) at age x for a person free of diabetes. 
 𝑝𝑥 = exp⁡(−5𝜇𝑥)5 ,  [5] 
where 
xp5 = probability of surviving from age x to age x+5 for a randomly-chosen member of    
the population 
x =  death rate at age x for a randomly-chosen member of the population. 
 Equations 4 and 5 assume that death rates and the incidence rate of diabetes are 
constant in the age interval x to x+5, producing the exponential functional form. 
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 Call the non-diabetes population at age x OxN  and the total population at age x 𝑁𝑥. 
Then the prevalence of non-diabetes at age x is 
x
O
x
x
N
N

. 
 The prevalence of non-diabetes in the same cohort at age x+5 is 
]5exp[
)](5exp[
5
5
5
xx
O
x
O
x
O
x
x
O
x
x
N
N
N
N








 
= Π𝑥 exp(−5𝛿𝑥
0) exp(−5(𝜇𝑥
0 − 𝜇𝑥)). [6] 
  
 Rewriting equation 6 gives 
exp(−5𝛿𝑥
0) =
Π𝑥+5exp⁡(−5𝜇𝑥)
Π𝑥exp⁡(−5𝛿𝑥
0)
 
or 
𝛿𝑥
0 = −
1
5
ln⁡(
Π𝑥+5∗ 𝑝𝑥5
Π𝑥∗ 𝑝𝑥
0
5
𝑀 ),  [7] 
where 
O
x
M p5 = probability of surviving the risk of death from x to x+5 for a diabetes-free person 
at age x. 
 Equation 7 shows that the incidence rate of diabetes between ages x and x+5 can 
be derived from the ratio of non-diabetes prevalence at x and x+5 and from differences in 
the survival probabilities between the entire population and the diabetes-free population 
over that age span. It also shows why a moving average of incidence estimates made 
using this equation is appropriate: errors in prevalence estimates at any particular age will 
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appear in the numerator of one age-specific incidence estimate and in the denominator of 
the adjacent incidence estimate. 
 Substituting expressions for discrete five-year intervals into the equivalent terms 
in Equation 7 gives 
 
]ln[
5
1
555
555
5
55
10
O
x
MO
x
M
xx
x
x
O
x
LL
LL





,  [8] 
where 
O
x10  = rate of developing diabetes for a non-diabetic person in the age interval x to x+10, 
x5 = prevalence of non-diabetes at ages x to x+5 
xL5 = person-years lived between ages x and x+5 in a life table for the population 
O
x
M L5 = person-years lived between ages x and x+5 in a life table for persons free of 
diabetes. 
 We interpret 
O
x10 as pertaining to the age interval x+2.5 to x+7.5, i.e. the five-
year age span at the middle of the ten-year age interval x to x+10. We use equation 8 for 
our incidence estimates in this study, assuming the incidence rate and differential 
mortality are constant within the five-year age intervals used. Values of Π𝑥5  are 
calculated from fitted values in the age-cohort model of prevalence. Values of L𝑥5  and 
L𝑥
𝑂
5
𝑀 ⁡come from the life tables as described above in the Statistical Methods section. 
 All statistical analysis was performed using Stata version 11 (StataCorp, College 
Station, TX). Standard errors were estimated using first-order Taylor series linearization.  
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1.3 RESULTS 
Prevalence Estimates and Modeled Age and Cohort Patterns 
 Figure 1-1 plots estimates of age-specific diabetes prevalence during the four 
observation periods under study. The underlying values and their standard errors are 
reported in Appendix Tables A.1.2a and A.1.2b. As reported elsewhere (Y. J. Cheng et 
al. 2013), there is a general upward trend in prevalence at each age.  
 Figure 1-1 shows a pattern in which the prevalence of diabetes declines at some 
set of ages above 60-64 in each of the four periods. Such a decline could be produced by 
higher mortality rates among those with diabetes than among those without. However, we 
show below that this pattern of decline with age is not present when prevalence rates are 
arrayed by birth cohort. In other words, the declines in prevalence with age in Figure 1-1 
result from the increasing prevalence of diabetes among later-born cohorts.  
 Figure 1-2 presents estimates of diabetes prevalence among birth cohorts. It is 
clear that prevalence is rising from one birth cohort to the next, even at younger ages 
where prevalence is low. Furthermore, prevalence continues to rise even at the oldest 
ages, which is consistent with a continued positive incidence of diabetes as cohorts age.  
Declining prevalence with age, a pattern suggested by period data, is not observed among 
real birth cohorts as they age.  
 The age-pattern of diabetes, as well as changes in diabetes prevalence from birth 
cohort to birth cohort, are summarized by our statistical model. Figure 1-3 plots the 
coefficients for each birth cohort in the age/cohort regression model. That the coefficients 
are monotonically increasing shows that more recent birth cohorts have higher diabetes 
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prevalence than older cohorts. The increase is exceptionally rapid among cohorts born 
after 1950-59. The implication of the cohort coefficients is that the prevalence of diabetes 
at any age for the cohort born 1980-89 will be nearly triple that of the cohort born in 
1950-59 and 4.9 times that of the cohort born in 1910-19 (derived from Appendix Table 
A.1.3a).  
 Just as the age/cohort model produces rapidly increasing cohort effects, the 
age/period model produces rapidly rising period effects. This nearly straight-line increase 
in prevalence across periods is shown in Figure 1-4 (see Appendix Table A.1.3b for 
actual values). By themselves, there is nothing in Figures 1-3 and 1-4 that would indicate 
which model is preferred. Both models produce R2 values above 0.94. But when we add a 
cohort variable to the age/period model, the prevalence of obesity at age 25, the period 
effects nearly disappear, as shown in Figure 1-4 (Appendix Table 3c). They also become 
statistically insignificant.  
 Figure 1-5 compares the age-patterns of diabetes prevalence that are produced by 
the age/cohort model, the age/period model, and the age/period/cohort model. By far the 
most level age pattern is produced by the age/period model. As argued earlier, that age 
pattern is misleading because it fails to account for the rise in diabetes prevalence from 
one birth cohort to the next. As was suggested by a comparison of Figures 1-1 and 1-2, 
the age pattern of diabetes prevalence in a birth cohort is steeper than that in a period. 
The age-pattern in the age/period model becomes much steeper when birth-cohort obesity 
is introduced, as shown in Figure 1-5. The age-pattern identified in the age/period/cohort 
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model is very similar to that in the age/cohort model. The same pattern of results holds 
when FPG rather than HbA1c is used to define diabetes (Appendix A.1.4). 
 
Incidence estimates 
  Based on Equation 8 above, Figure 1-6 shows the age pattern of diabetes 
incidence that is implied by the age pattern of prevalence that we have uncovered. The 
values on the graph apply to the cohort born 1950-1959, but the shape of the curve is the 
same for all birth cohorts. The age-pattern of incidence rises to a peak in the age interval 
55 to 64 (centered at age 60) and then declines slowly. At its peak from ages 55 to 64, for 
the cohort born 1950-1959, approximately 1.1% of the diabetes-free population will 
develop diabetes each year. Appendix A.1.5 presents numerical details of our incidence 
estimates. As shown in Appendix A.1.6, the age pattern of diabetes incidence is similar 
when foreign-born subjects are removed from the sample, suggesting that our results are 
not sensitive to the assumption that migrants experience the same relevant rates as native-
born individuals. 
 
Sensitivity of results to threshold choice 
 To examine the sensitivity of results to the choice of the HbA1c threshold, we 
adopt a threshold of HbA1c levels ≥ 6.0%. Recent guidelines from the American 
Diabetes Association consider individuals at this level to be at “very high risk” of 
incident diabetes (American Diabetes Association 2012). See Appendix A.1.7 for a 
discussion of this choice of threshold. Using this lower threshold, we estimate the 
24 
 
prevalence of being “at least at high risk” of diabetes over time and across birth cohorts, 
as shown in Appendix Figures A.1.7a and A.1.7b. 7,370 individuals in our sample met 
the more inclusive criterion. A comparison of Figure 1-2 to Appendix Figure A.1.7b 
shows that the increase across birth cohorts in age-specific prevalence of “at least high-
risk” is even more striking than that using the higher cut-off. In particular, the higher 
prevalence seen in more recent birth cohorts appears at earlier ages in “at least high-risk” 
than it does in diabetes itself. 
 We also estimate age/period, age/cohort, and age/period/cohort models of “at least 
high-risk” prevalence. The patterns described above are largely replicated using the lower 
cut-off. Consistent with the higher level of prevalence, the rise in prevalence across ages 
and birth cohorts is greater when HbA1c ≥ 6.0% is used. However the introduction of 
obesity at age 25 into the age/period model has much the same effect as when HbA1c ≥ 
6.5% is used; it steepens the age effects and reduces the period effects, though a 
significant period effect remains in the most recent period (see Appendix Figures 
A.1.7c-7e and Figure 1-4). Once again, this result places the spotlight on birth cohort 
influences in the rise of diabetes in the United States. Appendix Tables A.1.7a-7c 
present numerical details of the results of our modeling of the prevalence of HbA1c ≥ 
6.0%. 
 
1.4 DISCUSSION 
 Birth cohorts are an attractive vehicle for investigating changes in the prevalence 
of diabetes because prevalence at any age is a cumulative product of influences in the 
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past. These influences manifest themselves over the lifetime of birth cohorts, creating 
close associations in the prevalence of diabetes across age within a cohort. 
 We show that the prevalence of diabetes in the United States is rapidly increasing 
from one birth cohort to the next. We demonstrate this increase graphically and by means 
of an age/cohort model. The increase is especially rapid across cohorts born after 1950-
59.  
Our results also reveal that the pattern of increase with age in the prevalence of 
diabetes is considerably faster within a birth cohort than it is across ages in a particular 
period. The increase with age during any particular period is too mild, or even negative, 
because it does not account for the higher levels of diabetes evident among more recent 
birth cohorts.  
 An additional suggestion of the importance of birth cohort influences on diabetes 
prevalence is supplied by our age/period/cohort model. While an age/period model shows 
sharply increasing period effects, the addition of a term measuring birth cohort obesity at 
age 25 renders the period effects small and insignificant. This result indicates that birth 
cohort influences – in particular, birth cohort obesity levels – are important determinants 
of diabetes prevalence.  
   An innovation of our approach is that we convert estimates of birth cohort 
diabetes prevalence to estimates of incidence. Such estimates cannot be made using 
period data alone without the extreme assumption that no population rates are changing 
(Greenland & Rothman 2008). This assumption is clearly not warranted in the case of 
diabetes, as shown in Figure 1-1. But such calculations of incidence can be made by 
26 
 
comparing prevalence at different ages for the same birth cohort since any changes in 
prevalence within a birth cohort must be attributed to some combination of new 
diagnoses (incidence), differential mortality by diabetes status, and recovery (if any). To 
estimate incidence, we use the age effect coefficients from the age/cohort model, which is 
based on observations across eight birth cohorts. We demonstrate that the incidence of 
diabetes among diabetes-free persons rises steadily to a peak at ages 55 to 64 and then 
declines slowly.  
To the best of our knowledge, these are the first estimates of the age-pattern of 
diabetes incidence that are based on measured data in a nationally-representative sample. 
Other estimates of age-patterns of diabetes incidence are few and inconsistent. Age 
patterns of diabetes incidence that peak and then decline are found in some populations 
(Berger, Stenström, & Sundkvist 1999; Khan et al. 2011; McDermott, Li, & Campbell 
2010; Pavkov et al. 2007). Other studies find that incidence continues to rise with age 
(Thunander et al. 2008; Wilson, Anderson, & Kannel 1986) or levels off at older ages 
(Geiss et al. 2006; Monesi et al. 2012). Annual estimates of incidence in the U.S. from 
the Centers for Disease Control and Prevention (CDC), which are based on retrospective 
self-reports, show a peak in the age interval 45-64 in some years and at ages 65-79 in 
other years (Centers for Disease Control and Prevention 2012). Experimental evidence 
suggests a biological mechanism for increasing incidence with age at the individual level 
(H.-Y. Lee et al. 2010). One possible explanation for the peak and decline in diabetes 
incidence in a birth cohort is population heterogeneity in vulnerability to diabetes, with 
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the most vulnerable individuals being successively selected out of the diabetes-free 
population as birth cohorts age.  
 Our study has several limitations. We assume that migration does not affect the 
prevalence of diabetes in birth cohorts. When we removed foreign-born respondents from 
the sample, however, the pattern of our results was essentially unchanged (e.g. Appendix 
A.1.6). We also assume no age-cohort interactions. We tested this assumption by 
including interactions between a continuous variable for age and indicators for the three 
birth cohorts that provided the most prevalence estimates; coefficients on these 
interaction terms were not statistically significant (p>.15 in all cases).  
The small sample sizes in NHANES required us to use ten-year wide birth cohorts 
and assume homogeneity within those birth cohorts. As a specification check, we divided 
the birth cohorts into different ten year intervals than reported in this paper (1915 to 
1924, 1925 to 1934, etc.). Resulting patterns of prevalence were similar to the results 
presented here (e.g. Appendix A.1.8). 
The NHANES data do not permit distinguishing between type 1 and type 2 
diabetes. However, because type 2 accounts for about 90-95% of all diabetes cases 
(American Diabetes Association 2012), this was not a serious limitation.  
We categorized as diabetic individuals below the 6.5% HbA1c threshold who reported 
taking medication for diabetes. On the other hand, we did not categorize as diabetic 
individuals below the 6.5% threshold with self-reported diabetes because we assume that 
the large majority of this group was assessed using alternative diagnostic criteria, such as 
FPG or Oral Glucose Tolerance Test. Prior research indicates that relative to these 
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measures, the HbA1c test identifies as diabetic a smaller group of high-risk individuals 
(Cowie et al. 2010). For this reason, we did not assume that individuals with self-reported 
diabetes were ever above the HbA1c threshold for diabetes.  
Our method for estimating diabetes incidence assumes that mortality differences 
between people with and without diabetes have been constant; the literature on this 
question is unresolved (Gregg et al. 2012; Gregg, Gu, Cheng, Narayan, & Cowie 2007; 
Stokes & Mehta 2013). Our calculations also assume that there is no remission once the 
diabetes-defining threshold is reached (i.e. one can only exit the diabetic state through 
death). Remissions would offset new cases and produce an underestimate of the 
incidence rate. The principal source of remission of diabetes is bariatric surgery. 
According to the American Society for Metabolic and Bariatric Surgery (ASMBS), the 
number of procedures reached 103,000 in 2003 (National Institute of Diabetes and 
Digestive and Kidney Diseases 2011). There were approximately 21,708,000 Americans 
aged 20+ with HbA1c values of 6.5% or greater in that year (Y. J. Cheng et al. 2013; U.S. 
Census Bureau 2005). Assuming that all those who had the surgery had diabetes, the 
annual rate of surgery among people with diabetes was .00497 in 2003. Two recent 
randomized clinical trials investigated the efficacy of bariatric surgery among those with 
diabetes. One found a one-year success rate in reducing HbA1c below 6.0% of 42% 
(Schauer et al. 2012) and the other a two-year rate of success of reducing HbA1c below 
6.5% of 75% (Mingrone et al. 2012). If we assume that the higher figure applies to the 5-
year success rate required in our calculations, bariatric surgery would produce a 
remission rate of (.75)(.00497) = .00373 among people with diabetes in 2003. Since the 
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ratio of people without diabetes to people with diabetes in that year was 9.12 (Y. J. 
Cheng et al. 2013), the rate of flow into the non-diabetic population as a result of 
successful bariatric surgery was .00373/9.12 = .00041. This value compares to an 
incidence rate above age 50 of about .010 in our calculations. So the incidence rate above 
age 50 would be perhaps higher by the factor 1.04 if allowance were taken of remission 
from bariatric surgery.  
There are other sources of remission, of course, but in these two randomized 
clinical trials the remission rates for very intensive non-surgical medical treatment was 
only 12% (Schauer et al. 2012) and 0% (Mingrone et al. 2012). Due to the intensive 
nature of the medical treatment, these findings can be considered an upper bound on 
remission rates in the diabetic population at large. It is worth noting that projections of 
future diabetes prevalence assume the cure rate for diabetes is zero (Boyle, Thompson, 
Gregg, Barker, & Williamson 2010), and clinical guidelines imply that people who have 
been diagnosed with diabetes are considered diabetic even if their blood glucose is under 
control (Ali et al. 2013). 
Two recent studies of individuals in NHANES found that secular changes in time-
of-survey BMI explained some but not all of the secular increase in the prevalence of 
diabetes and prediabetes (Bullard et al. 2013; Y. J. Cheng et al. 2013). Our findings also 
implicate the rise in obesity for increases in diabetes but we use aggregate data on birth 
cohorts and an historical rather than contemporary indicator of obesity.  That both current 
and past levels of obesity affect an individual’s risk of developing diabetes has been 
demonstrated in prior research (Abdullah et al. 2011). Thus, our results are consistent 
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with other analyses that identify increases in the prevalence of obesity as an important 
factor in the rise in diabetes.  
The prevalence of obesity has increased dramatically across recent US birth 
cohorts. We have shown that birth-cohort prevalence of diabetes is associated with birth-
cohort levels of obesity at age 25. Because cohort effects persist as cohorts age, our 
results suggest that diabetes prevalence is likely to continue increasing despite an 
apparent plateauing of obesity in recent years (Flegal et al. 2012). Additional analyses 
should investigate the implications of the birth cohort trends identified here for future 
diabetes prevalence in the United States.  
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Figure 1-1. Diabetes Prevalence across NHANES Waves 
 
Data: National Health and Nutrition Examination Surveys (NHANES), United States, 
1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 6.5% or taking 
diabetes medication. Values are weighted to reflect the contemporary U.S. population.  
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Figure 1-2: Age-Specific Prevalence, by Decadal Birth Cohort 
 
Data: National Health and Nutrition Examination Surveys (NHANES), United States, 
1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 6.5% or taking 
diabetes medication. Values are weighted to reflect the contemporary U.S. population.  
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Figure 1-3: Age-Adjusted Diabetes Prevalence in Birth Cohorts Relative to those 
born 1910-19 
 
The graph shows the age-adjusted prevalence of diabetes in each birth cohort as a 
multiple of the age-adjusted prevalence for the 1910-1919 birth cohort. 
Data: National Health and Nutrition Examination Surveys (NHANES), United States, 
1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 6.5% or taking 
diabetes medication. Estimates are weighted to reflect the contemporary U.S. population. 
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Figure 1-4: Age-Adjusted Prevalence as a Multiple of 1988-94 Prevalence 
 
This figure shows age-adjusted prevalence as a multiple of age-adjusted prevalence in the 
reference 1988-1994 period for the Age/Period model (diamonds) and Age/Period/Cohort 
model (squares). Data: National Health and Nutrition Examination Surveys (NHANES), 
United States, 1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 
6.5% or taking diabetes medication. Values are weighted to reflect the contemporary U.S. 
population.  
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Figure 1-5: Age Pattern of Diabetes Prevalence in Different Models 
  
This figure shows age-specific prevalence as a multiple of the prevalence at age 20-24 in 
the Age/Cohort model (triangles), Age/Period model (diamonds), and Age/Period/Cohort 
model (squares). Data: National Health and Nutrition Examination Surveys (NHANES), 
United States, 1988-1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 
6.5% or taking diabetes medication. Values are weighted to reflect the contemporary U.S. 
population.  
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Figure 1-6: Smoothed Age Pattern of Diabetes Incidence Using Prevalence Values 
from Age/Cohort Model 
 
Incidence estimated from Age/Cohort model of diabetes prevalence and differential 
mortality estimates, detailed in Statistical Methods section. Three-term moving average 
of incidence is plotted. For graphical purposes, incidence values are plotted for the cohort 
born 1950-1959, but the shape of the curve is the same for all birth cohorts. Data: 
National Health and Nutrition Examination Surveys (NHANES), United States, 1988-
1994 and 1998-2010. N=40,130. Diabetes defined as HbA1c at least 6.5% or taking 
diabetes medication. Values are weighted to reflect the contemporary U.S. population. 
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2 Lifetime risk of dementia in the United States 
2.1 INTRODUCTION 
Dementia is increasingly recognized as a major source of disease burden in the 
United States (Murray 2013). A national study estimated that 3.4 million American adults 
over 70 had dementia, corresponding to a prevalence of approximately 13.9% (Plassman 
et al. 2007). Dementia imposed a financial cost of over $40,000 per affected person per 
year, comparable to the financial costs of heart disease and cancer (Hurd et al. 2013). 
Americans over 60 reported fearing dementia more than any other disease, including 
cancer (Alzheimer’s Association 2014). As the U.S. population ages, the number of 
Americans with dementia is very likely to increase in the coming decades (He & Larsen 
2014; Kasper et al. 2015). Using nationally representative, longitudinal data, this study 
will estimate the probability that an average dementia-free person will develop dementia 
in the course of life. 
An approach that incorporates the competing risks of death and dementia 
incidence in a prospective cohort allows one to estimate the risk that the average 
dementia-free individual will develop dementia in the future. It can also provide an 
estimate of the related measures of dementia-free life expectancy and life expectancy 
with dementia. These quantities are important for individuals, businesses, and 
governments as they plan for retirement, save and contribute to pensions, and assess 
future health care costs and caregiving needs. For demographers and epidemiologists, 
these quantities provide meaningful insight into the question of whether long-run gains in 
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survivorship are being experienced in healthy or unhealthy states (Crimmins & Beltrán-
Sánchez 2010; Crimmins et al. 2009). 
Data from the Framingham Heart Study and from a national Canadian sample 
have been used to report the lifetime risk of developing dementia using a competing-risks 
framework (Carone, Asgharian, & Jewell 2014; Seshadri & Wolf 2007; Seshadri et al. 
1997). Dementia-free life expectancy was reported for a large cohort in the Pacific 
Northwest, known as the Adult Changes in Thought study (ACT) (Tom et al. 2015). 
Though informative, the Framingham, Canadian, and ACT cohorts are not representative 
of the U.S. population. For example, these cohorts had a larger proportion of subjects 
who were white than did the U.S. as a whole. Studies have generally found that African 
Americans have higher age-specific rates of mild cognitive impairment and of dementia 
than whites (Katz et al. 2013; Sheffield and Peek 2011). As the nation gets more racially 
and ethnically diverse, these cohorts are decreasingly representative of the U.S. elderly 
population. Therefore, there is a need for estimates of lifetime risk of dementia from 
nationally representative data. 
 
2.2 METHODS 
Sample and definitions 
This study uses the Aging, Demographics, and Memory Study (ADAMS), a 
nationally representative, longitudinal study of cognitive health and dementia conducted 
in four waves from 2001 to 2009 (Langa et al. 2005). ADAMS, a probability subsample 
of the Health and Retirement Study (HRS), examined adults aged 70 and older with a 
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series of cognitive, psychological, and neurological tests, and conducted an extensive 
medical history, an inventory of current prescription medications, a neurology-focused 
physical exam, and a family/caregiver questionnaire. The testing was conducted in person 
by trained technicians and nurses and supervised by neuropsychologists (Langa et al. 
2005). Diagnostic criteria were based on the Diagnostic and Statistical Manuals of 
Mental Disorders, DSM-III-R and DSM-IV, and final diagnosis of dementia was made by 
a consensus expert panel of physicians (Heeringa et al. 2009; Langa et al. 2005). Detailed 
descriptions of the ADAMS sample and assessment tools have been previously published 
(Heeringa et al. 2009; Langa et al. 2005; Plassman et al. 2007). 
According to the DSM, the essential feature of dementia is the development of 
multiple cognitive deficits that include memory impairment and at least one of aphasia 
(language deficit), apraxia (movement deficit), agnosia (deficit in recognition of objects 
or senses), or executive functioning deficit (American Psychiatric Association 2000). The 
cognitive deficits must represent a decline from past abilities and must be severe enough 
to cause impairment in occupational or social functioning (American Psychiatric 
Association 2000). The most common type of dementia is Alzheimer’s disease (AD), 
which accounts for 60% to 80% of dementia cases. The next most common type is 
vascular dementia, which alone accounts for about 10% of cases but which is often found 
together with AD (Alzheimer’s Association 2014).  
The initial wave of ADAMS, 2001-2003, examined 856 subjects to generate 
baseline estimates of dementia prevalence in the U.S. (Plassman et al. 2007). The 
subsequent waves followed 456 dementia-free individuals for dementia incidence 
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(Plassman et al. 2011). The second wave focused on subjects whose baseline status was 
“cognitively impaired, no dementia”; this second wave assessed subjects 16 to 18 months 
after their baseline assessment. For the third and fourth waves, all living subjects who 
were dementia-free at baseline were in the sampling frame. Subjects in the third wave 
averaged 3.7 years since their most recent assessment, and subjects in the fourth wave 
averaged 1.8 years since their most recent assessment (Plassman et al. 2011). Despite the 
relatively long intervals between assessments, ADAMS investigators could determine, 
based on informant reports, medical records, and clinical assessment, that a subject 
experienced the onset of dementia at any time since the previous assessment. For 
example, if a 72 year old subject was deemed dementia-free at baseline and then assessed 
at age 76 and found to have dementia, investigators could determine that his age at the 
onset of dementia was 73. The assignment of ages at dementia onset during the inter-
assessment interval allows for the estimation of dementia incidence rates, rather than 
probabilities. Thus the ADAMS data can be used to calculate age-specific incidence of 
dementia, an essential ingredient in making estimates of lifetime risk.  
Incidence rates in large age categories (below 80, 80 to 89, and 90+) have been 
published in a prior study (Plassman et al. 2011). In that study, incidence was measured 
as follows. First, the number of incident cases in the ADAMS sample, by age group, was 
counted. This number was converted to a comparable figure for the U.S. population using 
the sampling weights. Then, the number of person-years at risk for each ADAMS subject, 
by age group, was determined as the number of years from the first ADAMS assessment 
to the first of the following events: (1) dementia onset, (2) death, or (3) completion of the 
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final ADAMS assessment. Finally, the number of person-years at risk in the sample was 
converted to a comparable figure for the population using the sampling weights, and the 
number of new cases in the population was divided by the number of person-years at risk 
in the population (Plassman et al. 2011). Mortality rates were not specifically reported in 
that study. 
Mortality data for the current investigation come from ADAMS’ link to the 
Health and Retirement Study’s mortality tracking via the National Death Index (NDI), 
which provides vital status and, if deceased, month of death, as of December 2011. The 
856 ADAMS subjects constitute the individuals at risk of mortality. I use the mortality 
data to generate estimates of the age-specific ratio of mortality rates between those with 
and those without dementia. Mortality rates for the entire U.S. population come from the 
Social Security Administration (SSA) cohort life tables (Bell & Miller 2005). 
 
Demographic methods 
 In a stationary population subject to a given life table, any two parameters among 
disease incidence, prevalence, and differential mortality between those with and those 
without the disease imply the third parameter (Preston, Heuveline, and Guillot 2001, 
chapter 4). The ADAMS data allow for the estimation of all three parameters, as 
discussed above; they therefore enable one to assess the stationary population 
assumptions of the constancy of age-specific incidence rates and differential mortality 
over time. Alternatively, if there is a strong basis for assuming the constancy of rates, one 
can use estimates of two of the parameters along with the assumption of constancy of 
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rates to derive the third parameter. I will use ADAMS incidence and prevalence estimates 
and the assumption of stationarity to derive an estimate of differential mortality and to 
estimate lifetime risk of dementia. Then I will relax the assumption of stationarity and 
estimate differential mortality directly from the ADAMS data, producing a second set of 
lifetime-risk estimates. 
In the context of ADAMS and dementia, differential mortality is the parameter 
about which there is least agreement in the literature on age patterns and functional form 
(Guehne, Riedel-Heller, & Angermeyer 2005). Existing estimates of the ratio of mortality 
among women age 75 to 84 with dementia to mortality among same-age women without 
dementia vary from 4.07 in Canada (Ostbye, Hill, & Steenhuis 1999) to 2.59 in Spain 
(Villarejo et al. 2011). Although this ratio is consistently found to decline with age, the 
pace of decline varies widely across studies (James et al. 2014; Ostbye et al. 1999; 
Tschanz, Corcoran, & Skoog 2004; Villarejo et al. 2011), making estimates of the age 
pattern of differential mortality subject to strong parametric assumptions. The ADAMS 
team has published estimates of age-specific prevalence and incidence to which I can 
benchmark my own estimates (Plassman et al. 2007, 2011), but no comparable ADAMS-
based estimates of differential mortality exist.  
In this study, where ADAMS data go to 2009 and mortality data go to 2011, an 
additional challenge in estimating differential mortality relates to censoring. Individuals’ 
dementia status is known as of their last ADAMS assessment, but mortality follow-up 
continues for several additional years, during which time new cases of dementia go 
unobserved. Thus the question arises of when to censor individuals whose last ADAMS 
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assessment categorized them as without dementia. If one follows them as long as the 
mortality follow-up allows, one will misclassify many deaths as deaths without dementia. 
If one censors these individuals too early, one under-counts deaths and person-years 
without dementia. In either case, the distortions to the estimated differential mortality are 
potentially severe. The results will show that estimated differential mortality has the 
largest standard error among the three parameters, and given underlying questions about 
functional form and the censoring of individuals not diagnosed with dementia, it is likely 
that standard errors of estimates of differential mortality do not capture all the uncertainty 
associated with those estimates. 
The difficulties in directly estimating differential mortality motivate the use of the 
stationarity assumption of constancy of rates, and there is considerable evidence 
suggesting that age-specific dementia incidence has been constant over the last decades 
(Asgharian, Wolfson, & Zhang 2006; Ewbank 2004; Rocca et al. 2011). Since my 
estimates cover only ages 70 and above, the time interval during which I would assume 
constancy of incidence rates is relatively short. Given the evidence for stationarity and 
the difficulties directly estimating relative risks of death, I will begin with a method that 
assumes that age-specific dementia incidence and differential mortality have been 
constant over time, deriving differential mortality from stationary-population relations 
rather than estimating it directly.  
Other studies do find declines over time in prevalence of moderate or severe 
cognitive impairment (Langa et al. 2008; Manton & Ukraintseva 2005). Declines in 
prevalence could be consistent with constant incidence if average duration of dementia 
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declines, but these contrary findings provide some evidence against the stationarity 
assumption. I will therefore conduct additional analyses using differential mortality I 
estimate directly from the ADAMS data – despite the limitations of such estimation – and 
not assuming a stationary population. Comparing the prevalence estimated at baseline in 
ADAMS to that implied by my estimated incidence and differential mortality provides an 
informal test of the stationarity assumptions: if the two prevalence series are concordant, 
then the incidence and differential mortality that gave rise to baseline prevalence closely 
aligns with the incidence and differential mortality observed longitudinally. 
 
Approach 1: Assume constancy of incidence rates over time (stationary-population 
approach) 
Because of the small sample size in ADAMS, I fit simple models to generate 
smooth age patterns of dementia prevalence (P) and incidence (h): 
 𝑙𝑜𝑔𝑖𝑡(𝑃𝑥) = 𝛼 + 𝛽𝑥, [1] 
 𝑙𝑜𝑔𝑖𝑡(ℎ𝑥) = 𝛼′ + 𝛽′𝑥,    [2] 
where x is exact age. This model broadly conforms to the functional form of the age 
pattern of Alzheimer’s disease rates, and Alzheimer’s prevalence and incidence rates 
have been shown to have similar functional forms (Brookmeyer & Gray 2000; 
Brookmeyer et al. 2011; Ziegler-Graham, Brookmeyer, Johnson, & Arrighi 2008). For 
prevalence, I fit the model using logistic regression on the baseline ADAMS sample 
(n=856). Baseline age was provided in completed years (“last birthday”), so exact age (x) 
was the reported age plus 0.5. 
45 
 
For incidence, I fit the model using a discrete-time logistic regression on a person-
year data file (Allison 1984), using the 456 subjects followed longitudinally. Age of 
dementia onset was reported in completed years, so, for incident cases, the exact age at 
incidence was set at the reported age (last-birthday) of onset plus 0.5. Subjects who never 
received a diagnosis of dementia from ADAMS investigators, including those who died 
without a dementia diagnosis, were censored. Among the censored subjects, those whose 
status at the end of the ADAMS study period was “alive, dementia-free” contributed 
dementia-free person-years up to and including their exact age (in months) at their last 
assessment. Censored subjects whose status at the end of ADAMS was “died without 
dementia” contributed dementia-free person years until their exact age at death. For 
example, if a subject’s status at the end of ADAMS was “died without dementia,” and 
she died at age 78 and 5 months, then she contributed person-years of exposure until she 
was 78.41666. Her death would be assigned to the interval between exact ages 78.0 and 
79.0. The approach of carrying the last assessment of deceased individuals forward until 
death is consistent with previous ADAMS reports (Plassman et al. 2011) and 
recommendations based on simulations of censored time-to-dementia data (Leffondré, 
Touraine, Helmer, & Joly 2013). It is based on the idea that if the deceased individuals 
had survived and developed dementia, the investigators could have been able to observe 
their dementia onset; decedents were therefore at risk of dementia onset until their deaths. 
A sensitivity analysis will treat these two forms of censoring – death without dementia 
and survival without dementia to the end of the study period – in a more consistent 
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fashion by censoring surviving dementia-free subjects at the end of the ADAMS study 
period rather than at their last assessment. 
There is considerable evidence in the literature suggesting that age-specific 
incidence rates of dementia do not vary by sex (Chêne et al. 2015; Plassman et al. 2011; 
Ruitenberg, Ott, & Swieten 2001). When a sex term was included in Equation 2, its 
coefficient was statistically insignificant (p>0.20). 
Call the fitted prevalence vector (𝑛𝑃𝑥), and the incidence vector (𝑛ℎ𝑥); these are 
the same for males and females. The 1920 birth cohort would have been aged 81 to 88 
over the study period of ADAMS, making this cohort’s life table a good approximation 
of the overall level of mortality in the population the ADAMS cohort represents. The 
SSA life table for this cohort provides mortality rates (𝑛𝑚𝑥), survivors to exact age x 
(𝑙𝑥), and person-years lived in each age interval in the entire population (𝑛𝐿𝑥); these 
values are sex-specific. In other words, the level of mortality varies by sex, which will 
generate sex-specific estimates of lifetime risk, but the other input quantities are constant 
across sex. Employing the Sullivan method (Mathers & Robine 1997; Sullivan 1971) and 
using single-year age intervals, the number of person-years lived without and with 
dementia, respectively, in the age interval (x, x+1) are: 
 𝐿1 𝑥
𝐷𝐹 = 𝐿1 𝑥(1 − 𝑃𝑥1 ⁡) [3] 
 𝐿1 𝑥
𝐷 = 𝐿1 𝑥 ∗ 𝑃𝑥1 . [4] 
The assumptions of stationarity are sufficient for the Sullivan method to generate 
unbiased and consistent estimates of person-years lived in each state (Imai & Soneji 
47 
 
2007). Taking 𝑙70 as the radix for the entire population, I estimate the population with 
dementia at exact age 70 as  
 𝑙70
𝐷 = 𝑙70 ∗ 𝑃70.0 [5] 
and dementia-free (DF) population as 
 𝑙70
𝐷𝐹 = 𝑙70 ∗ (1 − 𝑃70.0). [6] 
I fill the life table as follows, assuming events occur on average halfway through 
intervals. For survivors: 
 𝑙𝑥+1
𝐷 = (2 ∗ 𝐿1 𝑥
𝐷) − 𝑙𝑥
𝐷 , [7] 
 𝑙𝑥+1
𝐷𝐹 = (2 ∗ 𝐿1 𝑥
𝐷𝐹) − 𝑙𝑥
𝐷𝐹. [8] 
The number of new dementia cases is 
 𝑑𝑥
𝐷𝐹
1
𝑑𝑒𝑚 = 𝐿1 𝑥
𝐷𝐹 ∗ ℎ1 𝑥. [9] 
In Approach 1, I assume that individuals do not develop dementia and die in the same 
single-year age interval. Therefore, the number of deaths from the dementia-free 
population is 
 𝑑𝑥
𝐷𝐹 = 𝑙𝑥
𝐷𝐹 − 𝑙𝑥+1
𝐷𝐹 − 𝑑𝑥
𝐷𝐹
1
𝑑𝑒𝑚
1
𝑑𝑒𝑎𝑡ℎ . [10] 
The death rate among the dementia-free population is 
 𝑚𝑥
𝐷𝐹 =
𝑑𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ
𝐿1 𝑥
𝐷𝐹⁄1
𝑑𝑒𝑎𝑡ℎ . [11] 
To derive the death rate among those with dementia, I first decompose the 
mortality rate in the entire population into a weighted average of the mortality rates of the 
population with and the population without dementia, where the weights are the 
prevalence of dementia and its complement: 
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 𝑚1 𝑥 = 𝑚1 𝑥
𝐷 ∗ 𝑃𝑥1 + 𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ ∗ (1 − 𝑃𝑥1 ), [12] 
which can be rearranged as 
 𝑚1 𝑥
𝐷 =
[ 𝑚1 𝑥 − 𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ ∗ (1 − 𝑃𝑥1 )]
𝑃𝑥1
⁄ . [13] 
Then the ratio of mortality rates (with dementia vs. without dementia) as implied by the 
prevalence, incidence, and stationary population assumption is  
 𝑅𝑅𝑥1 =
𝑚1 𝑥
𝐷
𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ . [14] 
The primary quantity of interest is the lifetime risk of dementia for an age-a person 
without dementia: 
 𝐿𝐹𝑇𝑀𝑎 =
Σ𝑥=𝑎
𝑤 𝑑𝑥
𝐷𝐹
1
𝑑𝑒𝑚
𝑙𝑎𝐷𝐹
⁄ , [15] 
where w is the highest age interval. Also of interest is dementia-free life expectancy, the 
average number of years a randomly chosen person age a can expect to live free of 
dementia, under current rates: 
 𝐷𝐹𝐿𝐸𝑎 =
Σ𝑥=𝑎
𝑤 𝐿1 𝑥
𝐷𝐹
𝑙𝑎
⁄ . [16] 
Total life expectancy is as in a single-decrement life table: 
 𝐿𝐸𝑎 =
Σ𝑥=𝑎
𝑤 𝐿1 𝑥
𝑙𝑎
⁄ , [17] 
and by construction, unconditional life expectancy with dementia – that is, the average 
number of years an age-a person randomly chosen from the population can expect to live 
with dementia, under current rates, is 
 𝐷𝐿𝐸𝑎 = 𝐿𝐸𝑎 −𝐷𝐹𝐿𝐸𝑎. [18] 
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We can also define conditional life expectancy without dementia as the average number 
of years a dementia-free person of a given age can expect to live free of dementia: 
 𝐷𝐹𝐿𝐸𝑎
′ =⁡
Σ𝑥=𝑎
𝑤 𝐿1 𝑥
𝐷𝐹
𝑙𝑎𝐷𝐹
⁄ .⁡ [19] 
This quantity is valuable because the number of dementia-free person-years lived above 
age a for someone who already has dementia at age a is zero, and the people contributing 
these zeros are counted in the denominator of Equation 16; they are not counted in the 
denominator of Equation 19. The conditional DFLE is estimable using this method 
because all person-years lived in a dementia-free state above age a are experienced by 
people who were dementia-free at age a; the numerator and denominator therefore match. 
In contrast, (Σ𝑥=𝑎
𝑤 𝐿1 𝑥
𝐷) 𝑙𝑎
𝐷𝐹⁄  is not equal to the average number of years a dementia-free 
person age a can expect to live with dementia, because some of the person-years lived 
with dementia above age a – years contributing to the numerator – are experienced by 
people who already had dementia at age a and who thus do not contribute to the 
denominator. 
 
Approach 2: No assumption of stationarity; estimate differential mortality directly from 
ADAMS data 
Disease prevalence at a point in time embodies a history of disease incidence and 
differential mortality. Therefore, age-specific prevalence and incidence estimated in a 
stationary population – that is, one in which incidence and differential mortality have not 
changed over time – imply a unique pattern of differential mortality. If the population is 
non-stationary, then past incidence and differential mortality embodied in current 
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prevalence estimates do not necessarily convey information about current incidence and 
differential mortality. 
To estimate a current age pattern of differential mortality directly from the 
ADAMS data, without assuming the population is stationary, I use a Gompertz-type 
model of death rates as a function of an indicator for dementia presence, exact age x, and 
their interaction, fit with a Poisson regression on a person-year data file (Loomis 2005). 
Dementia status is modeled as a time-varying indicator to incorporate both baseline 
prevalent cases and incident cases (Palloni & Thomas 2013). The model is:  
 ln(𝑚𝑥,𝑑𝑒𝑚) = 𝛼 + 𝛽1𝑥 + 𝛽2𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎 + 𝛽3𝑥 ∗ 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎. [20] 
As with the estimation of dementia incidence discussed above, subjects who died 
without a dementia diagnosis during the ADAMS study period contribute dementia-free 
person years until their exact age at death, and subjects who survived ADAMS without a 
dementia diagnosis contributed dementia-free person years until their last ADAMS 
assessment. Mortality data for the period after ADAMS (2009 to 2011) was used only for 
those with a dementia diagnosis, whose state could not change until death. Not using 
mortality data from the post-ADAMS period for individuals without a dementia diagnosis 
avoids large misclassification errors whereby persons who develop dementia subsequent 
to ADAMS would wrongly contribute deaths without dementia and person-years without 
dementia to the calculations.  
Based on Equation 20, the ratio of the mortality rate among persons with 
dementia to that among persons without dementia – also known as the risk ratio, rate 
ratio, or relative risk (RR) – is  
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 𝑅𝑅𝑥 =
exp⁡(𝛼 + 𝛽1𝑥 + 𝛽2 + 𝛽3𝑥)
exp⁡(𝛼 + 𝛽1𝑥)
⁄ = exp⁡(𝛽2 + 𝛽3𝑥). [21] 
In this way, the ratio of the two mortality rates is estimated from the ADAMS sample, 
but the actual values of the mortality rates can be adjusted to match national data with 
many more deaths using the SSA 1920 cohort life tables. Consistent with most of the 
literature, the ratio of mortality rates between those with and those without dementia were 
held constant across sex (Agüero-Torres, Fratiglioni, & Guo 1999; Garcia-Ptacek et al. 
2014; Johnson, Brookmeyer, & Ziegler-Graham 2007; Lönnroos, Kyyrönen, Bell, van 
der Cammen, & Hartikainen 2013; Meller, Fichter, & Schroppel 1999; Villarejo et al. 
2011; Witthaus, Ott, Barendregt, Breteler, & Bonneux 1999). When a sex term and a sex-
by-dementia-status interaction term were included in Equation 2, the coefficient on the 
sex-by-dementia term was not statistically significant (p>0.30), providing additional 
justification for keeping differential mortality constant across sex. As with the modeling 
of incidence rates, pooling males and females to estimate differential mortality is useful 
with a small sample size such as in ADAMS. In this model, the only quantity that 
differed by sex was the overall level of age-specific mortality in the entire U.S. 
population. 
 The inclusion of the interaction term with the coefficient β3 implies that the 
excess risk of death associated with having dementia declines (assuming β3 is negative) 
with age (Helmer, Joly, Letenneur, Commenges, & Dartigues 2001). This decline arises 
from two related but distinct forces. The first is the aging of all the individuals in the 
cohort: as the underlying risk of death rises with age for everyone, the excess risk of 
death associated with dementia declines. The second force is heterogeneity in frailty 
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within each group (Vaupel, Manton, & Stallard 1979). Heterogeneity within population 
groups selects out the frailest individuals first. This force acts more strongly on the 
higher-mortality group (people with dementia), leaving heartier individuals remaining. In 
the context of dementia, heterogeneity could arise from changes with age in the average 
duration of dementia or changes in the prevalence of the APOE e4 allele in the dementia 
population relative to that in the non-dementia population (Ewbank 2004). This process is 
similar to the consistent finding of black-white mortality differentials, which decline at 
older ages (Eberstein, Nam, & Heyman 2008).  
In a sensitivity analysis, subjects who survived ADAMS without a dementia 
diagnosis were censored at the end of the ADAMS observation period, rather than at their 
last ADAMS assessment, in parallel with the sensitivity analysis for incidence estimates. 
By increasing the number of person-years lived without dementia and not changing the 
number of deaths without dementia, the sensitivity analysis will reduce the estimated 
mortality rate among the non-dementia population, raising the estimated mortality rate 
ratio. 
For a given age, the mortality rate for the entire population can be decomposed 
into a weighted average of mortality rates of the diseased and disease-free populations, 
weighted by the age-specific prevalence of the disease, as in Equations 12 to 14 above: 
 𝑚1 𝑥 = 𝑚1 𝑥
𝐷 ∗ 𝑃𝑥1 + 𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ ∗ (1 − 𝑃𝑥1 ) 
 = 𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ ∗ 𝑅𝑅𝑥1 ∗ 𝑃𝑥1 + 𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ ∗ (1 − 𝑃𝑥1 ). [22] 
The terms can be rearranged to solve for the mortality rate in the dementia-free 
population: 
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 𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ =
𝑚1 𝑥
( 𝑃𝑥1 ∗ 𝑅𝑅𝑥1 + 1 − 𝑃𝑥1 )
⁄  [23] 
and in the population with dementia: 
 𝑚1 𝑥
𝐷 = 𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ ∗ 𝑅𝑅𝑥1 , [24] 
where the overall mortality rate vector 𝑚1 𝑥 comes from the SSA life table, the age-
specific prevalence is described below (see Equation 39), and the mortality rate ratio 
(𝑅𝑅𝑥) is as above in Equation 21.  
 I then construct a multiple-decrement life table for the population without 
dementia, incorporating elements of the increment-decrement life table to keep track of a 
model population with dementia (Preston, Heuveline, & Guillot 2001). As with Approach 
1, I use single-year age groups and assume no recovery from dementia. The overall rate 
of decrement from the dementia-free population is the dementia incidence rate, which 
comes from Equation 2, plus the mortality rate for the dementia-free population: 
 𝑚1 𝑥
𝐷𝐹 = 𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ + ℎ𝑥1 , [25] 
and the probability of exiting the dementia-free population at a given age, assuming 
decrements occur on average halfway through each age interval, is 
 𝑞1 𝑥
𝐷𝐹 =
𝑚1 𝑥
𝐷𝐹
(1 + 0.5 𝑚1 𝑥
𝐷𝐹)
⁄ . [26] 
The probabilities of exiting the dementia-free population as a result of dementia onset or 
death, respectively, are: 
 𝑞𝑥
𝐷𝐹
1
𝐷𝑒𝑚 = 𝑞1 𝑥
𝐷𝐹 ∗ (
𝑖𝑛𝑐𝑖𝑥1
𝑚1 𝑥
𝐷𝐹⁄ ), [27] 
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 𝑞𝑥
𝐷𝐹
1
𝐷𝑒𝑎𝑡ℎ = 𝑞1 𝑥
𝐷𝐹 ∗ (
𝑚𝑥
𝐷𝐹
1
𝑑𝑒𝑎𝑡ℎ
𝑚1 𝑥
𝐷𝐹⁄ ). [28] 
Define 𝑙𝑥
𝐷𝐹 as the number of dementia-free survivors to the xth birthday, so that the 
number of exits from the dementia-free population, by type of exit, is 
 𝑑𝑥
𝐷𝐹
1
𝑖 = 𝑙𝑥
𝐷𝐹 ∗ 𝑞𝑥
𝐷𝐹
1
𝑖 , 𝑖 = 𝐷𝑒𝑚,𝐷𝑒𝑎𝑡ℎ. [29] 
The number of dementia-free survivors to the next age is 
 𝑙𝑥+1
𝐷𝐹 = 𝑙𝑥
𝐷𝐹 − 𝑑𝑥
𝐷𝐹
1
𝐷𝑒𝑚 − 𝑑𝑥
𝐷𝐹
1
𝐷𝑒𝑎𝑡ℎ . [30] 
For an approximation of the prevalence of dementia at age 70, I use the fitted 
value of prevalence for age 70.0 from Equation 1 in the life table, obtaining 𝑙70
𝐷𝐹 as in 
Equation 6. After age 70, the population with dementia is tracked as follows. The only 
way to exit the population with dementia is death, so the probability of death with 
dementia is 
 𝑞1 𝑥
𝐷 = 𝑞𝑥
𝐷 =
𝑚1 𝑥
𝐷
(1 + 0.5 𝑚1 𝑥
𝐷)
⁄1
𝐷𝑒𝑎𝑡ℎ . [31] 
The size of the population reaching the xth birthday with dementia is defined as 𝑙𝑥
𝐷, so the 
number of deaths is  
 𝑑𝑥
𝐷 = 𝑙𝑥
𝐷
1
𝐷𝑒𝑎𝑡ℎ ∗ 𝑞𝑥
𝐷
1
𝐷𝑒𝑎𝑡ℎ  [32] 
However, those who develop dementia while age x are subject to the risk of death 𝑚𝑥
𝐷 
once they develop dementia. If they develop dementia halfway through the age interval 
on average, then the probability of death with dementia for these new cases in that 
interval is 
 𝑞𝑥
𝐷 =
𝑚1 𝑥
𝐷
(2 + 0.5 𝑚1 𝑥
𝐷)
⁄𝑛𝑒𝑤
𝐷𝑒𝑎𝑡ℎ  [33] 
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and the number of deaths among new dementia cases is 
 𝑑𝑥
𝐷 = 𝑑𝑥
𝐷𝐹
1
𝐷𝑒𝑚 ∗ 𝑞𝑥
𝐷 .𝑛𝑒𝑤
𝐷𝑒𝑎𝑡ℎ
𝑛𝑒𝑤
𝐷𝑒𝑎𝑡ℎ  [34] 
The size of the population with dementia at the subsequent (exact) age is 
 𝑙𝑥+1
𝐷 = 𝑙𝑥
𝐷 + 𝑑𝑥
𝐷𝐹
1
𝐷𝑒𝑚 − 𝑑𝑥
𝐷
1
𝐷𝑒𝑎𝑡ℎ − 𝑑𝑥
𝐷
𝑛𝑒𝑤
𝐷𝑒𝑎𝑡ℎ . [35] 
Person-years lived in the dementia-free state are calculated assuming exits occur linearly 
within age intervals: 
 𝐿1 𝑥
𝐷𝐹 = 𝑙𝑥+1
𝐷𝐹 + 0.5(𝑙𝑥
𝐷𝐹 − 𝑙𝑥+1
𝐷𝐹 ). [36] 
Person-years lived in a state of dementia are simply 
 𝐿1 𝑥
𝐷 = 𝐿1 𝑥 − 𝐿1 𝑥
𝐷𝐹 . [37] 
Filling in the table for the subsequent age (x+1) requires an approximation of the 
proportion of survivors with dementia in the middle of the age (x+1, x+2) interval, 
because the mortality rates in Equations 22-24 pertain to age intervals rather than exact 
ages. My approximation again uses the assumption that the number of survivors declines 
linearly over each one-year interval. I assume that half the attrition recorded from exact 
ages x to x+1 will occur from exact age x+1 to the middle of the (x+1, x+2) interval. I 
denote approximated number of persons in state i in the middle of the age (x+1, x+2) 
interval as 1?̂?𝑥+1
𝑖 , while I assume that the L column for the entire population (from 
SSA) records all survivors in the middle of the given age interval: 
 
1?̂?𝑥+1
𝐷 = 𝐿1 𝑥+1 − ?̂?1 𝑥+1
𝐷𝐹 = 𝐿1 𝑥+1 − [𝑙𝑥+1
𝐷𝐹 − 0.5(𝑙𝑥
𝐷𝐹 − 𝑙𝑥+1
𝐷𝐹 )]
= 𝐿1 𝑥+1 − [1.5𝑙𝑥+1
𝐷𝐹 − 0.5𝑙𝑥
𝐷𝐹].
 [38] 
Prevalence of dementia at the subsequent age is estimated as the proportion of mid-
interval survivors living in a state of dementia: 
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 𝑃𝑥+11 =
?̂?1 𝑥+1
𝐷
𝐿1 𝑥+1
⁄ , [39] 
which is used to solve for the mortality rate in the dementia-free population for the age 
x+1 interval, using Equations 22 and 23.  
Because I use narrow (one-year) age intervals, the resulting ?̂?𝑥
𝑖  columns from 
Equation 38 will be close to the 𝐿𝑥
𝑖  columns from Equations 36-37. (The similarity of 
the two columns is shown in Appendix A.2.4). The age schedule of prevalence as 
calculated in Equation 39 can be compared to that estimated in baseline ADAMS in 
Equation 1 as an informal test of stationarity, under the assumption that the model of 
differential mortality is correct.  
 Once the multiple-decrement life table is completed, the summary quantities of 
interest – lifetime risk of developing dementia, unconditional expectancies, and certain 
conditional expectancies – can be calculated as in Equations 15 through 19. 
 
Simulated reductions in mortality, and simulated delays or reductions in dementia 
incidence 
Approach 2, which does not assume the constancy of rates over time, lends itself 
to simulations of future lifetime risk based on changes in mortality or dementia incidence. 
To assess lifetime risk for younger, lower-mortality cohorts, a secondary analysis used 
values for 𝑚1 𝑥 from the 1940 cohort life tables from SSA. The results estimate lifetime 
risk using current incidence rates and mortality rate ratios as estimated in ADAMS, 
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isolating the role of declines in the overall level of mortality in changing lifetime risk of 
dementia. 
I also estimate the lifecycle effects of an intervention that delays the onset of 
dementia. I consider interventions that vary along two parameters: δ, the length of the 
delay of dementia onset in years, and π, the proportion of the population at risk for whom 
the intervention is effective. I model these interventions by splitting the model dementia-
free population into groups of size 𝑙70
𝐷𝐹(1 − 𝜋) and 𝑙70
𝐷𝐹(𝜋), subjecting the first group to 
the dementia incidence rates as modeled in Equation 2, and subjecting the second group 
to the dementia incidence rates as modeled by 
 𝑙𝑜𝑔𝑖𝑡(ℎ𝑥
′ ) = 𝛼 + 𝛽(𝑥 − 𝛿), [40] 
where δ is the number of years of delay of dementia onset induced by the intervention. 
This equation assigns what had been the age-70 incidence rate to age 70+ δ, what had 
been the age-71 incidence rate to age 71+ δ, and so forth.  
Another type of intervention would reduce the risk of dementia at every age, 
rather than delaying its onset. Such an intervention generates an incidence equation such 
as: 
 𝑙𝑜𝑔𝑖𝑡(ℎ𝑥
′′) = 𝛼 + (𝛽𝑘)𝑥, [41] 
where k is a value between 0 and 1 that represents the extent to which dementia incidence 
rises less steeply with age due to the intervention. The closer k is to zero, the more 
effective is the intervention in the sense of reducing the acceleration of dementia 
incidence. I simulate an intervention where k = 0.9, to reduce the (logit of) acceleration of 
dementia incidence with age by 10%. 
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Both the dementia-free and with-dementia populations are subject to the same 
mortality rates as before (Equations 23-24); the changing sizes of these two populations 
resulting from the simulated intervention are assumed to change the overall mortality rate 
(Equation 12).  
 
Estimation of standard errors and confidence intervals 
 To generate standard errors and confidence intervals around the lifetime-
probability and life expectancy estimates, I considered as stochastic the parameter 
estimates generating the age-specific dementia incidence schedules (the fitted values of 
[α’ β’] in Equation 2) and either prevalence (for Approach 1 – the fitted values of [α β] 
in Equation 1) or differential mortality (for Approach 2 – the fitted values for [α β1 β2 β3] 
in Equation 20). Total mortality, derived from the SSA cohort life tables, was treated as 
deterministic (i.e. having zero variance) (Abatih, Van Oyen, Bossuyt, & Bruckers 2008; 
Loukine, Waters, Choi, & Ellison 2012), and the life table assumptions, such as linearity 
of survival within age intervals, were also considered not to contribute any additional 
variance.  
For dementia incidence, I used the estimates of [α’ β’] in Equation 2, along with 
their associated variance-covariance matrix, as the parameters of a bivariate Normal 
distribution to draw 1,000 independent values of [α’ β’], generating 1,000 incidence 
schedules (Salomon, Mathers, Murray, & Ferguson 2001). Separately, I used an 
analogous procedure with the estimated parameters and variance-covariance matrix from 
Equation 1 or Equation 20 to generate 1,000 age schedules of prevalence (Approach 1) 
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or the mortality rate ratio between those with and those without dementia (Approach 2). 
Each incidence schedule was paired with one schedule of the second parameter 
(prevalence or mortality rate ratios) and run through the life table operations, producing 
1,000 lifetime-probability and expectancy estimates. In figures, the median of the 1,000 
estimates is shown as the point estimate, and the 2.5th and 97.5th percentiles are shown as 
the confidence bounds (Fishman 2015; Mooney 1997; Salomon et al. 2001). Tables show 
the means and standard errors (square roots of variances) of the 1,000 estimates. A 
deterministic result using the estimated parameters of incidence, prevalence, and 
differential mortality as fixed quantities will also be presented. 
 Parameters from Equations 1, 2, and 20 were estimated using Stata version 14 
(StataCorp, College Station, TX), using first-order Taylor Series linearization for 
variance estimation with the svy routine (Heeringa et al. 2009). Random sampling for the 
estimation of standard errors was conducted in R using the mvrnorm command in the 
MASS package (Venables & Ripley 2002), and life table operations were conducted 
using base R (R Core Team, Vienna, Austria). The HRS and ADAMS data are available 
to the public after a registration procedure (Health and Retirement Study 2013). 
 
2.3 RESULTS 
 There were 308 cases of dementia at baseline out of 856 unweighted sample 
members. All baseline sample members were at risk of death, generating 519 deaths in 
3,520 person-years at risk. Among the 456 individuals without dementia at baseline who 
were followed longitudinally, 106 developed dementia in 2,142 person-years at risk. The 
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estimates of the regression parameters in Equations 1, 2, and 20, along with the 
variance-covariance matrices used to sample the 1,000 simulated incidence, prevalence, 
and mortality rate-ratio schedules for the confidence intervals, are shown in Appendix 
A.2.1. 
Table 2-1 shows the estimated age schedule of dementia prevalence, which aligns 
closely with published estimates from ADAMS (Plassman et al. 2007), at 6.1% for age 
75, 22.7% for age 85, and 38.4% at age 90. The fitted age-specific dementia incidence 
rates are also shown in Table 1, with 16 new cases per 1,000 person-years at age 75, 37 
new cases per 1,000 person-years at age 85, and 56 to 86 new cases per 1,000 person-
years at ages 90-95. The incidence rates shown here are close to those from the previous 
ADAMS incidence study, which reported incidence rates of 18.9 (95% CI: 10.1, 27.8) 
new cases per 1,000 person-years for ages below 80, 42.2 (95% CI: 26.0, 58.5) for ages 
80 to 89, and 82.1 (95% CI: 39.9, 124.3) for ages 90 and above (Plassman et al. 2011). 
The small differences between the current incidence estimates and those from the prior 
study are attributable to the parametric model fit to the data in this study. 
The age pattern of mortality rate ratios shown in Table 2-1, showing a rapid 
decline in differential mortality with age, is largely consistent with that found in other, 
non-national and non-U.S. samples; however, as mentioned previously, the pace of 
decline of differential mortality with age varies widely in the literature (Guehne et al. 
2005; Ostbye et al. 1999; Tschanz et al. 2004; Villarejo et al. 2011). The estimated 
mortality rate ratio (RR) at age 70 of 13.3 is highly unreliable, as shown by its high 
standard error, arising from the low number of deaths at age 70; the true RR is probably 
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not quite that high. Since the prevalence of dementia is very low at age 70, results are not 
sensitive to the RR estimate at that age. The RR implied by estimated incidence, baseline 
prevalence, and the stationary population assumption is around 1 for ages above 85, 
which is plausible given the high level of mortality in the general population at those 
ages. The close correspondence between the point estimates using stochastic inputs 
(Table 2-1) and the deterministic estimates (Appendix Table A.2.2a), with the exception 
of the highly unreliable age-70 estimate of RR, suggest that the resampling strategy used 
to generate the stochastic estimates was on target. 
 Using Approach 1, Table 2-2 shows calculations of the various life table 
quantities of interest: total life expectancy, dementia-free life expectancy and life 
expectancy with dementia (for a randomly chosen person in the population), and, of most 
interest, the probability that a currently dementia-free person will develop dementia later 
in life. It also shows conditional dementia-free life expectancy (DFLE’) – dementia-free 
life expectancy for a dementia-free person at the given ages. About 23.7% (SE: 2.9%) of 
dementia-free 70 year old males are expected to develop dementia later in the course of 
life, compared to 31.8% (SE: 3.6%) of dementia-free females age 70. The lifetime 
probability remains roughly constant with age for males, meaning the force of dementia 
incidence increases about as quickly as the force of male mortality. For females, lifetime 
probability declines to 25.2% at age 95, indicating that the force of female mortality 
increases more quickly than the force of dementia incidence. Lifetime probability is 
higher for females than males because females have lower overall mortality, the only 
input that varies by sex. Appendix Table 2.2.2b again shows concordance between the 
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stochastic point estimates of expectancies and lifetime risk and the deterministic 
calculations. 
For both sexes at ages 70 to 85, the vast majority of remaining life for a randomly 
chosen person is expected to be dementia-free, as shown by the high ratio of DFLE to 
DLE at these ages. However, at the oldest ages, 90 and above, DFLE and DLE are about 
equal – with DLE even greater than DFLE at age 95 – because mortality, incidence, and 
prevalence are all high at these ages. Dementia-free life expectancy for a dementia-free 
person (DFLE’) is slightly higher than unconditional DFLE because the latter includes 
people with dementia, whose DFLE is zero. The gap between DFLE’ and DFLE widens 
with age because the prevalence of dementia rises with age.  
 Table 2-3 (with Appendix Table A.2.2c for deterministic quantities) shows the 
same quantities as Table 2-1 – prevalence, incidence, and the mortality rate ratio (RR) – 
but uses estimated incidence and RR to infer prevalence (i.e. Approach 2), rather than 
using estimated incidence and prevalence to infer RR. For all except the youngest and 
oldest ages, estimated RR is higher than that implied by stationary-population incidence 
and prevalence in Table 2-1. For example, 80-year-olds with dementia are estimated to 
die at 4.6 times the rate of 80-year-olds without dementia, whereas the stationary 
population implied a multiplier of just 1.8 times. A higher estimated RR implies a lower 
prevalence, also shown in Table 2-3, because exits from the population with dementia 
(relative to the population without) occur more quickly when RR is higher. Figure 2-1 
shows that the prevalence series implied by the estimated RRs is not even within the 
confidence bands of the prevalence from baseline ADAMS for ages 80 and above.  
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There are several possible explanations for the discordant results shown in Figure 
2-1. If the estimated RRs are correct, then the figure implies a departure from stationarity, 
i.e. a change in dementia incidence rates, such that the rates that produced baseline 
prevalence were higher than the rates observed longitudinally in ADAMS. Another 
possible, though less likely, departure from stationarity consistent with Figure 2-1 is that 
RR has increased over time, since a higher RR implies a lower prevalence. However, if 
we are confident that dementia incidence rates and differential mortality have not 
changed, then the figure implies a misspecification of the RR function (Equations 21-
22). A final possibility is that the discrepancy arises from differences in the ascertainment 
of dementia status between the baseline study and the longitudinal follow-up study. 
Although the assessments of subjects were similar across waves of ADAMS, the baseline 
study by definition did not have access to the results of prior dementia examinations by 
the ADAMS team. To obtain a cognitive history of the subject (that is, measures of 
cognition prior to the baseline examination), the baseline study used medical records and 
interviews of knowledgeable informants. These methods have high reliability and validity 
(Langa et al. 2005; Plassman et al. 2007), but they are not the same as observing the 
person’s cognitive performance in detail over time, as was done for the longitudinal 
ADAMS incidence sample.  
 When using the non-stationary approach, estimated lifetime risk of dementia is 
higher by about 3 to 5 percentage points than when using stationary population relations. 
For example, Table 2-4 (with Appendix Table A.2.2d for deterministic quantities) 
shows that at age 70, the lifetime risk for males without dementia was 26.9% and for 
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females 34.7%. However, there is considerable overlap in the confidence intervals around 
the estimated-RR and stationary-population estimates of lifetime risk (Figure 2-2), 
suggesting statistical concordance in the results of the two approaches. In other words, 
the lifetime-risk estimates shown in Table 2-2 are robust to the possible departures from 
stationarity implied by Figure 2-1. The higher estimate of differential mortality 
employed in Approach 2 means the competing risk of death without dementia is lower, 
raising lifetime risk of developing dementia.  
 Using the 1940 cohort life table rather than that of 1920 (with Approach 2) raises 
lifetime risk at all ages (Table 2-5). The increase is between 3 and 4 percentage points 
for both males and females. The probability that a dementia-free 70 year old male from 
this cohort develops dementia later in life is about 28.9%; for a dementia-free 70 year old 
female it is 34.9%. The increase in lifetime risk results from population-wide reductions 
in mortality between the two birth cohorts, reducing the competing risk of death and 
allowing a larger proportion of the population to survive to ages of high dementia 
incidence. The changes in the results based on the choice of an input life table do not 
negate the results for the older cohort, nor do they cast doubt on Approach 1, which 
requires only that incidence and differential mortality be constant over time. Rather, the 
1940 results simply illustrate that individuals in younger, lower-mortality cohorts face 
higher age-specific lifetime risks of dementia than individuals in older, higher-mortality 
cohorts. The percentage increase in lifetime risk across the two cohorts is larger for males 
than females because females have lower mortality than males to begin with (a larger 
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base leads to smaller percentage change), and/or because mortality declined less for 
females than for males between these two cohorts (Preston & Wang 2006). 
 Table 2-6 shows the lifetime-risk estimates under a series of alternative scenarios 
where dementia incidence is reduced, again using Approach 2. Appendix A.2.3 shows 
the age pattern of incidence under the alternative scenarios. In the first two scenarios, an 
intervention delays the risk of dementia by one year; in Scenario 1 the intervention 
affects 50% of dementia-free 70-year-olds, and in Scenario 2 it affects 90%. The 
estimates for Scenarios 1 and 2 in Table 2-6 indicate that this intervention would reduce 
lifetime risk at age 70 by only one to two percentage points, with similar reductions at 
older ages. The small difference between Scenarios 1 and 2 shows that the proportion of 
the age-70 population for which this intervention is effective has a small effect on 
lifetime risk estimates. Extending the reach from 50% to 90% of dementia-free 70-year-
olds reduces lifetime risk by less than one percentage point.  
A larger reduction in lifetime risk is achieved by an intervention that delays 
dementia onset by five years and reaches 50% of the dementia-free population age 70 
(Scenario 3) – now the reduction is 3.7 percentage points for males and 4.5 for females. If 
this five-year delay affected 90% of dementia-free 70 year olds (Scenario 4), it would 
reduce lifetime risk at age 70 by 6.7 percentage points for males and 8.1 percentage 
points for females, a 25% reduction in lifetime risk for males and a 23% reduction for 
females. Similar reductions in lifetime risk are achieved by an intervention that reduces 
the rate of acceleration of dementia incidence with age, as in Scenario 5. This 
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intervention achieves a 5.6 percentage-point reduction in lifetime risk for males and 7.1 
percentage-point reduction for females. 
 
Sensitivity analysis 
To test the sensitivity of the results to the choice of censoring subjects who 
survived ADAMS without dementia at their last assessment, a secondary analysis 
censored these subjects at the end of the ADAMS study period. This approach treats the 
two forms of not experiencing dementia onset – dying without developing dementia and 
surviving without developing dementia – in roughly the same way, following both groups 
until the end of ADAMS. This secondary approach increased the number of person-years 
at risk of death to 4,191 and the number of person-years at risk of dementia onset to 
2,350. Because this sensitivity analysis only changed the treatment of subjects who were 
not observed as having experienced either event (dementia onset or death), estimates both 
of dementia incidence rates and of the mortality rate among the dementia-free population 
are lower than in the main analysis. 
Appendix Table A.2.5a shows the estimated incidence rates under this 
alternative censoring strategy. They are in much less alignment than the main incidence 
rates (Table 2-1) with incidence rates previously published (Plassman et al. 2011). 
Furthermore, the relative risks implied by the incidence rates in Appendix Table 9 
suggest the unlikely result that, for those aged 85 to 95, individuals with dementia died at 
a lower rate than individuals without dementia. 
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A comparison of Appendix Table A.2.5b to Table 2-2 shows that lifetime risk of 
dementia is lower using the alternative censoring approach, by about 2 to 4 percentage 
points at younger ages and 5 to 6 percentage points at older ages. The lower incidence 
rates under this censoring strategy generate lower lifetime risks. Furthermore, the lower 
RR implied by imposing lower incidence rates on constant prevalence values raises 
competing risk of death without dementia.  
Appendix Table A.2.5c also uses this alternative method of censoring but uses 
Approach 2, not assuming a stationary population and estimating relative risks of death 
directly from the data. Directly-estimated relative risks of death are higher using this 
method of censoring than when using the original method of censoring (Table 2-3) 
because this method of censoring counts more person-years lived without dementia, 
reducing the estimated mortality rate in the population without dementia and raising the 
RR. Incidence is again lower than in the main approach to censoring, with the same 
incidence estimates as in Appendix Table A.2.5a. In Appendix Table A.2.5c, the low 
estimates of incidence combine with the high estimates of RR to produce implausibly low 
estimates of dementia prevalence at old ages. 
Lower incidence would imply lower lifetime risk of dementia than that estimated 
using the main approach to censoring, while higher RR would imply higher lifetime risk. 
Appendix Table A.2.5d shows that lifetime risk of dementia under this alternative 
censoring strategy is indeed lower than that estimated using the main censoring strategy 
(compare to Table 2-4), by about 2 to 4 percentage points for both sexes. Appendix 
Table A.2.5e is parallel to Table 2-5, showing results with Approach 2 (non-stationary 
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population) with the 1940 cohort life tables, but censoring those who survive ADAMS 
without dementia at the end of ADAMS rather than at their last assessment.  As with the 
main results, using the 1940 life table raises lifetime risk of dementia by reducing the 
competing risk of mortality at ages of low dementia incidence, surviving a larger fraction 
of the population into ages of higher dementia incidence rates. The increase in lifetime 
risk due to the transition from 1920 to 1940 cohort mortality is about 3 to 4 percentage 
points at each age, similar in magnitude to the increase when using the main censoring 
strategy.  
The discordance between the incidence rates in the sensitivity analysis and those 
in Plassman et al. 2011, and the implausibility of the implied RRs (Appendix Table 
A.2.5a) or the implied prevalence values (Appendix Table A.2.5c) cast doubt on the 
appropriateness of the censoring strategy employed in the sensitivity analysis and thus 
strengthen the validity of the approach taken in the main analysis. 
2.4 DISCUSSION 
 This study provides, to my knowledge, the first nationally representative estimates 
of the lifetime probability of developing dementia in the U.S. These estimates suggest 
that about 23% to 27% of dementia-free 70 year-old males and about 31% to 35% of 
dementia-free 70-year-old females in the 1920 birth cohort will develop (or have 
developed) dementia before they die. For the 1940 birth cohort, these estimates rise to 
about 31% for males and 37% for females. The expected number of years that a randomly 
chosen individual at age 70 could expect to live with dementia is only about one to 1.5 
years for males and two years for females, but given the high care needs of people with 
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dementia, this estimate still implies a large need for individuals and families to plan for a 
life stage with dementia. 
A recent study, known as Adult Changes in Thought (Tom et al. 2015), reported 
dementia-free life expectancy for dementia-free cohort members (what I call DFLE’) age 
70, estimating 14.3 years for males and 15.7 years for females. My estimates were 11.1 
years for males and 13.4 years for females (Table 2-2). The ACT population was clearly 
at lower baseline risk of mortality than the 1920 birth cohort in the U.S. as a whole, as the 
ACT cohort had a total life expectancy at age 70 of 16.0 years for males and 18.0 years 
for females, in contrast to the national cohort’s 12.3 and 15.3 years. Since the ACT 
cohort had much longer life expectancy overall, it is not surprising that it also had longer 
conditional dementia-free life expectancy.  
Another past study of an individual’s lifetime risk of dementia that incorporated a 
competing-risks framework used Framingham data from 1975-1995 (Seshadri et al. 
1997). It estimated that a dementia-free male age 65 had a 14.3% probability of 
developing dementia at some point in his remaining life, and a dementia-free female age 
65 had 21.7% probability of developing dementia at some point in her remaining life 
(Seshadri & Wolf 2007).  
There are several reasons why my estimates of the probability of developing 
dementia are considerably higher than the Framingham-based estimates. First, overall 
mortality during ADAMS was lower than overall mortality during Framingham. The age-
standardized mortality rate (ASMR) in the U.S. population age-65+ in 2005, the middle 
of the ADAMS study period, was 4,804 deaths per 100,000 person-years lived; this rate 
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was much lower than the ASMR in Massachusetts for age 65+ in 1985, the middle of 
Framingham’s study period, which was 5,679 deaths per 100,000 person-years lived 
(Centers for Disease Control and Prevention 2014). The comparison of the 1920 SSA 
cohort table to that of 1940 shows that lower mortality levels imply higher lifetime risks 
of dementia. Second, the mortality rate ratios I use could be higher than the differential 
mortality in the Framingham study, which was not specifically reported (Seshadri & 
Wolf 2007; Seshadri et al. 1997). A higher mortality rate ratio would reduce the 
competing risk of death without dementia and thus raise the estimated lifetime risk of 
developing dementia. Additionally, the authors of the Framingham study noted that 
because the Framingham sample was disproportionately white, it might not generalize to 
the U.S. population, due to known differences in incidence across racial and ethnic 
groups in the U.S. (Seshadri & Wolf 2007). ADAMS included a larger proportion of 
African American subjects, who are at higher risk of developing dementia at any given 
age (Plassman et al. 2011). Racial disparities in mortality also narrow with age (Eberstein 
et al. 2008; Preston, Elo, Rosenwaike, & Hill 1996). The higher incidence rates among 
African Americans could certainly contribute to higher estimates of lifetime risk of 
developing dementia. My estimates – especially those using the 1940 cohort life table 
from SSA – are closer to those estimated for a national sample from Canada, where the 
authors estimated that slightly over 40% of 70-year-olds in Canada would develop 
dementia before death (Carone et al. 2014).  
A recent simulation study using ADAMS and HRS found that an intervention that 
delayed the onset of Alzheimer’s Disease (AD) for five years would result in a 41% 
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lower prevalence of AD in 2050 among those aged 70+ than if onset had not been 
delayed (Zissimopoulos, Crimmins, & St.Clair 2014). Setting aside possible differences 
between AD and other dementias, a 41% decline in AD prevalence could be consistent 
with my estimate of a 25% decline in lifetime risk of dementia (Scenario 4 in Table 2-6), 
if the average duration of AD fell substantially as a result of the delayed onset of AD. In 
the literature, average duration of dementia among those who get it varies from 4.4 to 9.9 
years depending on the age of diagnosis (Treves & Korczyn 2012). Additionally, since 
the average duration of AD is longer than that of vascular dementia (Treves & Korczyn 
2012), an intervention reducing the duration of AD could have a larger effect on AD 
prevalence than an intervention reducing the duration of all types of dementia could have 
on all-dementia prevalence. Further research can use increment-decrement methods to 
estimate age-specific average duration of dementia under different possible interventions. 
There are several other possible explanations for the difference between the 
potential reduction in prevalence obtained in the aforementioned simulation study and the 
potential reduction in lifetime risk estimated here. First, the prior study used a model 
incorporating changes in risk factors for dementia and death across real (not synthetic) 
cohorts, whereas I just used age and sex and a national life table. Second, they assumed 
that any intervention would be effective for 100% of the population at risk, while I only 
allowed up to 90% effectiveness. Additionally, it is unclear how they operationalized a 
five-year delay in onset of AD. They might have done so as I did, pushing age-specific 
incidence rates back five years and “filling in” the younger ages with lower rates 
consistent with the functional form of the model age pattern of dementia incidence. But 
72 
 
they might have set incidence to zero in the first five years and then continued five years 
of age later with the initial set of rates. Or perhaps they reestimated a different equation 
entirely. If they used a different operationalization of a “five year delay in onset,” they 
could produce different results.  
Another direction for future research is the estimation of quantities associated 
with family members of persons with dementia, such as the risk of having a parent who 
develops dementia. The estimates of lifetime risk presented here imply that informal care 
givers will face an increasing burden in the near future (Kasper et al. 2015). Because of 
the generally advanced age of persons with dementia, spouses are often not available to 
provide care, with daughters picking up the lion’s share of the load (Friedman, Shih, 
Langa, & Hurd 2015). The lower parity of cohorts born in the 1940s and 1950s, relative 
to cohorts born in the 1920s and 1930s, implies that fewer aging Baby Boomers will have 
daughters who can take care of them than members of older generations have had 
(Human Fertility Database 2015). Research has found that middle-aged and young adults 
consistently underestimate their future need for personal care (Henning-Smith & Shippee 
2015; Kemper, Komisar, & Alecxih 2005; Spillman & Lubitz 2002). The results shown 
here suggest that a large fraction of current and near-future elderly will develop dementia 
in their lifetimes, even if treatments delaying or reducing dementia risk become 
widespread. 
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Table 2-1: Dementia Prevalence, Incidence, and Differential Mortality – Stationary 
Population Approach 
  Fitted prevalence & incidence Implied 
Age Prevalence (SE) Incidence (SE) RR (SE) 
70 0.030 (0.007) 0.010 (0.003) 13.313 (12.999) 
75 0.061 (0.009) 0.016 (0.003) 4.395 (2.107) 
80 0.121 (0.012) 0.024 (0.003) 1.846 (0.121) 
85 0.227 (0.022) 0.037 (0.005) 1.108 (0.300) 
90 0.384 (0.043) 0.056 (0.011) 1.024 (0.295) 
95 0.569 (0.061) 0.086 (0.023) 1.037 (0.271) 
100 0.734 (0.064) 0.130 (0.042) 1.259 (0.346) 
 
RR = Relative risk of death, with dementia vs. without dementia; SE = standard error. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social 
Security Administration life tables for 1920 birth cohort. Mortality by dementia status 
data from Health and Retirement Study (HRS), United States, 2001-2011.  
 
Parametric models were fitted to prevalence and incidence data to generate single-year 
age-specific estimates. RR was implied by the fitted prevalence and incidence estimates 
along with stationary-population relations. 
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Table 2-2: Life Cycle Quantities for Dementia – Stationary Approach 
 
A. Males 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 12.31 10.83 1.48 (0.129) 0.237 (0.029) 11.14 (0.119) 
75 9.65 8.04 1.61 (0.142) 0.233 (0.027) 8.53 (0.134) 
80 7.26 5.54 1.72 (0.162) 0.226 (0.032) 6.25 (0.143) 
85 5.20 3.43 1.76 (0.182) 0.215 (0.041) 4.37 (0.135) 
90 3.64 1.91 1.74 (0.187) 0.208 (0.052) 3.01 (0.109) 
95 2.61 0.96 1.64 (0.163) 0.213 (0.067) 2.15 (0.078) 
100 2.02 0.47 1.55 (0.123) 0.246 (0.089) 1.71 (0.039) 
 
B. Females 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 15.25 13.17 2.08 (0.190) 0.318 (0.036) 13.41 (0.191) 
75 11.91 9.77 2.14 (0.205) 0.304 (0.037) 10.19 (0.205) 
80 8.91 6.74 2.16 (0.227) 0.286 (0.044) 7.41 (0.209) 
85 6.37 4.25 2.12 (0.249) 0.267 (0.054) 5.17 (0.190) 
90 4.42 2.41 2.00 (0.251) 0.253 (0.067) 3.53 (0.149) 
95 3.10 1.26 1.83 (0.220) 0.252 (0.081) 2.47 (0.102) 
100 2.32 0.63 1.69 (0.167) 0.277 (0.102) 1.90 (0.061) 
 
LE = total life expectancy for a randomly chosen person in the population of given age, 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementia-
free person of given age. 
 
By construction, DFLE and DLE have the same standard error, and LE has zero variance. 
 
Quantities calculated using fitted values of dementia incidence and prevalence and 
implied relative risk of death (with dementia vs. without) shown in Table 1. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social 
Security Administration life tables for 1920 birth cohort. Mortality by dementia status 
data from Health and Retirement Study (HRS), United States, 2001-2011. 
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Table 2-3: Dementia prevalence, incidence, and differential mortality – non-
stationary approach 
  Implied   Estimated Estimated 
Age Prevalence (SE) Incidence (SE) RR (SE) 
70 0.030 (0.173) 0.010 (0.003) 8.86 (3.344) 
75 0.058 (0.241) 0.016 (0.003) 6.37 (1.761) 
80 0.093 (0.304) 0.024 (0.003) 4.63 (0.896) 
85 0.137 (0.371) 0.037 (0.005) 3.41 (0.513) 
90 0.196 (0.443) 0.056 (0.011) 2.54 (0.447) 
95 0.286 (0.535) 0.086 (0.023) 1.91 (0.479) 
100 0.453 (0.673) 0.130 (0.042) 1.48 (0.472) 
 
RR = Relative risk of death, with dementia vs. without dementia 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011.  
 
Parametric models were fitted to incidence and mortality data from ADAMS to generate 
single-year age-specific estimates. Prevalence in the cohort arises from the life table 
relations as described in the Methods section, under Approach 2. 
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Table 2-4: Life Cycle Quantities – Non-Stationary Approach 
A. Males 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 12.31 11.55 0.76 (0.220) 0.269 (0.032) 11.91 (0.190) 
75 9.65 8.90 0.75 (0.228) 0.271 (0.032) 9.35 (0.154) 
80 7.26 6.51 0.76 (0.223) 0.267 (0.036) 7.04 (0.123) 
85 5.20 4.47 0.73 (0.211) 0.257 (0.044) 5.04 (0.094) 
90 3.64 2.93 0.72 (0.200) 0.247 (0.056) 3.49 (0.080) 
95 2.61 1.85 0.76 (0.200) 0.244 (0.072) 2.43 (0.082) 
100 2.02 1.10 0.92 (0.207) 0.255 (0.091) 1.77 (0.084) 
 
B. Females 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 15.25 13.51 1.74 (0.292) 0.347 (0.037) 13.93 (0.278) 
75 11.91 10.21 1.69 (0.303) 0.341 (0.038) 10.88 (0.213) 
80 8.91 7.34 1.56 (0.300) 0.329 (0.043) 8.15 (0.172) 
85 6.37 4.99 1.38 (0.285) 0.312 (0.052) 5.84 (0.133) 
90 4.42 3.21 1.21 (0.262) 0.293 (0.064) 4.02 (0.101) 
95 3.10 1.97 1.12 (0.243) 0.281 (0.079) 2.76 (0.088) 
100 2.32 1.13 1.19 (0.228) 0.284 (0.097) 1.97 (0.086) 
 
LE = total life expectancy for a randomly chosen person in the population of given age. 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementia-
free person of given age. 
 
By construction, DFLE and DLE have the same standard error, and LE has zero variance. 
 
Quantities calculated using fitted values of dementia incidence and relative risk of death 
(with dementia vs. without) shown in Table 3.  
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011.  
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Table 2-5: Life Cycle Quantities Using 1940 Cohort Life Table – Non-Stationary 
Approach 
  
A. Males 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 13.64 12.54 1.10 (0.262) 0.308 (0.034) 12.93 (0.237) 
75 10.65 9.57 1.08 (0.272) 0.306 (0.035) 10.13 (0.192) 
80 7.96 6.93 1.03 (0.268) 0.298 (0.040) 7.59 (0.156) 
85 5.70 4.74 0.96 (0.253) 0.286 (0.049) 5.44 (0.121) 
90 4.05 3.13 0.93 (0.239) 0.276 (0.063) 3.82 (0.101) 
95 2.95 1.97 0.97 (0.233) 0.273 (0.080) 2.68 (0.098) 
100 2.30 1.15 1.14 (0.227) 0.285 (0.099) 1.96 (0.095) 
 
B. Females 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 15.99 14.01 1.97 (0.332) 0.374 (0.038) 14.44 (0.315) 
75 12.62 10.67 1.95 (0.343) 0.370 (0.041) 11.38 (0.252) 
80 9.57 7.73 1.84 (0.340) 0.359 (0.047) 8.62 (0.209) 
85 6.93 5.26 1.66 (0.324) 0.342 (0.057) 6.23 (0.166) 
90 4.89 3.40 1.49 (0.301) 0.325 (0.070) 4.35 (0.129) 
95 3.49 2.09 1.40 (0.277) 0.313 (0.087) 3.02 (0.109) 
100 2.63 1.18 1.46 (0.248) 0.316 (0.105) 2.16 (0.101) 
 
LE = total life expectancy for a randomly chosen person in the population of given age. 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementia-
free person of given age. 
 
By construction, DFLE and DLE have the same standard error, and LE has zero variance. 
 
Quantities calculated using fitted values of dementia incidence and relative risk of death 
(with dementia vs. without) shown in Table 3. Mortality rates for total population come 
from Social Security Administration, 1940 birth cohort life tables. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1940 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011.  
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Table 2-6: Lifetime risk of dementia under intervention scenarios – non-stationary approach 
 
A. Males 
  Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
Age Estimate SE Estimate SE  Estimate SE  Estimate SE Estimate SE  
70 0.261 (0.032) 0.255 (0.032) 0.232 (0.032) 0.202 (0.032) 0.213 (0.031) 
75 0.263 (0.031) 0.256 (0.031) 0.233 (0.029) 0.203 (0.028) 0.212 (0.028) 
80 0.259 (0.034) 0.253 (0.033) 0.229 (0.030) 0.199 (0.026) 0.205 (0.026) 
85 0.249 (0.042) 0.243 (0.041) 0.219 (0.035) 0.192 (0.029) 0.194 (0.029) 
90 0.240 (0.054) 0.234 (0.052) 0.209 (0.044) 0.184 (0.038) 0.181 (0.035) 
95 0.236 (0.069) 0.231 (0.068) 0.205 (0.057) 0.182 (0.051) 0.171 (0.043) 
100 0.247 (0.088) 0.242 (0.087) 0.213 (0.074) 0.193 (0.068) 0.170 (0.052) 
 
B. Females 
  Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
Age Estimate SE Estimate SE  Estimate SE  Estimate SE Estimate SE  
70 0.338 (0.036) 0.330 (0.036) 0.302 (0.035) 0.266 (0.034) 0.276 (0.034) 
75 0.331 (0.037) 0.324 (0.036) 0.296 (0.034) 0.260 (0.032) 0.268 (0.031) 
80 0.320 (0.042) 0.312 (0.041) 0.284 (0.036) 0.250 (0.032) 0.255 (0.031) 
85 0.303 (0.050) 0.296 (0.049) 0.268 (0.042) 0.236 (0.036) 0.237 (0.035) 
90 0.285 (0.062) 0.278 (0.060) 0.251 (0.052) 0.222 (0.045) 0.217 (0.041) 
95 0.273 (0.077) 0.267 (0.075) 0.239 (0.064) 0.214 (0.058) 0.200 (0.049) 
100 0.277 (0.094) 0.271 (0.093) 0.240 (0.080) 0.218 (0.074) 0.192 (0.057) 
Lifetime Risk = probability that a dementia-free person of given age will develop dementia later in life. Scenario 1: Dementia incidence delayed by 1 year, 
effective for 50% of dementia-free population age 70. Scenario 2: Dementia incidence delayed by 1 year, effective for 90% of dementia-free population age 70. 
Scenario 3: Dementia incidence delayed by 5 years, effective for 50% of dementia-free population age 70. 
Scenario 4: Dementia incidence delayed by 5 years, effective for 90% of dementia-free population age 70. Scenario 5: Acceleration of dementia incidence with 
age reduced by 10%. Original incidence shown in Table 3. 
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Figure 2-1: Baseline fitted prevalence vs. prevalence implied by non-stationary 
approach 
 
Notes: Baseline fitted prevalence from Aging, Demographics, and Memory Study 
(ADAMS) Wave A, United States, 2001-2003, n=856.  
Estimated relative risks of death, used in Non-Stationary Approach, are from ADAMS 
and Health and Retirement Study, longitudinal follow-up 2001-2011, n=856 with 519 
deaths. Prevalence implied by non-stationary approach arises from life table relations 
described in Methods section under Approach 2. 
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Figure 2-2: Lifetime risk of dementia, stationary approach vs. non-stationary 
approach 
A) Males 
 
B) Females 
 
Notes: Lifetime risk = probability that a dementia-free person will develop dementia later 
in life. Stationary approach used baseline dementia prevalence and longitudinal dementia 
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incidence along with life-table relations and 1920 U.S. birth cohort life tables. Non-
stationary approach used longitudinal dementia incidence and differential mortality 
estimates with the 1920 cohort life tables. 
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3 Incident diabetes and mobility limitations: reducing bias with risk-set matching 
3.1 INTRODUCTION 
Diabetes was estimated to account for $176B in annual medical costs and an 
additional $69B in lost productivity in the U.S. in 2012 (American Diabetes Association 
2013). Population aging, increased age-specific diabetes incidence, and improved 
survival among people with diabetes are projected to cause the prevalence of diabetes in 
the U.S. among adults to increase from about 12% in 2010 (Y. J. Cheng et al. 2013) to 
between 21% and 33% by 2050 (Boyle et al. 2010). If the strong cross-sectional 
association between diabetes and disability (Wong et al. 2013) persists in the future, that 
projected prevalence of diabetes implies a massive burden of disability and medical costs 
on individuals, businesses, and government. 
The cross-sectional associations between diabetes and physical functioning 
outcomes – the subject of most prior studies (Wong et al. 2013) – reflect causal pathways 
that can run in both directions: diabetes can cause mobility limitations and disability 
(Bianchi, Zuliani, & Volpato 2013), but mobility limitations among non-diabetic 
individuals can cause reductions in physical activity and other lifestyle changes that raise 
the risk of developing diabetes (Bardenheier et al. 2014). The latter pathway is a type of 
reverse causality that biases prevalence-based estimates of the association between 
diabetes and mobility limitations. Using incident, rather than prevalent, diabetes as the 
exposure of interest would reduce the strength of reverse causal pathways that plague 
previous studies of this topic. This paper will using risk-set matching, a type of 
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propensity score matching, to estimate the relationship between incident diabetes and 
subsequent mobility limitations, using data from the Health and Retirement Study (HRS). 
The inability of prevalence-based estimates to identify the time-ordering of 
covariates can also create bias due to confounding. In prevalence-based studies, including 
longitudinal studies of the association between baseline diabetes prevalence and 
subsequent functional limitations (Chiu & Wray 2011; Cigolle et al. 2011), the values of 
common control variables such as body mass index (BMI), income, and comorbidities 
could actually have resulted from, rather than contributed to, the person’s diabetes status 
(Bertoni & Goff 2011; Brown, Pagán, & Bastida 2005; Caruso, Silliman, Demissie, 
Greenfield, & Wagner 2000; C. Cheng et al. 2014). In estimating the association between 
prevalent diabetes and functional limitations, the investigator can either leave these 
covariates out of the model, raising the likelihood of confounding, or include them, 
running the risk of conditioning on a mediator. This study will provide a more accurate 
estimate of the relation between diabetes and functional limitation by controlling for 
factors known to precede diabetes diagnosis, including time-varying characteristics that 
change between baseline and diagnosis, and not for behaviors or conditions that follow it. 
Propensity-score methods are often preferred for reducing bias due to confounding 
(Rosenbaum & Rubin 1983; Rosenbaum 2010), and risk-set matching in particular is a 
preferred method for controlling for time-varying covariates when the exposure is time-
varying (Rosenbaum 2010). A propensity-score based assessment has not been applied in 
the study of the relationship between incident diabetes and mobility limitations. 
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3.2 METHODS 
Study population 
HRS is an ongoing longitudinal study representative of the U.S. population aged 
50 and older, with biennial interviews collecting data on health status, demographics, 
health behavior, health care use, income and wealth (Health and Retirement Study 2013). 
Details on HRS are reported elsewhere (Heeringa & Connor 1995). A standardized data 
file made available by the RAND corporation was used (RAND 2011), confined to the 
original HRS cohort, born 1931 to 1941, and the “War Babies” cohort, born 1942 to 
1947. The baseline observation for the original HRS cohort is 1992, and for the War 
Babies 1998. Each biennial interview of cohort members is called a wave and 
corresponds to a discrete date.  
Response rates in the initial wave of each cohort were calculated as the number 
who responded divided by the number of eligible sample members. For subsequent 
waves, response rates were defined as the number who responded divided by the number 
of initial-wave respondents still alive.  The original HRS cohort had an initial sample size 
(in 1992) of 12,652, representing an 81.6% overall response rate. Each subsequent wave 
had over an 85% response rate. The War Babies cohort had an initial sample size (in 
1998) of 2,529, for a 69.9% response rate. Response rates in subsequent waves were 
always at least 87% (Health and Retirement Study 2011). Spouses of target respondents 
were included in the sample by HRS; I excluded spouses whose actual birth cohort did 
not align with their survey cohort, e.g. a spouse born in 1948 who was included in the 
War Babies survey cohort. Individual respondent weights are provided for each year a 
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subject is observed to make each sample cohort representative of the U.S. population 
born during the given years.  
 There were 12,230 subjects in the appropriate survey and birth cohorts. 501 were 
excluded because they did not respond to the baseline survey (1992 for HRS, 1998 for 
War Babies) but had been added to the dataset later. An additional 1,094 subjects 
reported having diabetes at baseline. The 987 subjects who provided fewer than three 
survey responses over the course of the study period were excluded, and two additional 
subjects had zero values for sampling weights, indicating their responses were valid for 
individual-level analysis (Health and Retirement Study 2010). The analytic sample size 
was thus 9,646. Time between first and last observation averaged 14.7 years and ranged 
from 4 to 18 years.  
 
Measures 
Disability is a gap between personal capacity and environmental demand 
(Verbrugge & Jette 1994). Rather than being synonymous with diseases or impairments, 
disability is best viewed as a late stage in a pathway that begins with pathologies or 
diseases, such as diabetes, goes through impairments, such as neuropathy, then follows 
with functional limitations, such as pain or numbness in the lower extremities, and finally 
restrictions on a person’s ability to function in society, such as the inability to get from 
place to place. Impairments affect organs or systems in the body; functional limitations 
refer to basic bodily or mental actions irrespective of the social context; and participation 
restrictions are about the person’s interaction with society (Nagi 1976). The last category, 
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participation restrictions, is what the disabilities literature refers to as “disability” 
(Verbrugge & Jette 1994). Therefore, impairments and functional limitations are properly 
measured objectively, while disabilities are best understood subjectively. However, many 
activities, such as walking a specified distance or climbing stairs, the outcomes examined 
in this paper, fall on the boundaries between functional limitations and disabilities. 
 The outcome under study is lower-extremity mobility limitation, because of the 
biological link between diabetes and lower extremity impairments (Laditka & Laditka 
2006). HRS asks, “Because of a health or memory problem, do you have any 
difficulty…?”. The outcome variable can take values 0 through 5 because five lower-
extremity mobility activities were measured: walking one block, walking several blocks, 
walking across a room, climbing one flight of stairs, and climbing several flights of stairs. 
 Diabetes status is determined by self-reported diagnosis. HRS asks, “Has a doctor 
ever told you that you have diabetes or high blood sugar?”. Incident diabetes is defined as 
not reporting a diabetes diagnosis at one wave and reporting a diagnosis in the subsequent 
wave. An individual is considered to have diabetes for every wave subsequent to his/her 
initial report of diabetes diagnosis. There were 2,000 incident cases of diabetes during the 
years of data collection. The number of mobility limitations at the time of diagnosis is 
assumed to be the number of limitations at the last wave prior to diagnosis, to avoid 
possibly adjusting for limitations that follow from diabetes. A sensitivity analysis defined 
the number of mobility limitations at the time of diagnosis as the number of mobility 
limitations at the subject’s first report of a diagnosis. 
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 All covariates were self-reported. The following time-invariant covariates were 
used in the analysis: parents’ years of education, self-rated health in childhood, gender, 
race/ethnicity (white, black, Hispanic), whether foreign born, and own years of education. 
The time-varying covariates were: age, marital status, region of residence (Northeast, 
Midwest, South, West), health insurance, employment status, income, wealth, smoking 
(current, former, never), BMI (kg/m2), self-rated current health; the presence of high 
blood pressure, heart diseases, and arthritis; a history of stroke; and number of mobility 
limitations prior to diabetes diagnosis. A recent study showed that mobility limitations 
were associated with subsequent diabetes incidence, emphasizing the need to control for 
mobility limitations that precede it (Bardenheier et al. 2014). The rich set of 
socioeconomic variables, including parents’ education and total wealth, distinguish this 
study from most of the literature on this topic (Wong et al. 2013). 
Only four covariates had a large number of missing values: BMI (70 to 120 cases 
missing per wave), mother’s education (845 missing cases, time-invariant), father’s 
education (1,246 missing cases, time-invariant), and childhood health (355 missing cases, 
time-invariant – all individuals who were last observed in 1996). Missingness of a 
parent’s education variable is likely correlated with own education, race, and income, 
which are likely correlated with both diabetes onset and disability accumulation. Single 
random imputation was used to assign values of parents’ education to missing cases, 
under the assumption, known as “missing at random,” that whether parents’ education is 
missing is independent of its true value, conditional on observed variables. This is a much 
weaker assumption than the “missing completely at random” assumption employed by 
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other standard methods of dealing with missing data (Allison 2002). The parent’s 
education variable was regressed onto sociodemographic covariates (age, gender, 
race/ethnicity, nativity, education, region, income). The observations missing parent’s 
education take a value equal to the fitted value based on the regression plus a randomly 
generated error (Allison 2002).  
For the missing BMI values, linear interpolation was used to assign a value based 
on the values the individual supplies in other waves: If the subject’s BMI is 28 kg/m2 in 
1998 and 32 in 2002 and missing in 2000, their assigned BMI in 2000 is 30. All subjects 
had a valid baseline BMI value. Linear interpolation was unable to fill in BMI values for 
534 person-observations. The individuals missing values for childhood health were all 
last observed in 1996, before the question was asked. In other words, missingness of the 
childhood health variable is a function of attrition from the study.  Individuals last 
observed in 1996 were assigned the average childhood health value among individuals 
who died or were dropped from the study sample prior to 2010 but had nonmissing 
childhood health values; this average value was 1.80 with 1=best health, 5=worst health. 
All other covariates have fewer than 20 missing values per wave, negligible in a sample 
size of thousands.   
 
Matching method 
 When an exposure might occur at different times, risk-set matching can be used to 
ensure that exposed individuals – those who report incident diabetes – and control 
individuals look similar prior to exposure while avoiding matching on characteristics 
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occurring after exposure (Rosenbaum 2010; Sylvestre, Huszti, & Hanley 2006). By 
matching individuals with similar characteristics up to the time of diabetes diagnosis, 
risk-set matching ensures that exposed and control units have been observed for the same 
amount of time, respecting the temporal structure of the data and avoiding so-called 
“immortal time bias” (Sylvestre et al. 2006), in which assignment to exposed or control 
groups requires using information obtained after the exposure. This bias applies when 
treated units have a built-in health advantage because they must have survived up to the 
point of treatment, whereas control units could have died at any time, or, as in the case of 
this study, when control units have a built-in health advantage because they must have 
survived until the end of the study period without exposure (Rosenbaum 2010). 
A time-dependent propensity score was constructed using a discrete-time hazard 
model fit with logistic regression (Singer & Willett 1993). The propensity score is the 
predicted probability that the individual will develop diabetes in the given period, 
conditional on the values of the person’s covariates. The observation period for the 
estimation of the propensity scores extends from baseline until the individual develops 
diabetes or is censored, whichever comes first.  
Individuals are matched to minimize the total within-pair distance between 
exposed and control individuals, with “distance” defined as the rank-based Mahalanobis 
distance with a propensity-score caliper penalty function (Rosenbaum 2010; Silber et al. 
2009). The variables included in the calculation of the Mahalanobis distance were the 
time-invariant covariates, the time-varying covariates measured at the wave prior to 
initial report of diabetes, and baseline BMI and self-rated health. Matching based on the 
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Mahalanobis distance minimizes the total within-pair distance between the exposed 
group’s covariate matrix and the control group’s covariate matrix, while the propensity 
score-based penalty ensures that the distance between any two matched individuals 
within a single pair is not too large (Rosenbaum 2010). Covariate balance is assessed by 
comparing standardized exposed-control differences in covariates, with standardized 
differences below 0.1 considered good balance and below 0.2 considered acceptable 
(Rosenbaum & Rubin 1985; Silber et al. 2001), and with significance tests for differences 
in means. 
To be matched as an exposed unit, an individual needed to provide complete data 
– a full vector of independent variables and diabetes status – for both the first wave where 
diabetes is reported (i.e. when diabetes incidence is ascertained) and the wave 
immediately preceding it (when covariates are measured).  If some information was 
missing, and especially if the individual had missing data for the wave immediately 
preceding the first report of diabetes, and thus the period of onset of their diabetes was 
uncertain, the individual was only eligible to be matched as a control unit. (See (Lu 2005) 
for details about data requirements in risk-set matching.) 
At each wave, each incident diabetes case is matched to a diabetes-free individual. 
Cases are matched to controls separately for the original HRS and War Babies cohorts. 
Each control individual can only be matched to one case; see Figure 3-1 for an 
illustration of the matching procedure. The matching was implemented using the 
pairmatch command in the optmatch package (Hansen & Klopfer 2006) in R (R Core 
Team, Vienna, Austria).   
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Analysis of outcome 
The dependent variable is first defined as the difference between an individual’s 
mobility limitations at censoring and the individual’s average number of mobility 
limitations prior to diabetes diagnosis (Lu 2005). Censoring time is the last wave in 
which both individuals in the pair were observed, ensuring the same length of follow-up 
within pairs. A one-sided Wilcoxon signed rank test is applied to the dependent variable 
to test the null hypothesis of no effect of incident diabetes on mobility limitations, and an 
asymmetric confidence interval is constructed by inverting the Wilcoxon test 
(Rosenbaum 2003). A rejection of the null hypothesis would imply the following: Under 
the assumption of no unmeasured confounding, incident diabetes increases the number of 
mobility limitations a person accumulates.  
 Then, a right-censored Poisson model was fit (Winkelmann 2003), with the 
dependent variable defined as the number of limitations at censoring time, accounting for 
length of follow-up. The independent variables are an indicator exposure status and the 
matched pair’s total number of mobility limitations at censoring time (Lachin 2011). 
Because the matched pairs in this regression model are made using risk-set matching, the 
regression retains the useful properties of risk-set matching: time ordering is respected, 
and covariates are balanced both at baseline and just prior to exposure. The exponentiated 
coefficient, or rate ratio, for the exposure variable estimates the expected proportionate 
number of mobility limitations at study exit for a person who develops diabetes, relative 
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to a matched individual who does not. The model was fit using the rcpoisson command 
(Raciborski 2011) in Stata 13.1 (StataCorp, College Station, TX). 
 
3.3 RESULTS 
Descriptive statistics 
The average age of participants who reported no diabetes at study entry was 54.48 
(SD: 3.04) and average number of mobility difficulties was 0.78 (SD: 1.22) (Table 3-1). 
A comparison of individuals excluded from the analytic sample, due to having 
diabetes at baseline, to those included (Appendix Table A.3.1a) reveals that the 
excluded individuals tended to be more socioeconomically disadvantaged and less 
healthy at baseline than included individuals. Excluded individuals were more likely to 
be high school dropouts and to have had a history of smoking. They were less wealthy on 
average, and they reported more chronic conditions (high blood pressure, arthritis, and 
stroke) and more disabilities. Individuals who had diabetes at baseline had an average 
BMI more than 3 kg/m2 higher than included individuals, over twice the prevalence of 
high blood pressure, and over four times the prevalence of having had a stroke.  
Appendix Table A.3.1b shows the progression of each cohort through time. I 
observe 1,699 incident cases of diabetes in the HRS cohort and 301 in the War Babies 
cohort. In each cohort, the number of incident cases (and the implicit incidence rate, 
though this rate is subject to assumptions about mortality and attrition between the two 
data collection times) generally rise with age, but not monotonically. The number of 
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incident cases observed in a given wave is the maximum number of individuals who can 
be matched as “exposed” units for the period (interval) that precedes the given wave. 
 
Covariate balance 
Table 3-2 shows the results of the matching procedure. 1,602 individuals who 
developed diabetes were matched to 1,602 controls who had not been diagnosed with 
diabetes as of the wave of matching. There were 136 individuals who reported diabetes 
during the study period but whose period of onset was uncertain, of which 9 were 
matched as controls and 127 were left unmatched. Additionally, to be included in 
analysis of the outcome, both units in a matched pair had to provide nonmissing data on 
mobility limitations at baseline, at the last wave prior to first diabetes report, and at 
censoring time. Since censoring time is defined as the last wave in which both individuals 
in a matched pair are observed, censoring time is unknown prior to matching. That raises 
the possibility that some matched pairs will have to be dropped following matching, if 
they have missing values for mobility limitations at censoring time. Nine such pairs were 
matched and then dropped, leaving 1,593 case-control pairs for analysis.  
An approach to estimating the relation between incident diabetes and mobility 
limitations that does not use risk-set matching might take a sample of individuals who are 
non-diabetic at baseline and compare those who developed diabetes at any point during 
data collection to those who never developed diabetes. In the non-risk set matching 
approach, the difference in the mean number of mobility limitations at last wave prior to 
incident diabetes between the exposed group and the control group was 0.446 of a 
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limitation, or 62.7% of the mean in the never-diabetic group (Table 3-2). Comparisons of 
subsequent mobility limitations using the non-risk set matching approach would not 
control for this pre-exposure difference. An estimate of the diabetes-mobility limitation 
relationship using this approach would thus be biased upwards. In contrast, when using 
risk-set matching, the exposed-control group difference in means was 0.112 of a 
limitation, or 10.9% of the control group mean (Table 3-2), and in standard deviation 
units, the difference declined from 0.239 to 0.060. 
 Table 3-2 also shows that, without matching, the exposed and control groups 
were statistically significantly different in terms of other key covariates, including BMI at 
baseline (exposed mean: 29.86 kg/m2 vs. control mean: 26.31) and self-rated health just 
prior to diagnosis (3.031 vs. 2.568 where 1=excellent health). In all cases, the covariate 
differences between exposed and control groups prior to matching imply that the exposed 
group was both more likely to develop diabetes (see Appendix Table A.3.2a) and more 
likely to experience mobility limitation even without diabetes. Thus, a failure to balance 
exposed and control groups on these variables would bias estimates of the diabetes-
mobility limitation relationship upward. Table 3-2 shows that these variables were 
balanced after risk-set matching; for example, the difference in mean BMI at baseline 
between exposed individuals and matched controls was only 0.25 kg/m2. See Appendix 
Table A.3.2b for a complete accounting of covariate differences before and after 
matching. 
 
Outcome analysis 
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 Table 3-3 tests the null hypothesis that there was no difference in the change in 
mobility limitations between exposed individuals and their matched controls. At the 
median, individuals who developed diabetes experienced a 0.25-unit larger increase in 
mobility limitations than their matched controls (sign-rank P=0.0001). A 0.25-unit larger 
increase among cases than controls is substantively important, considering that the 
average number of limitations reported at baseline was only 0.79. The average post-
diagnosis increase in self-reported mobility limitations in the exposed group was 0.55 of 
a mobility limitation, and in the matched control group 0.37 of a limitation (sign-rank 
P=0.0001).   
The estimated rate ratio of 1.249 (Table 3-4, column 2) implies that people in the 
sample who developed diabetes had, on average, 24.9% more mobility limitations at 
study exit than matched individuals who did not develop diabetes, when both individuals 
were followed for the same post-exposure period. A comparison of the two columns in 
Table 4 shows a similar association between diabetes and mobility limitations regardless 
of the total number of mobility limitations in the matched pair.  
 
Sensitivity Analyses and Subgroup Analyses 
To test the sensitivity of the results to the use of self-reported diagnosis, similar 
analysis was performed excluding matched pairs in which the control unit would later 
develop diabetes. Such controls are most likely to have had undiagnosed diabetes at the 
time of matching. Results were similar when dropping matched pairs in which the control 
individual would later be diagnosed with diabetes (271 pairs; Appendix Table A.3.3a). 
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Appendix Table A.3.3b shows that results were also robust to an alternative 
parameterization of the number of mobility limitations at diabetes diagnosis. 
In Appendix A.3.4, the sensitivity of the results to possible unmeasured 
confounding are examined, following Rosenbaum (Rosenbaum 1987, 2002). Suppose 
there exists an unmeasured confounder that is positively associated with the development 
of mobility limitations, such as a genetic predisposition toward development of diabetes 
after age 50. Such a variable would have to raise the probability of developing diabetes 
by 15% for one subject in each matched pair in order to explain the associations 
discussed above. 
Finally, examining the association between diabetes incidence and mobility 
limitations among obese individuals could shed light on the complex relationships among 
obesity, diabetes, and mobility limitations. On the one hand, obesity could exacerbate the 
disabling consequences of diabetes; on the other hand, if obesity on its own exerts a 
strong negative effect on mobility, then it could mute the estimated effect of diabetes on 
mobility limitations. To explore the role of obesity, I analyze the outcome for the 466 
matched pairs in which both the exposed and control units were obese at baseline. 
 The average mobility decline in the exposed group was 0.63 of a limitation and in 
the control group was 0.43 of a limitation, close to the results found for all matched pairs 
(Appendix Table A.3.5a). Similarly, Appendix Tables A.3.5b and A.3.5c show that the 
nonparametric test of significance and sensitivity of the results to unmeasured 
confounding produce very similar results when looking only at pairs in which both units 
were obese at baseline as when looking at all the matched pairs: a significant difference 
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in mobility decline, an estimated median difference of 0.25 of a limitation, and results 
that are somewhat sensitive to unmeasured confounding. 
 
3.4 DISCUSSION 
 This study uses risk-set matching to estimate the association between incident 
diabetes and subsequent mobility limitations. Individuals who developed diabetes 
experienced significantly larger increases in mobility limitations than matched controls; 
the median difference in the change in mobility limitations was 0.25 limitations, out of a 
maximum of five. This is a fairly large difference, given that the average number of 
mobility limitations at baseline was 0.78 (Table 3-1). At study exit, people in the sample 
who developed diabetes reported an estimated 24.9% more limitations than were reported 
by matched controls. These results were robust to a number of alternative specifications. 
The study reduces many of the potential biases found in prior estimates of the 
relationship between diabetes and physical function limitations. In particular, by 
including only individuals who were diabetes-free at baseline and examining incident 
diabetes, bias from unobserved underlying health is reduced and factors that precede 
diabetes diagnosis are controlled without “controlling” for factors that follow it. Results 
show that the incident-diabetes and matched-control groups were balanced on measured 
confounders prior to diabetes onset.  
 The increased risk of physical functioning difficulties associated with diabetes as 
estimated in this study is lower than previous estimates (Cigolle et al. 2011; Dhamoon, 
Moon, Paik, Sacco, & Elkind 2014; Gregg et al. 2002; Kalyani, Saudek, Brancati, & 
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Selvin 2010; P. G. Lee et al. 2013; Wong et al. 2013; Wray, Ofstedal, Langa, & Blaum 
2005). One difference between this and past investigations is that the current study 
controlled for a richer set of background socioeconomic and health conditions than most 
of the literature has done (Haas 2008; Herd, Goesling, & House 2007; Wong & Gregg 
2013). Another important difference is that this study focuses on incident diabetes as the 
measure of exposure while prior studies focus on prevalent diabetes. As discussed in the 
introduction, prevalence-based estimates incorporate the effects of diabetes on 
functioning difficulties and the effects of functioning difficulties on the risk of 
developing diabetes. This study avoids incorporating the latter pathway, which is a source 
of bias.  
Prevalence-based estimates also incorporate the effect of the duration of diabetes 
on functioning limitations, while the incidence-based estimates presented in this paper do 
not account for duration (see Appendix A.3.6). Since the duration of diabetes likely 
increases the risk of limitations, due to the progression of peripheral neuropathy and 
accumulation of comorbidities (Bruce, Davis, & Davis 2005; Stenholm et al. 2014), the 
estimates presented here might thus be considered a “lower bound” of the overall effect 
of diabetes on physical functioning limitations.  
 The study is subject to several limitations. First, because diabetes status was 
ascertained based on self-report, undiagnosed individuals are treated as non-diabetic. An 
alternative specification (Appendix Table A.3.3a) that excluded pairs in which the 
control individual later developed diabetes suggests that this limitation might not be 
severe, but it does not address the possibility that exposed individuals might have 
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developed diabetes years before they were diagnosed. Second, although missing data 
were addressed using recommended techniques, they could still create selection bias in 
the matching process.  Third, the focus on mobility limitations ignores the many other 
types of functional limitations to which diabetes could contribute, such as limited vision 
(Cigolle et al. 2011). Examining other outcomes would provide a more comprehensive 
picture of the association between diabetes and physical limitations and would likely 
increase the estimated magnitude of the association (Cigolle et al. 2011). 
 An assumption used throughout the analysis is that whether and when a person is 
censored from the study – through death or attrition – does not provide information on 
their accumulation of mobility limitations. Censoring by death may be informative; 
however, in theory, informative censoring could bias the results in either direction, and it 
is difficult to determine which direction is more likely. Finally, because the analysis 
focuses only on individuals born 1931 to 1947, it might not generalize to younger 
cohorts. 
Although the results might be sensitive to unmeasured confounding (see 
Appendix A.3.4), the confounding would have to be of a fairly specific type. 
Unmeasured confounding that is positively associated with mobility limitation would 
have to raise the probability of developing diabetes, conditional not only on the host of 
early-life and current conditions this analysis controls for, but also on being diabetes-free 
at study entry. Those with diabetes at study entry were substantially sicker than the 
average sample individual on a range of measures. Unmeasured confounders that make 
people’s underlying health poor – and thus increase the probability of both diabetes and 
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mobility limitation – are likely strongest among the people who already had diabetes at 
entry into the study. Because these individuals were excluded, general, unmeasured 
underlying health is less likely to confound the results.  
 As the U.S. population ages and the prevalence of chronic diseases such as 
diabetes increases, increasing our knowledge of the relationships between specific 
diseases and physical functioning difficulties will enhance our understanding of barriers 
to healthy aging among older Americans. The methods used in this paper reduce the bias 
in estimates of the effect of diabetes on increased mobility limitation. Given the high 
prevalence of mobility limitations and disabilities at older ages (Freedman et al. 2013), 
the rate ratios estimated in this paper amount to a large number of people whose mobility 
limitations result from diabetes. A randomized trial among people with diabetes showed 
that an intensive lifestyle intervention for weight loss improved physical functioning 
outcomes (Rejeski et al. 2014), implying considerable potential for improved diabetes 
management to reduce the burden of physical functioning limitations in the old-age 
population.  
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Figure 3-1: Illustration of Risk-Set Matching 
 
Suppose there are eleven individuals in the cohort when the study begins in 1992, 
identified A through K. At the beginning of the study, they are aged 51 to 61 last 
birthday, respectively. In 1996, Subject A first reports having diabetes. At this point, 
Subject A is matched with someone in the risk set. The risk set consists of everyone who 
is still in the study, does not yet have diabetes, and has not yet been matched prior to 
1996 (represented by solid life lines up to 1996). In this cohort, all subjects are in the risk 
set in 1996. Based on the similarity of their covariate matrices (characteristics observed 
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in 1992 and 1994), Subject C is matched as a control to Subject A. The pair is followed 
until the end of the study, represented by the dotted life lines. Subject C remains a control 
for Subject A even though Subject C reports having diabetes in 2000. The vertical dashed 
line at 1996 is the first “post-exposure” wave, i.e. the first wave after Subject A was 
diagnosed with diabetes. The change in disability from 1996 to 2010 for Subject A is 
compared to the change in disability from 1996 to 2010 for Subject C. 
In 2006, subject F first reports having diabetes. Subject F is now matched with 
someone in the risk set, which consists of all the subjects with solid life lines up to 2006. 
Subjects A and C have already been matched, and subject K has died, so those three 
subjects are not in the risk set for 2006. Subject I is matched as a control to subject F. The 
pair is followed through 2008, which is the last time subject I is observed in the data set. 
The change in disability between from 2006 to 2008 for Subject F is compared to the 
change in disability from 2006 to 2008 for Subject I. 
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Table 3-1: Weighted means (SDs) or percentages at study entry for individuals 
included in propensity score matching 
Variable type Variable 
Mean (SD) or 
Percentage 
Time-invariant Mother's education (years) 9.82 (3.59) 
 Father's education (years) 9.46 (3.94) 
 Childhood health (1=excellent) 1.76 (0.96) 
 Female (%) 50.55 
 Black (%) 9.65 
 Hispanic (%) 6.57 
 Foreign born (%) 8.70 
 Education (years) 12.77 (2.95) 
Time-varying: demographic Age 54.48 (3.04) 
 Married (%) a 80.51 
 Not Married (%) a 19.48 
 Northeast (%) 19.42 
 Midwest (%) 24.79 
 South (%) 37.23 
 West (%) 18.55 
Time-varying: economic No health insurance (%) 17.32 
 Works full-time (%) 62.15 
 Works part-time (%) 10.02 
 Unemployed (%) 1.98 
 Retired (%) 12.97 
 Not in labor force (%) 9.35 
 On work disability (%) 3.52 
 Income per household member 
($) 27,119 (40,401) 
 Wealth ($) 230,037 (489,000) 
Time-varying: health Smokes now (%) 26.12 
 Ever smoked (%) 62.23 
 BMI (kg/m2) 27.09 (5.07) 
 Self-rated health (1=excellent) 2.39 (1.13) 
 High blood pressure (%) 28.04 
 Heart problems (%) b 7.70 
 Stroke (%) 1.75 
 Arthritis (%) 30.27 
 # Mobility limitations (max=5) 0.78 (1.22) 
    0 (%) 53.70 
    1 (%) 24.14 
    2 (%) 10.07 
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    3 (%) 5.18 
    4 (%) 4.15 
    5 (%) 2.72 
   Missing (%) 0.04 
   
 # subjects 9646 
Notes: Health and Retirement Study, United States, 1992-2010. 
a Marital status groups: married, partnered, widowed = “Married”; divorced, separated, 
never married = “Not married”. 
b Heart problems: heart attack, coronary heart disease, angina, congestive heart failure, or 
“other heart problems” (RAND 2011). 
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Table 3-2: Covariate balance without vs. with risk-set matching, selected variables 
When measured Variable 
No risk-set matching With risk-set matching 
Exposed 
mean 
Control 
mean 
Standar-
dized 
diff  a   
P for 
diff b 
Exposed 
mean 
Control 
mean 
Standar-
dized 
diff a  
P for 
diff b 
Time-invariant 
Female 0.500 0.532 -0.046 0.010 0.501 0.514 -0.019 0.458 
Own educ (yrs) 11.7 12.5 -0.181 <0.001 11.8 11.9 -0.010 0.914 
Black 0.215 0.140 0.138 <0.001 0.209 0.180 0.053 0.040 
Study entry 
Self-rated health c 2.730 2.379 0.216 <0.001 2.699 2.642 0.035 0.246 
BMI (kg/m2) d 29.86 26.31 0.497 <0.001 29.62 29.37 0.035 0.082 
# mobility lims e 1.203 0.822 0.202 <0.001 1.200 1.082 0.063 0.017 
Observation 
prior to incident 
diabetes 
Self-rated health  c 3.031 2.568 0.302 <0.001 3.000 2.948 0.034 0.201 
BMI (kg/m2)  d 30.941 30.080 0.106 <0.001 30.640 30.526 0.014 0.410 
# mobility lims e 1.156 0.710 0.239 <0.001 1.138 1.026 0.060 0.057 
Number of individuals 2,000 7,646   1,602 1,602   
Notes: 
a Standardized difference = ((exposed group mean) – (control mean))/(Pooled standard deviation). 
b P-values from Pearson chi-squared tests for binary variables (female, black), Wilcoxon rank-sum tests for numeric variables (e.g. 
BMI).  
c Self rated health: 1=excellent, 5=poor. 
d BMI = Body Mass Index. 
e Maximum = 5.
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Table 3-3: Change in mobility limitations, exposed vs. matched control individuals 
 
Parameter Estimate 
  
Hodges-Lehman estimate, 95% confidence interval a 0.25 [0.0001,0.2501] 
  Sign-rank P value b 0.0001 
  
Average change in # mobility limitations c: exposed group 0.554 
Average change in # mobility limitations c: matched 
controls 
0.366 
   P-value for difference b 0.0001 
  
 
Notes: 
Num. pairs = 1,593. 
a Hodges-Lehman estimate is the median of pairwise Walsh averages (approximately, the 
median within-pair difference). Confidence interval is asymmetric because of the highly 
discrete nature of the dependent variable. 
b P-value from Wilcoxon signed-rank test for H0: Change in mobility limitations among 
exposed = change in mobility limitations among matched controls. 
c Change in mobility limitations = (# limitations at censoring) – ([# limitations just prior 
to exposed individual’s diabetes diagnosis] + [# limitations at baseline])/2. 
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Table 3-4: Rate Ratios from Censored Poisson Regression of Mobility Limitations 
onto Incident Diabetes 
Dependent variable = Number of mobility limitations at censoring (maximum=5, 
median=1) a 
 (1) (2) 
   
Incident diabetes 1.220*** 1.249*** 
 [1.122,1.328] [1.149,1.357] 
   
# limitations in 
pair 
-- 1.362*** 
[1.341,1.384] 
   
N 3186 3186 
 
Notes: 
*P < 0.05, **P< 0.01, ***P< 0.001 (two-sided tests). 
a Censoring time defined as last wave in which both observations in a matched pair were 
observed.  
Model (1) regresses the dependent variable onto an indicator for being the “exposed” 
individual in the matched pair (i.e. the one who developed diabetes), accounting for 
length of follow-up. Model (2) adds a covariate for the total number of mobility 
limitations in the matched pair. Robust standard errors used. 
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A.1. Appendices to Chapter 1 (Cohort Dynamics of Diabetes) 
A.1.1. Cohort Obesity Prevalence 
The prevalence of obesity at age 25 in successive cohorts, used in our age/period/cohort 
model as a continuous variable, is shown in the following table: 
Table A.1.1 a: Prevalence of Obesity at age 25, by birth cohort 
Birth Years Percent 
1920-1924 2.00% 
1925-1929 2.58% 
1930-1934 3.34% 
1935-1939 3.46% 
1940-1944 3.96% 
1945-1949 4.85% 
1950-1954 5.99% 
1955-1959 6.99% 
1960-1964 8.47% 
1965-1969 11.32% 
1970-1974 14.52% 
1975-1979 15.92% 
 
Sources: Calculated from NHANES continuous waves 1999-2008 using the interview 
sample. 
 
One limitation of our study is that we used retrospective data on height and 
weight to estimate trends in cohort obesity at age 25 for subsequent US birth cohorts. 
Recall data may be subject to errors of misreporting. However, prior research using 
longitudinal data found a relatively high degree of correspondence between recall and 
contemporaneously reported data on BMI (Perry, Byers, Mokdad, Serdula, & Williamson 
1995). Validity of recall data over longer intervals of time has not been investigated. A 
second limitation is that we were not able to investigate cohort trends in obesity at 
younger ages because of lack of data on trends in childhood and adolescence.  
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A.1.2. Prevalence Estimates and Confidence Intervals 
 
Results displayed in Figures 1a and 1b are shown in more detail in the following tables.  
 
Table A.1.2 a: Age-Specific Prevalence Across Observation Periods 
Period: 1988-1994 1999-2002 2003-2006 2007-2010 
Age Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI 
20-24 0.004397 (0,0.009) 0.004269 (-0.001,0.009) 0.00623 (0.002,0.011) 0.005288 (-0.002,0.012) 
25-29 0.004864 (0.001,0.009) 0.017177 (0.007,0.027) 0.02294 (0.01,0.035) 0.021857 (0.011,0.033) 
30-34 0.008792 (0.004,0.014) 0.026586 (0.008,0.045) 0.02416 (0.013,0.035) 0.028596 (0.018,0.039) 
35-39 0.032287 (0.015,0.05) 0.029327 (0.016,0.043) 0.03726 (0.022,0.052) 0.039685 (0.028,0.051) 
40-44 0.045436 (0.03,0.06) 0.046697 (0.033,0.061) 0.04710 (0.03,0.064) 0.052208 (0.036,0.069) 
45-49 0.050596 (0.036,0.066) 0.070413 (0.045,0.096) 0.0677 (0.048,0.087) 0.085597 (0.061,0.11) 
50-54 0.091078 (0.063,0.119) 0.096351 (0.073,0.12) 0.11732 (0.095,0.14) 0.1389 (0.113,0.165) 
55-59 0.114349 (0.091,0.138) 0.114759 (0.087,0.142) 0.15295 (0.112,0.194) 0.156262 (0.12,0.192) 
60-64 0.153817 (0.129,0.178) 0.178177 (0.146,0.21) 0.16539 (0.138,0.193) 0.192598 (0.151,0.234) 
65-69 0.140782 (0.109,0.172) 0.193894 (0.158,0.23) 0.20029 (0.164,0.237) 0.264501 (0.204,0.325) 
70-74 0.142179 (0.112,0.173) 0.160267 (0.126,0.194) 0.21140 (0.175,0.247) 0.248475 (0.218,0.278) 
75-79 0.186321 (0.148,0.224) 0.160083 (0.113,0.207) 0.18344 (0.145,0.222) 0.230738 (0.182,0.279) 
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Table A.1.2 b: Age-Specific Diabetes Prevalence by Birth Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Cohort: 1910-1919 1920-1929 1930-1939 1940-1949 
Age Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI 
20-24 
        25-29 
        30-34 
        35-39 
        40-44 
      
0.0613 (0.031,0.091) 
45-49 
      
0.0506 (0.036,0.066) 
50-54 
    
0.0743 (0.048,0.1) 0.1043 (0.075,0.134) 
55-59 
    
0.1143 (0.091,0.138) 0.1460 (0.119,0.173) 
60-64 
  
0.1596 (0.128,0.191) 0.1626 (0.131,0.194) 0.1814 (0.158,0.205) 
65-69 
  
0.1408 (0.109,0.172) 0.2059 (0.178,0.234) 0.2430 (0.191,0.295) 
70-74 0.1337 (0.098,0.17) 0.1506 (0.119,0.182) 0.2190 (0.198,0.24) 0.2620 (0.13,0.394) 
75-79 0.1863 (0.148,0.224) 0.1724 (0.14,0.204) 0.2246 (0.179,0.27) 
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(Table A.1.2b, continued)
Cohort: 1950-1959 1960-1969 1970-1979 1980-1989 
Age Estimate 95% CI Estimate 95% CI Est. 95% CI Est. 95% CI 
20-24   0.0079 (0,0.016) 0.0022 (-0.001,0.006) 0.0058 (0.002,0.009) 
25-29   0.0049 (0.001,0.009) 0.0211 (0.013,0.03) 0.0201 (0.009,0.031) 
30-34 0.0051 (0.001,0.009) 0.0203 (0.01,0.031) 0.0257 (0.017,0.034) 0.0364 (-0.009,0.081) 
35-39 0.0323 (0.015,0.05) 0.0324 (0.023,0.042) 0.0403 (0.029,0.052)   
40-44 0.0364 (0.023,0.05) 0.0507 (0.04,0.061) 0.0497 (0.007,0.092)   
45-49 0.0733 (0.056,0.09) 0.0770 (0.057,0.097)     
50-54 0.1229 (0.106,0.14) 0.1054 (0.045,0.166)     
55-59 0.1406 (0.109,0.172)       
60-64 0.1721 (0.105,0.24)       
65-69         
70-74         
75-79         
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A.1.3. Results of Models of Prevalence of Diabetes 
Results displayed in Figures 2 and 3 are shown in more detail in the following tables. 
 
Table A.1.3 a: Results of Age-Cohort Model 
Dependent Variable = Log Diabetes Prevalence 
   Indicator Coefficient SE t-statistic p-value 95% CI 
Age 25-29 1.080695 0.292925 3.689325 0.001283 0.473206 1.688185 
Age 30-34 1.704125 0.314012 5.426944 1.89E-05 1.052904 2.355346 
Age 35-39 2.532282 0.328767 7.702351 1.1E-07 1.85046 3.214103 
Age 40-44 2.96014 0.342128 8.652146 1.57E-08 2.25061 3.669669 
Age 45-49 3.384705 0.367831 9.201791 5.36E-09 2.62187 4.14754 
Age 50-54 3.988511 0.395827 10.0764 1.05E-09 3.167616 4.809406 
Age 55-59 4.232604 0.430616 9.829178 1.65E-09 3.33956 5.125647 
Age 60-64 4.553761 0.435592 10.45419 5.35E-10 3.650399 5.457124 
Age 65-69 4.748697 0.46782 10.15069 9.19E-10 3.778497 5.718897 
Age 70-74 4.791991 0.494981 9.68117 2.17E-09 3.765464 5.818518 
Age 75-79 4.92001 0.536914 9.163504 5.77E-09 3.806519 6.0335 
1920-29 cohort 0.0491136 0.446574 0.109979 0.913423 -0.87702 0.975251 
1930-39 cohort 0.3153463 0.443356 0.711272 0.48439 -0.60412 1.234809 
1940-49 cohort 0.4939475 0.492615 1.002704 0.326905 -0.52767 1.515569 
1950-59 cohort 0.5045705 0.527574 0.956399 0.349263 -0.58955 1.598691 
1960-69 cohort 0.809644 0.554556 1.459987 0.158427 -0.34043 1.959722 
1970-79 cohort 1.161477 0.583122 1.991825 0.058947 -0.04784 2.370798 
1980-89 cohort 1.588968 0.630111 2.521726 0.019422 0.282197 2.895739 
constant -6.687672 0.60934 -10.9753 2.16E-10 -7.95137 -5.42398 
R-Squared 0.9486 
     N 41 
      
Age/Cohort Model: ln(Yia) = α +βaXa + βiXi, where Yia = the proportion of the population 
in cohort i at age a with diabetes, Xa is a dummy variable indicating that the observation 
pertains to age a, and Xi is a dummy variable indicating that the observation pertains to 
cohort i. 
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Table A.1.3 b: Results of Age-Period Model 
Age/Period model: ln(Yia) = α +βaXa + βpXp, where Yia = the proportion of the population 
in cohort i at age a with diabetes, Xa is a dummy variable indicating that the observation 
pertains to age a, and Xp is a dummy variable indicating that the observation pertains to 
period p. 
  
Dependent Variable: Log Diabetes Prevalence 
   Indicator Coefficient SE t-statistic p-value 95% CI 
Age 25-29 0.8340861 0.177858 4.689627 4.59E-05 0.472232 1.19594 
Age 30-34 1.229262 0.176308 6.972242 5.69E-08 0.87056 1.587963 
Age 35-39 1.935714 0.176051 10.99518 1.43E-12 1.577535 2.293892 
Age 40-44 2.256934 0.173813 12.98482 1.61E-14 1.903309 2.61056 
Age 45-49 2.564451 0.181592 14.12202 1.52E-15 2.194998 2.933903 
Age 50-54 3.056156 0.183954 16.61367 1.36E-17 2.681898 3.430414 
Age 55-59 3.259276 0.195733 16.65169 1.27E-17 2.861055 3.657497 
Age 60-64 3.512932 0.177514 19.78963 7.07E-20 3.151777 3.874086 
Age 65-69 3.625526 0.187088 19.37873 1.34E-19 3.244892 4.006159 
Age 70-74 3.586429 0.189392 18.93653 2.7E-19 3.201108 3.97175 
Age 75-79 3.620085 0.210792 17.17377 5.08E-18 3.191226 4.048944 
2001 
NHANES 0.2922673 0.108457 2.694766 0.010993 0.071609 0.512926 
2005 
NHANES 0.4265295 0.108519 3.930467 0.00041 0.205746 0.647313 
2009 
NHANES 0.5343021 0.100049 5.34043 6.76E-06 0.330752 0.737852 
constant -5.571567 0.133038 -41.8794 3.46E-30 -5.84224 -5.3009 
R-Squared 0.9686 
     N 48 
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Table A.1.3 c: Results of Age-Period-Cohort Obesity Model 
Age/Period/Cohort model: ln(Yia) = α +βaXa + βpXp + γCoh_ob, where Yia, Xa, and Xp are 
defined as in the Age/Period model and Coh_ob is a continuous variable representing the 
prevalence of obesity at age 25 in the cohort corresponding to the given age and period.  
Dependent Variable: Log Diabetes Prevalence 
   Indicator Coefficient SE t-statistic p-value 95% CI 
Age 25-29 0.9926029 0.155681 6.375895 5.71E-07 0.6742 1.311005 
Age 30-34 1.655445 0.18084 9.154213 4.71E-10 1.285587 2.025304 
Age 35-39 2.672352 0.22659 11.79378 1.38E-12 2.208924 3.13578 
Age 40-44 3.191595 0.25972 12.28859 5.08E-13 2.660407 3.722782 
Age 45-49 3.636119 0.288422 12.60695 2.71E-13 3.046231 4.226008 
Age 50-54 4.259973 0.314103 13.56235 4.38E-14 3.61756 4.902385 
Age 55-59 4.545092 0.333427 13.63146 3.86E-14 3.863158 5.227026 
Age 60-64 4.892977 0.345447 14.16418 1.46E-14 4.186459 5.599496 
Age 65-69 5.07219 0.360942 14.05265 1.79E-14 4.333981 5.810399 
Age 70-74 5.107939 0.392845 13.00242 1.26E-13 4.304481 5.911398 
Age 75-79 5.116603 0.416248 12.2922 5.04E-13 4.26528 5.967926 
2001 
NHANES 
-
0.0517601 0.119307 -0.43384 0.667616 -0.29577 0.192251 
2005 
NHANES 0.0782829 0.119932 0.652728 0.519073 -0.16701 0.323571 
2009 
NHANES 0.0561693 0.142336 0.394624 0.696008 -0.23494 0.347279 
obesity 13.10013 2.828275 4.631844 7.05E-05 7.315658 18.8846 
constant -7.107672 0.35859 -19.8212 2.09E-18 -7.84107 -6.37427 
R-Squared 0.9813 
     N 45 
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A.1.4. Results when using Fasting Plasma Glucose as the Indicator of Diabetes 
 
The figures below (A.1.4a- 4c) are analogous to Figures 1-3, 1-4, and 1-5 in the main 
manuscript. The difference is that in the figures below, diabetes is defined as fasting 
plasma glucose ≥ 126 mg/dL and not based on HbA1c. Data are from the National Health 
and Nutrition Examination Surveys (NHANES) II, III, and Continuous, United States, 
1976-2010. 
 
Figure A.1.4 a: Prevalence as a multiple of 1900-1910 birth cohort prevalence 
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Figure A.1.4 b: Age-adjusted diabetes prevalence across observation periods 
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Figure A.1.4 c: Age patterns of diabetes prevalence 
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A.1.5. Model Age Pattern of Diabetes Incidence 
 
The model age pattern of diabetes incidence (new cases per person-year without diabetes) 
shown in Figure 4 in the main text is shown in detail (values for 1950-59 birth cohort) in 
the following table: 
 
Table A.1.5 a: Estimates of Diabetes Incidence for 1950-59 birth cohort 
Age Interval Incidence 
Incidence 
with no 
differential 
mortality 
20-24 to 25-29 0.000994 0.000934 
25-29 to 30-34 0.001693 0.001617 
30-34 to 35-39 0.002422 0.002303 
35-39 to 40-44 0.003611 0.003429 
40-44 to 45-49 0.006399 0.00612 
45-49 to 50-54 0.007944 0.007516 
50-54 to 55-59 0.011015 0.010359 
55-59 to 60-64 0.011268 0.010269 
60-64 to 65-69 0.010361 0.008846 
65-69 to 70-74 0.009888 0.007609 
70-74 to 75-79 0.008723 0.006022 
 
Incidence estimates are based on cohort prevalence estimates from age-cohort model and 
life-table values by diabetes status (nondiabetic versus entire population); see Methods 
section in text for details. Figure 1-6 in the main text plots the values in the “Incidence” 
column above. To demonstrate the effect of using mortality differences by diabetes status 
on the estimates, the table shows estimates of incidence that would result if we had 
ignored mortality differences by diabetes status. 
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A.1.6. Incidence with foreign-born excluded from sample 
 
Figure A.1.6 a: Age pattern of diabetes incidence, foreign-born subjects excluded 
 
This calculation plots the 1950-59 birth cohort, but the shape of the curve is the same for 
all decadal birth cohorts. Foreign-born individuals were excluded from the sample. Data 
are from the National Health and Nutrition Examination Surveys (NHANES), United 
States, 1988 to 2010. 
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A.1.7. Results based on “High Risk” of Diabetes, and Discussion of Threshold 
Choice 
 
 Appendix Figures A.1.7a and A.1.7b show estimates of the prevalence of “at least 
high risk” of diabetes, using HbA1c ≥ 6.0% (42 mmol/mol) (American Diabetes 
Association 2012), by period and cohort. Appendix Figure A.1.7c shows the cohort 
coefficients from the age/cohort model. Appendix Figure A.1.7d shows the period effects 
in the age/period and age/period/cohort models discussed in the Statistical Methods 
section, as applied to the threshold HbA1c ≥ 6.0%. Appendix Figure A.1.7e shows the 
modeled age-pattern of “at least high risk.” 
 Although the recent ADA guidelines mention 6.0% as a possible threshold, they 
note that there is a “continuum of risk for diabetes with all glycemic measures” and did 
not formally identify 6.0% as a formal “high risk” threshold (American Diabetes 
Association 2012). A recent meta-analysis indicated that there is no clear HbA1c-based 
threshold above which the risk of incident diabetes increases dramatically (Gregg, Geiss, 
et al. 2013). Nevertheless, using the 6.0% threshold is a useful way to test the sensitivity 
of our methods to the choice of threshold. The patterns found using the 6.0% threshold 
are similar to the patterns found using the 6.5% threshold. 
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Figure A.1.7 a: Prevalence of HbA1c 6.0%+ in Successive NHANES Waves 
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Figure A.1.7 b: Prevalence of HbA1c 6.0%+ in Successive Decadal Birth Cohorts 
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Figure A.1.7 c: Age-Adjusted Prevalence of HbA1c 6.0%+ in Birth Cohorts Relative 
to 1910-1919 Birth Cohort 
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Figure A.1.7 d: Prevalence of HbA1c 6.0%+ Relative to that in 1988-1994 
Observation Period 
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Figure A.1.7 e: Age-Specific Prevalence of HbA1c 6.0%+ Relative to Age 20-24 
Prevalence 
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Table A.1.7 a: Results of Age-Cohort Model  
Dependent variable = Log Prevalence of (HbA1c ≥ 6.0%) 
  Indicator Coefficient SE t-statistic p-value 95% CI 
Age 25-29 0.8303195 0.121278 6.846402 7.07E-07 0.578804 1.081835 
Age 30-34 1.474147 0.130009 11.33883 1.17E-10 1.204525 1.743768 
Age 35-39 1.944194 0.136118 14.28316 1.31E-12 1.661903 2.226485 
Age 40-44 2.33351 0.141649 16.47384 7.35E-14 2.039747 2.627273 
Age 45-49 2.691181 0.152291 17.67128 1.74E-14 2.375348 3.007013 
Age 50-54 3.129008 0.163882 19.09303 3.51E-15 2.789137 3.468879 
Age 55-59 3.4235 0.178286 19.20231 3.11E-15 3.053757 3.793242 
Age 60-64 3.654953 0.180346 20.26636 1.01E-15 3.280939 4.028967 
Age 65-69 3.828174 0.193689 19.76451 1.71E-15 3.426487 4.229861 
Age 70-74 3.876574 0.204934 18.91618 4.26E-15 3.451566 4.301582 
Age 75-79 4.00686 0.222296 18.02492 1.16E-14 3.545847 4.467873 
1920-29 cohort 0.0330163 0.184893 0.17857 0.85991 -0.35043 0.41646 
1930-39 cohort 0.240484 0.18356 1.31011 0.203674 -0.1402 0.621165 
1940-49 cohort 0.3391446 0.203955 1.66284 0.110527 -0.08383 0.762121 
1950-59 cohort 0.3927891 0.218429 1.79825 0.085875 -0.0602 0.845782 
1960-69 cohort 0.4955284 0.2296 2.158226 0.042089 0.019368 0.971689 
1970-79 cohort 0.6965528 0.241427 2.885149 0.008593 0.195864 1.197242 
1980-89 cohort 0.9089721 0.260882 3.48423 0.002102 0.367937 1.450008 
constant -5.280235 0.252282 -20.9299 5.14E-16 -5.80344 -4.75703 
R-Squared 0.9878688 
     N 41 
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Table A.1.7 b: Results of Age-Period Model 
  
Dependent variable = Log Prevalence of (HbA1c ≥ 6.0%) 
  Indicator Coefficient SE t-statistic p-value 95% CI 
Age 25-29 0.785042 0.089818 8.740355 4.21E-10 0.602306 0.967778 
Age 30-34 1.382502 0.089036 15.52754 9.9E-17 1.201358 1.563646 
Age 35-39 1.750047 0.088906 19.68429 8.32E-20 1.569167 1.930927 
Age 40-44 2.079389 0.087776 23.6898 2.73E-22 1.900808 2.25797 
Age 45-49 2.381469 0.091704 25.96907 1.53E-23 2.194896 2.568043 
Age 50-54 2.77329 0.092897 29.85342 1.85E-25 2.58429 2.962291 
Age 55-59 3.016927 0.098845 30.52183 9.13E-26 2.815825 3.218028 
Age 60-64 3.201748 0.089644 35.71608 5.92E-28 3.019365 3.384131 
Age 65-69 3.317046 0.094479 35.10868 1.03E-27 3.124826 3.509265 
Age 70-74 3.311332 0.095643 34.6218 1.61E-27 3.116745 3.505919 
Age 75-79 3.376998 0.10645 31.7239 2.66E-26 3.160425 3.593572 
2001 
NHANES -0.0258708 0.054771 -0.47235 0.639789 -0.1373 0.085562 
2005 
NHANES 0.0411817 0.054802 0.751463 0.4577 -0.07031 0.152677 
2009 
NHANES 0.4200199 0.050525 8.313196 1.33E-09 0.317227 0.522813 
constant -4.683064 0.067184 -69.7048 2.09E-37 -4.81975 -4.54638 
R-Squared 0.9897704 
     N 48 
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Table A.1.7 c: results of Age-Period-Cohort Obesity Model  
Dependent variable = Log Prevalence of (HbA1c ≥ 6.0%) 
  Indicator Coefficient SE t-statistic p-value 95% CI 
Age 25-29 0.9286565 0.087923 10.5622 1.88E-11 0.748835 1.108479 
Age 30-34 1.61597 0.102132 15.82242 8.41E-16 1.407087 1.824853 
Age 35-39 2.088447 0.12797 16.31986 3.74E-16 1.82672 2.350175 
Age 40-44 2.484058 0.146681 16.93516 1.41E-16 2.184062 2.784053 
Age 45-49 2.834346 0.16289 17.40037 6.89E-17 2.501198 3.167493 
Age 50-54 3.271163 0.177394 18.44012 1.46E-17 2.908352 3.633973 
Age 55-59 3.541548 0.188307 18.8073 8.63E-18 3.156417 3.92668 
Age 60-64 3.757913 0.195096 19.26188 4.54E-18 3.358897 4.156929 
Age 65-69 3.893697 0.203847 19.1011 5.69E-18 3.476784 4.31061 
Age 70-74 3.946568 0.221865 17.78819 3.83E-17 3.492804 4.400332 
Age 75-79 3.984019 0.235082 16.94739 1.39E-16 3.503223 4.464814 
2001 
NHANES -0.1520016 0.06738 -2.25588 0.031793 -0.28981 -0.01419 
2005 
NHANES -0.0857865 0.067733 -1.26654 0.2154 -0.22432 0.052743 
2009 
NHANES 0.2139795 0.080386 2.661893 0.012539 0.049571 0.378388 
obesity 4.388277 1.597306 2.747298 0.010222 1.121419 7.655136 
constant -5.274105 0.202519 -26.0426 1.15E-21 -5.6883 -4.85991 
R-Squared 0.9925176 
     N 45 
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A.1.8. ALTERNATIVE DELINEATION OF BIRTH COHORTS 
Figure A.1.8 a: Age-specific diabetes prevalence in successive ten-year birth cohorts, 
using alternative delineation of birth cohorts 
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Figure A.1.8 b: Age pattern of diabetes prevalence, including alternative delineation 
of birth cohorts 
 
 
The “alternative cohorts” are born 1915-1924, 1925-1934, etc., rather than 1910-1919, 
1920-1929, etc. 
Data are from the National Health and Nutrition Examination Surveys (NHANES), 
United States, 1988 to 2010.  
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A.2. Appendices to Chapter 2 (Lifetime Risk of Dementia) 
A.2.1. Models of dementia incidence, prevalence, and differential mortality 
A) Prevalence model: 𝑙𝑜𝑔𝑖𝑡(𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒𝑥) = 𝛼 + 𝛽𝑥, 
Point estimates: 
Term Coefficient estimate 
Age (x) 0.152565 
Constant -14.2737 
 
Variance-covariance: 
 
Age Constant 
Age 0.000295 -0.02424 
Constant -0.02424 2.004415 
 
B) Incidence model: 𝑙𝑜𝑔𝑖𝑡(𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒𝑥) = 𝛼′ + 𝛽′𝑥, 
Point estimates: 
Term Coefficient estimate 
Age (x) 0.087151 
Constant -10.6868 
 
Variance-covariance: 
 
Age Constant 
Age  0.000407 -0.03363 
Constant -0.03363 2.793747 
 
C) Differential mortality 
Model: ln(𝑚𝑥,𝑑𝑒𝑚) = 𝛼 + 𝛽1𝑥 + 𝛽2𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎 + 𝛽3𝑥 ∗ 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎. 
 
Point estimates: 
Term Coefficient estimate 
Dementia 6.435545 
Age (x) 0.110955 
Age*Dementia -0.06139 
Constant -12.2631 
 
Variance-covariance: 
 
Dementia Age Age*Dementia Constant 
Dementia 3.427942 0.027964 -0.03975 -2.35307 
Age 0.027964 0.000299 -0.00033 -0.025 
Age*Dementia -0.03975 -0.00033 0.000464 0.027693 
Constant -2.35307 -0.025 0.027693 2.10715 
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A.2.2. Deterministic inputs and results 
 
Table A.2.2 a: Deterministic inputs to stationary approach 
  Estimated Estimated Implied 
Age Prevalence Incidence RR 
70 0.029 0.010 10.213 
75 0.060 0.016 4.041 
80 0.120 0.024 1.824 
85 0.226 0.036 1.062 
90 0.385 0.055 0.955 
95 0.574 0.083 0.962 
100 0.743 0.122 1.150 
 
RR = Mortality rate ratio, with dementia vs. without dementia. 
 
Parametric models were fit to ADAMS baseline data for prevalence, ADAMS 
longitudinal data for incidence. Parameters of the models – shown in Appendix Table 1 – 
were treated as non-stochastic and run through life table operations as described in the 
Methods section under Approach 1. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social 
Security Administration life tables for 1920 birth cohort.  
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Table A.2.2 b: Deterministic life cycle quantities using stationary approach 
 
A. Males 
        Lifetime   
Age LE DFLE DLE Risk DFLE' 
70 12.31 10.84 1.47 0.233 11.14 
75 9.65 8.05 1.60 0.230 8.52 
80 7.26 5.54 1.72 0.222 6.24 
85 5.20 3.43 1.77 0.209 4.36 
90 3.64 1.90 1.75 0.199 3.01 
95 2.61 0.95 1.66 0.200 2.14 
100 2.02 0.45 1.57 0.228 1.71 
 
B. Females 
        Lifetime   
Age LE DFLE DLE Risk DFLE' 
70 15.25 13.04 2.21 0.312 13.40 
75 11.91 9.62 2.29 0.298 10.18 
80 8.91 6.57 2.34 0.280 7.40 
85 6.37 4.06 2.32 0.259 5.16 
90 4.42 2.22 2.19 0.241 3.52 
95 3.10 1.09 2.00 0.236 2.46 
100 2.32 0.50 1.81 0.255 1.89 
 
LE = total life expectancy for a randomly chosen person in the population of given age. 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life. DFLE’ = Dementia-free life expectancy for a dementia-
free person in the population of given age. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social 
Security Administration life tables for 1920 birth cohort. Prevalence, incidence, and 
mortality rate ratios used in this table are shown in Appendix Table 2. 
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Table A.2.2 c: Deterministic inputs to non-stationary approach 
 
  Implied Estimated Estimated 
Age Prevalence Incidence RR 
70 0.029 0.010 8.486 
75 0.057 0.016 6.243 
80 0.090 0.024 4.593 
85 0.134 0.036 3.379 
90 0.191 0.055 2.486 
95 0.277 0.083 1.829 
100 0.443 0.122 1.346 
 
Parametric models were fit to ADAMS longitudinal data for incidence and differential 
mortality. Parameters of the models – shown in Appendix Table 1 – were treated as non-
stochastic and run through life table operations as described in the Methods section. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011.  
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Table A.2.2 d: Deterministic life cycle quantities using non-stationary approach 
 
A. Males 
        Lifetime   
Age LE DFLE DLE Risk DFLE' 
70 12.31 11.58 0.73 0.267 11.93 
75 9.65 8.93 0.72 0.269 9.37 
80 7.26 6.53 0.73 0.264 7.05 
85 5.20 4.49 0.71 0.253 5.05 
90 3.64 2.95 0.69 0.239 3.51 
95 2.61 1.87 0.73 0.232 2.44 
100 2.02 1.10 0.91 0.234 1.76 
 
B. Females 
        Lifetime   
Age LE DFLE DLE Risk DFLE' 
70 15.25 13.55 1.70 0.344 13.95 
75 11.91 10.25 1.66 0.338 10.90 
80 8.91 7.38 1.53 0.325 8.17 
85 6.37 5.02 1.35 0.307 5.86 
90 4.42 3.24 1.18 0.285 4.04 
95 3.10 2.00 1.09 0.269 2.77 
100 2.32 1.13 1.18 0.264 1.95 
 
LE = total life expectancy for a randomly chosen person in the population of given age. 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life. DFLE’ = Dementia-free life expectancy for a dementia-
free person in the population of given age. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011. 
Prevalence, incidence, and mortality rate ratios used in this table are shown in Appendix 
Table 4. 
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Table A.2.2 e: Deterministic life cycle quantities using 1940 cohort life table, non-
stationary approach 
 
A. Males 
        Lifetime   
Age LE DFLE DLE Risk DFLE' 
70 13.64 12.58 1.06 0.305 12.95 
75 10.65 9.60 1.04 0.303 10.15 
80 7.96 6.96 1.00 0.295 7.61 
85 5.70 4.77 0.93 0.280 5.46 
90 4.05 3.16 0.90 0.268 3.83 
95 2.95 2.00 0.95 0.260 2.69 
100 2.30 1.16 1.14 0.262 1.94 
 
B. Females 
        Lifetime   
Age LE DFLE DLE Risk DFLE' 
70 15.99 14.05 1.93 0.371 14.47 
75 12.62 10.71 1.91 0.366 11.41 
80 9.57 7.76 1.81 0.355 8.64 
85 6.93 5.30 1.63 0.336 6.26 
90 4.89 3.43 1.45 0.316 4.38 
95 3.49 2.11 1.37 0.300 3.03 
100 2.63 1.18 1.45 0.294 2.15 
 
Notes: This table uses as inputs the quantities shown in Appendix Table 4, along with 
1940 birth cohort life tables from the U.S. Social Security Administration. 
 
LE = total life expectancy for a randomly chosen person in the population of given age. 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1940 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011. 
Prevalence, incidence, and mortality rate ratios used in this table are shown in Appendix 
Table 4. 
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A.2.3. Incidence rates under intervention scenarios 
 
New cases per dementia-free person-year lived 
 
Age 
Scenario 
1&2 
Scenario 
3&4 
Scenario 
5 
70 0.0095 0.00685 0.0058 
75 0.0144 0.01032 0.0084 
80 0.0220 0.01566 0.0122 
85 0.0337 0.02394 0.0178 
90 0.0518 0.03675 0.0261 
95 0.0794 0.05648 0.0384 
100 0.1201 0.08636 0.0565 
 
Scenarios 1 & 2 delay dementia incidence by one year compared to rates estimated from 
ADAMS and shown in Table 1. Scenarios 3 & 4 delay dementia incidence by five years. 
Scenario 5 reduces the acceleration of dementia incidence with age by 10%. 
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A.2.4. Approximated dementia-free survivors to middle of age interval  
versus dementia-free person-years lived in the interval 
 
Males, non-stationary approach, deterministic calculation 
 
      Absolute Diff. as % 
Age ?̂?𝑥
𝑁𝐷 𝐿𝑥
𝑁𝐷 Difference of 𝐿𝑥
𝑁𝐷 
71 91351.4 91329.4 22.01 0.02% 
72 87440.3 87376.9 63.41 0.07% 
73 83361.0 83292.3 68.68 0.08% 
74 79139.0 79140.9 1.89 0.00% 
75 74991.4 74947.0 44.39 0.06% 
76 70708.7 70676.5 32.14 0.05% 
77 66374.0 66352.5 21.43 0.03% 
78 62007.1 61983.9 23.16 0.04% 
79 57592.1 57561.6 30.58 0.05% 
80 53108.6 53124.7 16.08 0.03% 
81 48703.9 48719.4 15.48 0.03% 
82 44329.6 44306.6 23.00 0.05% 
83 39870.7 39899.1 28.40 0.07% 
84 35520.1 35556.9 36.79 0.10% 
85 31251.5 31309.9 58.48 0.19% 
86 27121.4 27202.5 81.03 0.30% 
87 23176.1 23282.8 106.73 0.46% 
88 19469.8 19599.9 130.06 0.66% 
89 16047.1 16200.4 153.31 0.95% 
90 12954.2 13123.7 169.55 1.29% 
91 10216.6 10399.1 182.48 1.75% 
92 7857.0 8044.1 187.15 2.33% 
93 5876.3 6061.0 184.73 3.05% 
94 4262.6 4437.8 175.24 3.95% 
95 2990.0 3152.1 162.16 5.14% 
96 2028.6 2169.3 140.71 6.49% 
97 1327.1 1444.4 117.28 8.12% 
98 836.8 930.6 93.80 10.08% 
99 510.6 579.7 69.12 11.92% 
100 298.0 348.5 50.55 14.51% 
 
The ?̂?𝑥
𝑁𝐷 values are approximated dementia-free survivors; 𝐿𝑥
𝑁𝐷 are person-years lived without 
dementia in the age interval. The ?̂?𝑥
𝑁𝐷 values were used to estimate the dementia prevalence in 
each age group using the non-stationary approach and were estimated assuming linearity of 
survival within one-year age intervals; see Methods section, under Approach 2, for details.  
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A.2.5. Results using alternative censoring strategy 
 
Table A.2.5 a: Incidence, Prevalence, and Differential Mortality, censoring subjects 
without dementia at end of ADAMS study period (Stationary Approach) 
 
  Fitted prevalence & incidence Implied   
Age Prevalence (SE) Incidence (SE) RR (SE) 
70 0.030 (0.007) 0.010 (0.003) 13.542 (13.668) 
75 0.061 (0.009) 0.015 (0.003) 3.939 (1.921) 
80 0.121 (0.012) 0.022 (0.003) 1.487 (0.101) 
85 0.227 (0.022) 0.032 (0.005) 0.889 (0.261) 
90 0.384 (0.043) 0.046 (0.009) 0.875 (0.236) 
95 0.569 (0.061) 0.068 (0.019) 0.919 (0.202) 
100 0.734 (0.064) 0.099 (0.035) 1.106 (0.228) 
 
RR = Relative risk of death, with dementia vs. without dementia 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social 
Security Administration life tables for 1920 birth cohort.  
 
Parametric models were fitted to prevalence and incidence data to generate single-year 
age-specific estimates. Subjects who survived ADAMS without a diagnosis of dementia 
were censored at the end of the ADAMS study period, rather than at their last assessment. 
RR was implied by fitted prevalence, incidence, and stationary-population relations. 
 
  
140 
 
Table A.2.5 b: Life cycle quantities for dementia, stationary approach, censoring 
subjects without dementia at end of ADAMS study period 
 
A) Males 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 12.31 10.83 1.48 (0.129) 0.214 (0.028) 11.14 (0.119) 
75 9.65 8.04 1.61 (0.142) 0.206 (0.025) 8.53 (0.134) 
80 7.26 5.54 1.72 (0.162) 0.194 (0.028) 6.25 (0.143) 
85 5.20 3.43 1.76 (0.182) 0.179 (0.035) 4.37 (0.135) 
90 3.64 1.91 1.74 (0.187) 0.168 (0.044) 3.01 (0.109) 
95 2.61 0.96 1.64 (0.163) 0.166 (0.056) 2.15 (0.078) 
100 2.02 0.47 1.55 (0.123) 0.187 (0.073) 1.71 (0.039) 
 
B) Females 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 15.25 13.17 2.08 (0.190) 0.283 (0.034) 13.41 (0.191) 
75 11.91 9.77 2.14 (0.205) 0.265 (0.033) 10.19 (0.205) 
80 8.91 6.74 2.16 (0.227) 0.244 (0.038) 7.41 (0.209) 
85 6.37 4.25 2.12 (0.249) 0.221 (0.047) 5.17 (0.190) 
90 4.42 2.41 2.00 (0.251) 0.203 (0.056) 3.53 (0.149) 
95 3.10 1.26 1.83 (0.220) 0.196 (0.067) 2.47 (0.102) 
100 2.32 0.63 1.69 (0.167) 0.210 (0.085) 1.90 (0.061) 
 
LE = total life expectancy for a randomly chosen person in the population of given age. 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementia-
free person of given age. 
By construction, DFLE and DLE have the same standard error, and LE has zero variance. 
 
Quantities were calculated using fitted values of dementia incidence and relative risk of 
death (with dementia vs. without) shown in Appendix Table 9.  
 
Subjects who survived ADAMS without a diagnosis of dementia were censored at the 
end of the ADAMS study period, rather than at their last assessment. 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For prevalence, n=856. For incidence, n=456. Mortality data from United States Social 
Security Administration life tables for 1920 birth cohort.   
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Table A.2.5 c: Incidence, Prevalence, and Differential Mortality, censoring subjects 
without dementia at end of ADAMS study period (non-stationary approach) 
 
  Implied   Estimated   Estimated   
Age Prevalence (SE) Incidence (SE) RR (SE) 
70 0.030 (0.173) 0.010 (0.003) 10.56 (4.290) 
75 0.052 (0.228) 0.015 (0.003) 7.94 (2.322) 
80 0.075 (0.274) 0.022 (0.003) 6.04 (1.200) 
85 0.098 (0.313) 0.032 (0.005) 4.67 (0.699) 
90 0.119 (0.345) 0.046 (0.009) 3.65 (0.664) 
95 0.145 (0.381) 0.068 (0.019) 2.89 (0.777) 
100 0.206 (0.454) 0.099 (0.035) 2.33 (0.874) 
 
RR = Relative risk of death, with dementia vs. without dementia 
 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011.  
 
Parametric models were fitted to incidence and mortality data from ADAMS to generate 
single-year age-specific estimates. Prevalence in the cohort arises from the life table 
relations as described in the Methods section, under Approach 2. 
 
Subjects who survived ADAMS without a diagnosis of dementia were censored at the 
end of the ADAMS study period, rather than at their last assessment. 
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Table A.2.5 d:  Life cycle quantities for dementia, non-stationary approach, 
censoring subjects without dementia at end of ADAMS study period 
 
A) Males 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 12.31 11.83 0.48 (0.186) 0.252 (0.033) 12.19 (0.150) 
75 9.65 9.21 0.44 (0.182) 0.249 (0.033) 9.63 (0.106) 
80 7.26 6.85 0.42 (0.163) 0.240 (0.036) 7.28 (0.069) 
85 5.20 4.82 0.37 (0.140) 0.225 (0.044) 5.24 (0.042) 
90 3.64 3.31 0.34 (0.119) 0.211 (0.054) 3.66 (0.035) 
95 2.61 2.28 0.33 (0.112) 0.205 (0.065) 2.59 (0.036) 
100 2.02 1.63 0.39 (0.136) 0.216 (0.083) 1.95 (0.047) 
 
B) Females 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 15.25 13.84 1.41 (0.249) 0.323 (0.038) 14.27 (0.234) 
75 11.91 10.59 1.32 (0.255) 0.312 (0.039) 11.22 (0.157) 
80 8.91 7.76 1.14 (0.245) 0.295 (0.044) 8.46 (0.111) 
85 6.37 5.45 0.92 (0.220) 0.274 (0.052) 6.10 (0.071) 
90 4.42 3.70 0.72 (0.186) 0.252 (0.062) 4.24 (0.042) 
95 3.10 2.51 0.59 (0.160) 0.238 (0.073) 2.95 (0.035) 
100 2.32 1.74 0.57 (0.164) 0.242 (0.090) 2.18 (0.044) 
 
LE = total life expectancy for a randomly chosen person in the population of given age. 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementia-
free person of given age. 
By construction, DFLE and DLE have the same standard error, and LE has zero variance. 
 
Quantities calculated using fitted values of dementia incidence and relative risk of death 
(with dementia vs. without) shown in Appendix Table 11.  
 
Subjects who survived ADAMS without a diagnosis of dementia were censored at the 
ADAMS study period, rather than at their last assessment. 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1920 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011.   
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Table A.2.5 e: Life cycle quantities for dementia, non-stationary approach, 
censoring subjects without dementia at end of ADAMS study period, 1940 cohort 
life table 
 
A) Males 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 13.64 12.88 0.76 (0.222) 0.289 (0.036) 13.28 (0.193) 
75 10.65 9.95 0.70 (0.223) 0.282 (0.036) 10.47 (0.139) 
80 7.96 7.35 0.62 (0.207) 0.270 (0.041) 7.91 (0.097) 
85 5.70 5.18 0.52 (0.181) 0.253 (0.050) 5.71 (0.061) 
90 4.05 3.59 0.46 (0.156) 0.239 (0.062) 4.05 (0.047) 
95 2.95 2.50 0.45 (0.147) 0.235 (0.076) 2.90 (0.049) 
100 2.30 1.77 0.52 (0.167) 0.247 (0.096) 2.20 (0.061) 
 
B) Females 
          Lifetime       
Age LE DFLE DLE (SE) Risk (SE) DFLE' (SE) 
70 15.99 14.41 1.58 (0.288) 0.349 (0.040) 14.85 (0.269) 
75 12.62 11.11 1.51 (0.294) 0.340 (0.043) 11.80 (0.194) 
80 9.57 8.22 1.35 (0.285) 0.325 (0.049) 9.01 (0.145) 
85 6.93 5.80 1.13 (0.261) 0.304 (0.059) 6.57 (0.098) 
90 4.89 3.97 0.91 (0.229) 0.283 (0.070) 4.65 (0.063) 
95 3.49 2.71 0.77 (0.202) 0.271 (0.084) 3.29 (0.051) 
100 2.63 1.88 0.76 (0.202) 0.276 (0.103) 2.44 (0.058) 
 
LE = total life expectancy for a randomly chosen person in the population of given age. 
DFLE = Dementia-free life expectancy for a randomly chosen person in the population of 
given age, DLE = life expectancy with dementia for a randomly chosen person in the 
population of given age, Lifetime Risk = probability that a dementia-free person will 
develop dementia later in life, DFLE’ = Dementia-free life expectancy for a dementia-
free person of given age. 
By construction, DFLE and DLE have the same standard error, and LE has zero variance. 
Quantities calculated using fitted values of dementia incidence and relative risk of death 
(with dementia vs. without) shown in Appendix Table 11.  
Subjects who survived ADAMS without a diagnosis of dementia were censored at the 
end of the ADAMS study period, rather than at their last assessment. 
Data: Aging, Demographics, and Memory Study (ADAMS), United States, 2001-2009. 
For relative risk of death, n=856. For incidence, n=456. Mortality data from United States 
Social Security Administration life tables for 1940 birth cohort. Mortality by dementia 
status data from Health and Retirement Study (HRS), United States, 2001-2011.  
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A.3. Appendices to Chapter 3 (Diabetes and mobility limitations) 
A.3.1. Additional sample characteristics  
 
Table A.3.1 a: Weighted means or proportions of characteristics of individuals who 
had diabetes at baseline vs. individuals included in propensity score matching 
procedure 
 Diabetic at baseline 
(excluded) 
All included 
individuals Sig.† 
Mother's education (years) 8.886 9.837 *** 
Father's education (years) 8.367 9.470 *** 
Childhood health 
(1=excellent) 1.904 1.758 
** 
Age (last birthday)  55.029 54.483 *** 
Female 47.1% 50.6%  
Black 20.1% 9.7% *** 
Hispanic 9.4% 6.6% *** 
Foreign born 9.1% 8.7%  
Own education (years) 11.9 12.8 *** 
Less than high school 29.3% 18.0% *** 
High school graduate 35.1% 37.1% * 
Some college 19.4% 22.1% ** 
College graduate 16.2% 22.7% *** 
Northeast 18.6% 19.4%  
Midwest 26.1% 24.8%  
South 41.7% 37.2% *** 
West 13.6% 18.6% *** 
Married 75.7% 80.5% * 
Divorced 24.1% 19.5% * 
Uninsured 17.4% 17.3%  
Works full time 44.4% 62.2% *** 
Works part-time 7.4% 10.0% ** 
Unemployed 2.6% 2.0%  
Retired 23.5% 13.0% *** 
Not in labor force 10.5% 9.4%  
On work disability 11.5% 3.5% *** 
HH income per head ($) 18088 27119 *** 
Wealth ($) 128368 230037 *** 
Smokes now 22.0% 26.1% ** 
Ever smoked 67.0% 62.2% * 
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BMI (kg/m2) 30.89 27.09 *** 
Self-rated health 
(1=excellent) 3.572 2.392 
*** 
Has high blood pressure 60.0% 28.0% *** 
Has had stroke 7.4% 1.7% *** 
Has arthritis 46.2% 30.3% *** 
# Mobility limitations 
(max=5) 1.697 0.784 
*** 
Number of subjects 1094 9646  
Source: Author’s calculations from Health and Retirement Study (United States, 1992-
2010). 
† Significance tests: Pearson Chi-Squared test for differences between groups 
(proportions); Wilcoxon rank-sum test for differences between groups (sample means): 
*p<0.05, **p<0.01, ***p<0.001.
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Table A.3.1 b: Diabetes incidence and survival in Original HRS and War Babies cohorts 
Original HRS cohort (born 1931-1941) 
     
Year Wave Respondents Diabetic At risk New cases 
New 
deaths  Censored 
No 
response 
1992 1 8006 0 8006 0 0 0 0 
1994 2 7639 0 7639 135 0 0 367 
1996 3 7575 129 7446 168 0 0 431 
1998 4 7235 269 6966 154 134 135 771 
2000 5 6865 379 6486 190 187 240 1141 
2002 6 6590 521 6069 227 249 314 1416 
2004 7 6317 687 5630 225 189 254 1689 
2006 8 5994 833 5161 214 248 407 2012 
2008 9 5712 961 4751 180 262 299 2294 
2010 10 5225 1006 4219 206 367 402 2781 
         War Babies cohort (born 1942-1947) 
     
Year Wave Respondents Diabetic At risk New cases 
New 
deaths  Censored 
No 
response 
1998 4 1642 0 1642 0 0 0 0 
2000 5 1583 0 1583 31 0 0 59 
2002 6 1593 30 1563 60 0 0 49 
2004 7 1534 83 1451 39 12 12 108 
2006 8 1482 116 1366 54 26 27 160 
2008 9 1441 159 1282 51 25 27 201 
2010 10 1369 194 1175 66 27 29 273 
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Diabetic = Number of subjects who had already reported having diabetes in a previous wave. 
At risk = Number of subjects at risk of incident diabetes this wave. 
New cases = Number of diabetes cases first observed this wave. 
New deaths = Number of new deaths reported this wave. 
Censored = Number of subjects censored this wave = Number of new deaths + Number newly dropped from survey. 
No response = Number of subjects who did not respond to survey this wave. 
 
Source: Author’s calculations from Health and Retirement Study (United States, 1992-2010). 
 
Number of incident cases in row for wave w equals the number of diabetes cases first observed at wave w, i.e. the number of incident 
cases that occurred between wave w-1 and wave w. Number already diabetic in wave w is approximately the sum of all incident cases 
prior to wave w. Without sample attrition, nonresponse, and mortality, it would be exactly equal. Data were collected every two years; 
calculating an incidence rate requires additional knowledge or assumptions about when in the interval people died or were lost to 
follow-up. # censored = # who died since previous wave + # dropped from sample since previous wave. In general, individuals who 
did not respond in a given wave remained in the sample, and the HRS data collection team attempted to reach them in subsequent 
waves. Individuals who died before their cohort was observed three times were excluded from the sample because they did not 
provide enough data to identify an effect of incident diabetes on subsequent disability. 
 
 
 
148 
 
A.3.2. Propensity score model fit and matching results 
 
Table A.3.2 a: Propensity score model fit  
Dependent variable = Diagnosed with diabetes 
Independent variable Odds ratio 95% Conf. 
Int. 
   
Mother’s education (years) 0.988 [0.968,1.009] 
Father’s education (years) 0.994 [0.974,1.015] 
Childhood health b 0.971 [0.916,1.031] 
Age (last birthday) 1.010 [0.996,1.024] 
Female 0.765*** [0.677,0.864] 
Black 1.231 [0.996,1.523] 
Hispanic 1.452** [1.167,1.806] 
Foreign born 0.995 [0.753,1.314] 
Own education (years) 0.987 [0.968,1.006] 
Midwest 0.924 [0.765,1.116] 
Northeast 0.928 [0.816,1.055] 
West 0.999 [0.868,1.149] 
Divorced 0.915 [0.769,1.089] 
Uninsured 1.197 [0.972,1.473] 
Works full-time 1.130 [0.976,1.308] 
Wealth (Z-score) a 0.949 [0.847,1.064] 
Household income per head (Z-score) a 0.511* [0.267,0.977] 
Current smoker 1.034 [0.859,1.245] 
Former smoker 0.977 [0.827,1.155] 
BMI (kg/m2) 1.101*** [1.086,1.116] 
Self-rated health b 1.177*** [1.101,1.259] 
High blood pressure 1.641*** [1.477,1.823] 
Heart problems 1.254** [1.077,1.460] 
Stroke 1.071 [0.833,1.378] 
Arthritis 0.923 [0.778,1.094] 
Number mobility limitations (max=5) 0.980 [0.927,1.036] 
   
1994-1996 interval 1.327* [1.047,1.682] 
1996-1998 interval 1.270 [0.936,1.722] 
1998-2000 interval 1.330* [1.066,1.659] 
2000-2002 interval 2.060*** [1.675,2.533] 
2002-2004 interval 1.776*** [1.381,2.284] 
2004-2006 interval 2.088*** [1.555,2.804] 
2006-2008 interval 1.953*** [1.427,2.673] 
2008-2010 interval 2.429*** [1.735,3.401] 
N (person-waves) 64776  
(Continued on next page) 
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Notes: Author's calculations from Health and Retirement Study (United States, 1992-
2010). 
* p < 0.05, ** p < 0.01, *** p < 0.001. 
a Household wealth and income per head were measured in standard-deviation units, so 
their odds ratios show the proportionate increased odds of developing diabetes associated 
with a one-standard-deviation increase in wealth or income per head, respectively. 
Sample mean wealth across all person-observations was $333,774 with standard 
deviation $1,285,870. Income per head sample mean was $30,359 with standard 
deviation $227,406. 
b Childhood health (self-rated) and current self-rated health were measured on a scale 
from 1 to 5, with 1 indicating the best health. 
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Table A.3.2 b: Balance of covariates before and after risk-set matching 
 
When 
measured Variable 
Std diff 
before 
matching 
Std diff 
after 
matching 
Exposed 
mean 
before 
Control 
mean 
before 
P 
before 
Exposed 
mean 
after 
Control 
mean 
after P after 
Time-
invariant 
Mother's education (yrs) -0.171 -0.008 8.695 9.6 <0.001 8.8 8.8 0.980 
Father's education (yrs) -0.147 0.010 8.378 9.2 <0.001 8.5 8.4 0.607 
Childhood health 0.048 0.047 1.868 1.800 0.010 1.865 1.799 0.240 
female -0.046 -0.019 0.500 0.532 0.010 0.501 0.514 0.458 
Own education (yrs) -0.181 -0.010 11.7 12.5 <0.001 11.8 11.9 0.914 
Black 0.138 0.053 0.215 0.140 <0.001 0.209 0.180 0.040 
Hispanic 0.126 0.081 0.128 0.074 <0.001 0.120 0.086 0.001 
Foreign born 0.062 0.090 0.121 0.094 <0.001 0.115 0.076 <0.001 
 
(Table continues on next three pages.)  
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When 
measured Variable 
Std diff before 
matching 
Std diff after 
matching 
Exposed 
mean before 
Control 
mean before 
P 
before 
Exposed 
mean after 
Control 
mean after P after 
Baseline 
(study entry) 
Age  -0.014 -0.020 54.95 55.01 0.541 54.97 55.06 0.280 
South  0.066 -0.067 0.451 0.405 <0.001 0.440 0.487 0.008 
West  -0.028 0.070 0.153 0.167 0.120 0.156 0.120 0.003 
Midwest  -0.020 -0.010 0.235 0.247 0.252 0.232 0.238 0.677 
Northeast  -0.036 0.032 0.162 0.181 0.046 0.172 0.155 0.198 
 
Married  -0.016 -0.118 0.816 0.824 0.354 0.808 0.873 <0.001 
Divorced  0.016 0.118 0.185 0.176 0.254 0.192 0.127 <0.001 
Household income ($) -0.151 -0.037 18,480 24,441 <0.001 18,767 20,239 0.025 
Wealth ($) -0.137 -0.025 143,552 224,561 <0.001 145,068 159,926 0.002 
Works full time  -0.045 0.005 0.570 0.601 0.011 0.571 0.567 0.830 
 
Works part time  -0.017 -0.046 0.097 0.104 0.336 0.094 0.114 0.073 
Unemployed  0.008 0.006 0.025 0.023 0.651 0.026 0.024 0.821 
Retired  0.020 0.000 0.149 0.139 0.252 0.151 0.151 1.000 
On disability  0.050 0.014 0.047 0.033 0.003 0.046 0.042 0.607 
Not in labor force  0.031 0.024 0.114 0.100 0.080 0.112 0.101 0.330 
 
BMI (kg/m2)  0.497 0.035 29.86 26.31 <0.001 29.62 29.37 0.082 
Smokes now 0.006 0.088 0.271 0.267 0.735 0.272 0.217 <0.001 
Former smoker -0.004 -0.037 0.354 0.357 0.814 0.358 0.383 0.143 
Uninsured  0.061 0.047 0.223 0.188 0.001 0.215 0.188 0.058 
Self-rated health 0.216 0.035 2.730 2.379 <0.001 2.699 2.642 0.246 
 High blood pressure 0.254 -0.006 0.437 0.267 <0.001 0.423 0.426 0.830 
 Heart disease 0.060 0.014 0.101 0.077 <0.001 0.100 0.094 0.591 
 Stroke  0.014 0.061 0.021 0.018 0.420 0.024 0.012 0.013 
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When 
measured Variable 
Std diff before 
matching 
Std diff after 
matching 
Exposed 
mean before 
Control 
mean before 
P 
before 
Exposed 
mean after 
Control 
mean after P after 
Baseline Arthritis 0.079 -0.017 0.355 0.303 <0.001 0.352 0.363 0.507 
(Study entry) # Mobility limitations 0.202 0.063 1.203 0.822 <0.001 1.200 1.082 0.017 
Just before 
diabetes onset 
Age  0.033 -0.014 61.98 61.74 0.637 62.34 62.44 0.687 
South  0.128 -0.075 0.452 0.363 <0.001 0.454 0.506 0.003 
West  -0.004 0.079 0.148 0.150 0.826 0.157 0.117 0.001 
Midwest  0.008 -0.010 0.220 0.215 0.644 0.226 0.232 0.705 
Northeast  0.005 0.032 0.152 0.149 0.765 0.162 0.146 0.203 
 
Married  0.115 -0.124 0.799 0.730 <0.001 0.814 0.888 <0.001 
Divorced  0.045 0.140 0.171 0.148 0.010 0.184 0.112 <0.001 
Household income ($) -0.121 0.007 21661 33022 <0.001 22285 21660 0.108 
Wealth ($) -0.113 0.001 203585 339099 <0.001 216712 215473 0.008 
Works full time  0.006 0.003 0.319 0.315 0.722 0.320 0.318 0.909 
 
Works part time -0.018 -0.018 0.058 0.064 0.329 0.058 0.064 0.461 
Unemployed  0.020 0.019 0.011 0.008 0.247 0.011 0.009 0.477 
Retired  0.091 -0.014 0.443 0.379 <0.001 0.466 0.476 0.571 
On disability  0.062 0.040 0.051 0.033 <0.001 0.052 0.041 0.132 
Not in labor force  0.030 0.002 0.092 0.080 0.085 0.092 0.092 0.951 
 
BMI (kg/m2)  0.106 0.014 30.941 30.080 <0.001 30.640 30.526 0.410 
Smokes now -0.021 0.051 0.181 0.193 0.251 0.180 0.152 0.033 
Former smoker 0.086 0.003 0.435 0.375 <0.001 0.454 0.452 0.915 
Uninsured  0.070 0.067 0.136 0.104 <0.001 0.130 0.100 0.007 
Self-rated health 0.302 0.034 3.031 2.568 <0.001 3.000 2.948 0.201 
 High blood pressure 0.318 -0.017 0.614 0.395 <0.001 0.610 0.622 0.490 
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Std diff = Standardized difference = ((exposed group mean) – (control mean))/(Pooled standard deviation). BMI = Body Mass Index. 
Childhood health and self rated health: 1=excellent, 5 is the worst possible health. 
Household income is household income per person living in the household. 
P-values are from Pearson chi-squared tests for binary variables (e.g. “smokes now”), and Wilcoxon rank-sum tests for numeric 
variables (e.g. household income per head). Small P-values indicate a statistically significant difference in means between the exposed 
and control group. 
When 
measured Variable 
Std diff before 
matching 
Std diff after 
matching 
Exposed 
mean before 
Control 
mean before 
P 
before 
Exposed 
mean after 
Control 
mean after P after 
Just before 
diabetes onset 
Heart disease 0.148 0.070 0.215 0.136 <0.001 0.220 0.182 0.008 
Stroke  0.042 0.098 0.053 0.040 0.016 0.059 0.030 <0.001 
Arthritis 0.104 -0.021 0.554 0.481 <0.001 0.553 0.568 0.393 
 # Mobility limitations 0.239 0.060 1.156 0.710 <0.001 1.138 1.026 0.057 
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A.3.3. Results using alternative specifications 
 
 To test the sensitivity of the results to the restriction that only diagnosed diabetes 
is observed, matched pairs in which the control unit was diagnosed with diabetes in some 
later wave, after being matched, were dropped. Individuals subsequently diagnosed with 
diabetes are probably more likely than those who are never diagnosed to have had 
undiagnosed diabetes when matched as controls. Because those with undiagnosed 
diabetes might experience some of the disabling effects of the disease, removing pairs 
with control units who later got diabetes could increase the within-pair differences in 
disability accumulation, increasing the magnitude of the estimated association between 
incident diabetes and mobility limitation. In fact, as shown in Appendix Table 5, the 
results are almost identical when these pairs are excluded, which suggests that ignoring 
undiagnosed diabetes does not produce a major bias in either direction.  
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Table A.3.3 a: Signed-rank test results, excluding pairs with control individual who 
later developed diabetes  
(Number of pairs = 1323) 
Hodges-Lehman estimate 0.25 
95% CI for H-L estimate [0.000009, 0.25001] 
p-value for H0: No difference between 
exposed and matched-controls 
0.0001 
Notes: Author’s calculations from Health and Retirement Study (United States, 1992-
2010). 
Hodges-Lehman estimate is the median of pairwise Walsh averages; it can be interpreted 
roughly as the median within-pair difference between an exposed and control unit. 
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Table A.3.3 b: Comparing mobility change among incident cases of diabetes to 
mobility change among matched controls, defining number of mobility limitations at 
diagnosis as number of mobility limitations at first report of diabetes diagnosis 
 
(Number of pairs = 1559) 
p-value for H0: No difference 
between exposed and 
matched-controls 
0.000001557 
Hodges-Lehman estimate: 
median of pairwise Walsh 
averages (approximately, the 
median within-pair 
difference) 
0.2499 
95% CI for H-L estimate [0.2499, 0.2500] 
 
Source: Author’s calculations from Health and Retirement Study (United States, 1992-
2010). 
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A.3.4.  Sensitivity to unmeasured confounding 
 
The Wilcoxon signed-rank test and its associated Hodges-Lehman estimate 
represent a test and estimate of the effect of incident diabetes on subsequent mobility 
limitation, under the assumption of no unmeasured confounding (Rosenbaum 2002). By 
observing incident diabetes and subsequent disabilities and ensuring balance between 
exposed (incident-diabetes) and control groups prior to diabetes onset, this paper reduces 
the potential confounding found in other studies. However, there could still be 
unmeasured forces that affect both diabetes onset above age 50 and subsequent mobility 
limitation. This appendix estimates the magnitude of unmeasured confounding (also 
called hidden bias) that would be needed to explain any observed association between 
incident diabetes and subsequent mobility limitation. 
The claim underlying matched-sets inference is that within matched sets, i.e. 
conditional on all the covariates used in the matching process, the probability of exposure 
for any unit in the set is the same. When dealing with matched pairs, that probability is ½. 
The signed-rank test then assesses whether the difference in outcomes between the 
exposed and control units could plausibly have resulted from random sampling error, 
given that each unit in the pair had a probability of exposure of ½. The sensitivity 
analysis addresses how inferences would be altered if  unmeasured confounders, which 
have arbitrarily strong associations with the outcome, increased the probability of 
exposure for one unit in each pair (Gastwirth, Krieger, & Rosenbaum 1998; Rosenbaum 
1987; Silber et al. 2009). The procedure estimates the magnitude of bias needed to 
explain the study’s observed findings by simulating Wilcoxon signed-rank tests for 
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within-pair probabilities of exposure other than ½. The procedure was designed for use in 
studies based on propensity-score matching and detailed by Rosenbaum (2002). 
 
Results 
 
 Table A.3.4 a shows the results of a simulation of different magnitudes of hidden 
bias, that is, unmeasured variables that are arbitrarily highly associated with mobility 
limitation and raise the probability of developing diabetes for one unit in each matched 
pair. A research finding unlikely to have resulted from unmeasured confounding is one in 
which the maximum p-value remains below a specified threshold (conventionally 0.05) 
even when the magnitude of hidden bias, represented by Gamma (Γ), is fairly large. This 
table shows that if some unmeasured confounder that was highly positively associated 
with mobility limitations increased the probability of developing diabetes by 15%, the 
significant Hodges-Lehman result shown in Table 3-3 could be completely explained by 
this unmeasured confounder.  
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Table A.3.4 a: Sensitivity of signed-rank test results to unmeasured confounding 
 
Gamma (Γ) Minimum p-value Maximum p-value 
1 0.000074 0.000074 
1.1 0.000000034 0.014 
1.15 0.00000000040 0.072 
1.2 0.0000000000033 0.23 
 
Gamma (Γ) is a measure of the magnitude of unmeasured confounding (hidden bias), 
where Γ=1 means no unmeasured confounding. For all values of Γ, the association 
between the unmeasured confounder and the outcome is arbitrarily strong and positive. 
Minimum and maximum p-values are for Wilcoxon signed-rank test of the null 
hypothesis of no difference in change in mobility limitations between exposed and 
matched control units. A range of p-values is produced because the results are based on 
simulating alternative probabilities of exposure, based on the magnitude of the hidden 
bias.  
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A.3.5. Results when considering only pairs in which both units were obese at 
baseline 
 
Table A.3.5 a: Signed-rank test results, pairs in which both units were obese at 
baseline 
(Number of pairs = 466) 
p-value for H0: No difference 
between exposed and 
matched-controls 
0.02983 
Hodges-Lehman estimate: 
median of pairwise Walsh 
averages (approximately, the 
median within-pair 
difference) 
0.25 
95% CI for H-L estimate [0.00003196, 0.49996307] 
Source: Author’s calculations from Health and Retirement Study (United States, 1992-
2010). 
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Table A.3.5 b: Sensitivity of results to hidden bias, pairs in which both units were 
obese at baseline 
Gamma (Γ) Minimum p-value Maximum p-value 
1 0.01577 0.01577 
1.05 0.004686 0.04425 
1.06 0.003623 0.05298 
1.1 0.001236 0.1006 
Source: Author’s calculations from Health and Retirement Study (United States, 1992-
2010). 
Gamma is a measure of the magnitude of hidden bias, where Γ=1 means no hidden bias. 
Minimum and maximum p-values are for Wilcoxon signed-rank test of the null 
hypothesis of no difference in disability change between exposed and matched control 
units. A range of p-values is produced because the results are based on simulating 
alternative probabilities of exposure, based on the magnitude of the hidden bias.  
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Table A.3.5 c: Differences in average number of mobility limitations, both units in 
pair obese at baseline 
(Number of pairs = 466) 
Time 
Exposed 
mean 
Exposed 
SD 
Control 
mean 
Control 
SD 
Baseline 1.562 (1.531529) 1.519 (1.49862) 
Last observation 
pre-diagnosis 1.479 (1.542436) 1.386 (1.438691) 
Censoring time 2.152 (1.722827) 1.880 (1.667701) 
Average change 0.632 0.427 
Average change = (# mobility limitations at censoring time) – [(# at baseline)+(# at time 
t)]/2. See Equation 3 in text. 
Time t = last observation before diabetes onset in exposed individual 
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A.3.6.  Association between duration of diabetes exposure and mobility limitations 
 
To assess the association between duration of time since initial exposure and 
mobility limitations at censoring time, against the alternative of not being exposed at the 
initial exposure time (but possibly being exposed at subsequent times), I include length of 
follow-up as a covariate in my Poisson model along with an interaction between exposed 
status (exposed or control) and length of follow-up. The rate ratio for the interaction term 
represents how many more mobility limitations are expected for the exposed person for 
an additional unit of follow-up. Median length of follow-up following diabetes diagnosis 
was three waves (six years), with a maximum of nine waves (18 years). Results are 
shown with and without fixed effects for the total number of mobility limitations in each 
matched pair; the fixed effects model is the preferred model (Lachin 2011). 
The results provide no evidence for the importance of duration. The rate ratio for 
the interaction term was approximately 1 and not statistically significant in either model. 
The predominance of individuals with short follow-up periods (i.e. few years after 
diabetes diagnosis) and the exclusion of individuals who had diabetes at study entry are 
likely explanations for this null finding. 
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Table A.3.6 a: Poisson regression when incorporating length of follow-up 
Dependent variable = Number of mobility limitations at censoring time 
Independent 
variable 
(1) No fixed effects (2) Fixed effects for total # 
mobility limitations at 
censoring time in matched pair 
   
exposed 1.238*** 1.238*** 
 [1.109,1.381] [1.109,1.380] 
   
follow-up 
length 
1.023* 1.003 
 [1.004,1.042] [0.985,1.022] 
   
interaction 0.994 0.994 
 [0.969,1.019] [0.969,1.019] 
   
N 3172 2534 
 
Notes: Author’s calculations from Health and Retirement Study (United States, 1992-
2010). 
* p < 0.05, ** p < 0.01, *** p < 0.001.  
Model (2) dropped observations in matched pairs with a total number of mobility 
limitations of zero. 
Point estimate is the incidence rate ratio, which is the exponentiated coefficient. 95% 
Confidence Intervals shown. 
Each unit of follow-up length is one wave of data collection, corresponding to two years. 
Interaction is the product of exposed and follow-up length. 
 
 
  
165 
 
References 
Abatih, E., Van Oyen, H., Bossuyt, N., & Bruckers, L. (2008). Variance estimation 
methods for health expectancy by relative socio-economic status. European Journal 
of Epidemiology, 23, 243–249. doi:10.1007/s10654-008-9227-5 
Abdullah, A., Stoelwinder, J., Shortreed, S., Wolfe, R., Stevenson, C., Walls, H., … 
Peeters, A. (2011). The duration of obesity and the risk of type 2 diabetes. Public 
Health Nutr, 14(1), 119–126. doi:10.1017/S1368980010001813 
Agüero-Torres, H., Fratiglioni, L., & Guo, Z. (1999). Mortality from dementia in 
advanced age: a 5-year follow-up study of incident dementia cases. Journal of 
Clinical Epidemiology, 52(8), 737–743. Retrieved from 
http://www.sciencedirect.com/science/article/pii/S0895435699000670 
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. 
(2013). Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med, 
368(17), 1613–1624. doi:10.1056/NEJMsa1213829 
Allison, P. D. (1984). Event History Analysis. Beverly Hills, CA: SAGE Publications. 
Allison, P. D. (2002). Missing Data. Thousand Oaks, CA: SAGE Publications. 
Alzheimer’s Association. (2014). 2014 Alzheimer’s disease facts and figures. 
Alzheimer’s & Dementia, 10(2), e47–e92. doi:10.1016/j.jalz.2014.02.001 
American Diabetes Association. (2012). Diagnosis and classification of diabetes mellitus. 
Diabetes Care, 35 Suppl 1, S64–71. doi:10.2337/dc12-s064 
American Diabetes Association. (2013). Economic costs of diabetes in the U.S. in 2012. 
Diabetes Care, 36(4), 1033–46. doi:10.2337/dc12-2625 
American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision. Arlington, VA. 
Asgharian, M., Wolfson, D. B., & Zhang, X. (2006). Checking stationarity of the 
incidence rate using prevalent cohort survival data. Statistics in Medicine, 25(10), 
1751–1767. doi:10.1002/sim.2326 
Bardenheier, B. H., Gregg, E. W., Zhuo, X., Cheng, Y. J., & Geiss, L. S. (2014). 
Association of Functional Decline With Subsequent Diabetes Incidence in U.S. 
Adults Aged 51 Years and Older: The Health and Retirement Study 1998-2010. 
Diabetes Care, 1–7. doi:10.2337/dc13-2216 
Bell, F. C., & Miller, M. L. (2005). Life Tables for the United States Social Security Area 
1900-2100. Actuarial Study No. 120. Retrieved from 
http://www.ssa.gov/oact/NOTES/as120/LifeTables_Tbl_7.html 
Berger, B., Stenström, G., & Sundkvist, G. (1999). Incidence, prevalence, and mortality 
of diabetes in a large population. A report from the Skaraborg Diabetes Registry. 
166 
 
Diabetes Care, 22(5), 773–778. 
Bertoni, A. G., & Goff, D. C. J. (2011). Diabetes and Cardiovascular Disease. In K. M. 
V. Narayan, D. E. Williams, E. W. Gregg, & C. C. Cowie (Eds.), Diabetes Public 
Health (pp. 173–194). New York, NY: Oxford University Press. 
Bianchi, L., Zuliani, G., & Volpato, S. (2013). Physical disability in the elderly with 
diabetes: epidemiology and mechanisms. Current Diabetes Reports, 13(6), 824–30. 
doi:10.1007/s11892-013-0424-6 
Bonora, E., & Tuomilehto, J. (2011). The pros and cons of diagnosing diabetes with 
A1C. Diabetes Care, 34 Suppl 2, S184–90. doi:10.2337/dc11-s216 
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010). 
Projection of the year 2050 burden of diabetes in the US adult population: dynamic 
modeling of incidence, mortality, and prediabetes prevalence. Population Health 
Metrics, 8, 29. doi:10.1186/1478-7954-8-29 
Brookmeyer, R., Evans, D. A., Hebert, L., Langa, K. M., Heeringa, S. G., Plassman, B. 
L., & Kukull, W. A. (2011). National estimates of the prevalence of Alzheimer’s 
disease in the United States. Alzheimer’s & Dementia, 7(1), 61–73. 
doi:10.1016/j.jalz.2010.11.007 
Brookmeyer, R., & Gray, S. (2000). Methods for projecting the incidence and prevalence 
of chronic diseases in aging populations: application to Alzheimer’s disease. 
Statistics in Medicine, 19(11-12), 1481–93. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10844713 
Brown, H. S., Pagán, J. A., & Bastida, E. (2005). The impact of diabetes on employment: 
genetic IVs in a bivariate probit. Health Economics, 14(5), 537–44. 
doi:10.1002/hec.942 
Bruce, D. G., Davis, W. A., & Davis, T. M. E. (2005). Longitudinal Predictors of 
Reduced Mobility and Physical Disability in Patients With Type 2 Diabetes: The 
Fremantle Diabetes Study. Diabetes Care, 28(10), 2441–7. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/16186277 
Bullard, K. M., Saydah, S. H., Imperatore, G., Cowie, C. C., Gregg, E. W., Geiss, L. S., 
… Caspersen, C. J. (2013). Secular Changes in U.S. Prediabetes Prevalence Defined 
by Hemoglobin A1c and Fasting Plasma Glucose: National Health and Nutrition 
Examination Surveys, 1999-2010. Diabetes Care, 36(8), 2286–2293. 
doi:10.2337/dc12-2563 
Carone, M., Asgharian, M., & Jewell, N. P. (2014). Estimating the Lifetime Risk of 
Dementia in the Canadian Elderly Population Using Cross-Sectional Cohort 
Survival Data. Journal of the American Statistical Association, 109(505), 24–35. 
doi:10.1080/01621459.2013.859076 
Caruso, L. B., Silliman, R. A., Demissie, S., Greenfield, S., & Wagner, E. H. (2000). 
167 
 
What can we do to improve physical function in older persons with type 2 diabetes? 
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 
55(7), M372–7. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10898253 
Centers for Disease Control and Prevention. (2012). Crude and Age-Adjusted Incidence 
of Diagnosed Diabetes per 1,000 Population Aged 18-79 Years, United States, 1980-
2007. (U.S. Department of Health and Human Services, Ed.). Atlanta, GA. 
Retrieved from http://www.cdc.gov/diabetes/statistics/incidence/fig2.htm 
Centers for Disease Control and Prevention. (2014). Compressed Mortality Files, 1979-
1998 and 1999-2013. Hyattsville, MD: National Center for Health Statistics: CDC 
WONDER. Retrieved from http://wonder.cdc.gov/cmf-icd10.html 
Chêne, G., Beiser, A., Au, R., Preis, S. R., Wolf, P. a, Dufouil, C., & Seshadri, S. (2015). 
Gender and incidence of dementia in the Framingham Heart Study from mid-adult 
life. Alzheimer’s & Dementia, 11(3), 310–320. doi:10.1016/j.jalz.2013.10.005 
Cheng, C., Lin, C.-H., Tsai, Y.-W., Tsai, C.-J., Chou, P.-H., & Lan, T.-H. (2014). Type 2 
Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis. The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences, (12), 
1–7. doi:10.1093/gerona/glu073 
Cheng, Y. J., Imperatore, G., Geiss, L. S., Wang, J., Saydah, S. H., Cowie, C. C., & 
Gregg, E. W. (2013). Secular changes in the age-specific prevalence of diabetes 
among U.S. adults: 1988-2010. Diabetes Care, 36(9), 2690–6. doi:10.2337/dc12-
2074 
Chiu, C.-J., & Wray, L. A. (2011). Physical disability trajectories in older Americans 
with and without diabetes: the role of age, gender, race or ethnicity, and education. 
The Gerontologist, 51(1), 51–63. doi:10.1093/geront/gnq069 
Cigolle, C. T., Lee, P. G., Langa, K. M., Lee, Y.-Y., Tian, Z., & Blaum, C. S. (2011). 
Geriatric conditions develop in middle-aged adults with diabetes. Journal of 
General Internal Medicine, 26(3), 272–9. doi:10.1007/s11606-010-1510-y 
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Gregg, E. W., Ford, E. S., Geiss, L. S., … 
Fradkin, J. E. (2010). Prevalence of diabetes and high risk for diabetes using A1C 
criteria in the U.S. population in 1988-2006. Diabetes Care, 33(3), 562–568. 
doi:10.2337/dc09-1524 
Crimmins, E., & Beltrán-Sánchez, H. (2010). Mortality and Morbidity Trends : Is There 
Compression of Morbidity ? Journals of Gerontology Series B: Psychological 
Sciences and Social Sciences, 66B, 75–86. doi:10.1093/geronb/gbq088.Advance 
Crimmins, E., Hayward, M., & Hagedorn, A. (2009). Change in disability-free life 
expectancy for Americans 70 years old and older. Demography, 46(3), 627–646. 
Retrieved from http://link.springer.com/article/10.1353/dem.0.0070 
Deckers, K., van Boxtel, M. P. J., Schiepers, O. J. G., de Vugt, M., Muñoz Sánchez, J. L., 
168 
 
Anstey, K. J., … Köhler, S. (2014). Target risk factors for dementia prevention: a 
systematic review and Delphi consensus study on the evidence from observational 
studies. International Journal of Geriatric Psychiatry, n/a–n/a. 
doi:10.1002/gps.4245 
Dhamoon, M. S., Moon, Y. P., Paik, M. C., Sacco, R. L., & Elkind, M. S. V. (2014). 
Diabetes predicts long-term disability in an elderly urban cohort: the Northern 
Manhattan Study. Annals of Epidemiology, 24(5), 362–368.e1. 
doi:10.1016/j.annepidem.2013.12.013 
Eberstein, I. W., Nam, C. B., & Heyman, K. M. (2008). Causes of death and mortality 
crossovers by race. Biodemography and Social Biology, 54(2), 214–228. 
doi:10.1080/19485565.2008.9989143 
Ewbank, D. (2004). From Alzheimer’s disease to a demography of chronic disease: the 
development of demographic synthesis for fitting multistate models. Population and 
Development Review, 63–86. Retrieved from http://www.jstor.org/stable/3401463 
Fishman, E. I. (2015). Variance Estimation for a Complex Life Table Quantity: Disease-
Free Life Expectancy (No. University of Pennsylvania Population Studies Center 
WPS 15-2). Philadelphia, PA. Retrieved from 
http://repository.upenn.edu/psc_working_papers/60/ 
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012). Prevalence of obesity 
and trends in the distribution of body mass index among us adults, 1999-2010. 
JAMA: The Journal of the American Medical Association, 307(5), 491–497. 
doi:10.1001/jama.2012.39 
Freedman, V. A., Spillman, B. C., Andreski, P. M., Cornman, J. C., Crimmins, E. M., 
Kramarow, E., … Waidmann, T. A. (2013). Trends in late-life activity limitations in 
the United States: an update from five national surveys. Demography, 50(2), 661–
71. doi:10.1007/s13524-012-0167-z 
Friedman, E. M., Shih, R. A., Langa, K. M., & Hurd, M. D. (2015). US Prevalence And 
Predictors Of Informal Caregiving For Dementia. Health Affairs, 34(10), 1637–
1641. doi:10.1377/hlthaff.2015.0510 
Garcia-Ptacek, S., Farahmand, B., Kåreholt, I., Religa, D., Cuadrado, M. L., & 
Eriksdotter, M. (2014). Mortality risk after dementia diagnosis by dementia type and 
underlying factors: a cohort of 15,209 patients based on the Swedish Dementia 
Registry. Journal of Alzheimer’s Disease, 41(2), 467–77. doi:10.3233/JAD-131856 
Gastwirth, J., Krieger, A., & Rosenbaum, P. R. (1998). Dual and simultaneous sensitivity 
analysis for matched pairs. Biometrika, 85(4), 907–920. Retrieved from 
http://biomet.oxfordjournals.org/content/85/4/907.short 
Geiss, L. S., Pan, L., Cadwell, B., Gregg, E. W., Benjamin, S. M., & Engelgau, M. M. 
(2006). Changes in incidence of diabetes in US adults, 1997–2003. Am J Prev Med, 
30(5), 371–377. 
169 
 
Greenland, S., & Rothman, K. J. (2008). Measures of Occurrence. In K. J. Rothman, S. 
Greenland, & T. L. Lash (Eds.), Modern Epidemiology (3rd ed.). Philadelphia, PA: 
Lippincott Williams & Wilkins. 
Gregg, E. W., Boyle, J. P., Thompson, T. J., Barker, L. E., Albright, A. L., & 
Williamson, D. F. (2013). Modeling the impact of prevention policies on future 
diabetes prevalence in the United States: 2010--2030. Population health metrics, 
11(1), 18. doi:10.1186/1478-7954-11-18 
Gregg, E. W., Cadwell, B. L., Cheng, Y. J., Cowie, C. C., Williams, D. E., Geiss, L., … 
Vinicor, F. (2004). Trends in the prevalence and ratio of diagnosed to undiagnosed 
diabetes according to obesity levels in the US. Diabetes Care, 27(12), 2806–2812. 
Gregg, E. W., Cheng, Y. J., Saydah, S., Cowie, C., Garfield, S., Geiss, L., & Barker, L. 
(2012). Trends in death rates among U.S. adults with and without diabetes between 
1997 and 2006: findings from the National Health Interview Survey. Diabetes Care, 
35(6), 1252–1257. doi:10.2337/dc11-1162 
Gregg, E. W., Geiss, L., Zhang, P., Zhuo, X., Williamson, D. F., & Albright, A. L. 
(2013). Implications of risk stratification for diabetes prevention: the case of 
hemoglobin A1c. Am J Prev Med, 44(4 Suppl 4), S375–80. 
doi:10.1016/j.amepre.2012.12.012 
Gregg, E. W., Gu, Q., Cheng, Y. J., Narayan, K. M. V., & Cowie, C. C. (2007). Mortality 
trends in men and women with diabetes, 1971 to 2000. Annals of Internal Medicine, 
147(3), 149–155. 
Gregg, E. W., Mangione, C. M., Cauley, J. A., Thompson, T. J., Schwartz, A. V., Ensrud, 
K. E., & Nevitt, M. C. (2002). Diabetes and Incidence of Functional Disability in 
Older Women. Diabetes Care, 25(1), 61–67. doi:10.2337/diacare.25.1.61 
Gregg, E. W., Zhuo, X., Cheng, Y. J., Albright, A. L., Narayan, K. M. V., & Thompson, 
T. J. (2014). Trends in lifetime risk and years of life lost due to diabetes in the USA, 
1985–2011: a modelling study. The Lancet Diabetes & Endocrinology, 8587(14), 1–
8. doi:10.1016/S2213-8587(14)70161-5 
Guehne, U., Riedel-Heller, S., & Angermeyer, M. C. (2005). Mortality in Dementia. 
Neuroepidemiology, 25(3), 153–162. doi:10.1159/000086680 
Haas, S. A. (2008). Trajectories of functional health: the “long arm” of childhood health 
and socioeconomic factors. Social Science & Medicine, 66(4), 849–61. 
doi:10.1016/j.socscimed.2007.11.004 
Hansen, B. B., & Klopfer, S. O. (2006). Optimal full matching and related designs via 
network flows. Journal of Computational and Graphical Statistics, 15, 609–627. 
He, W., & Larsen, L. J. (2014). Older Americans With a Disability: 2008 − 2012. U.S. 
Census Bureau and National Institute on Aging report. Retrieved from 
https://www.census.gov/content/dam/Census/library/publications/2014/acs/acs-
170 
 
29.pdf 
Health and Retirement Study. (2010). Sampling weights revised for Tracker 2.0 and 
beyond. Ann Arbor, MI. Retrieved from 
http://hrsonline.isr.umich.edu/index.php?p=weightinfo 
Health and Retirement Study. (2011). Sample Sizes and Response Rates. Retrieved 
January 20, 2014, from hrsonline.isr.umich.edu/sitedocs/sampleresponse.pdf 
Health and Retirement Study. (2013). Public Use Dataset. Ann Arbor, MI: Produced and 
distributed by the University of Michigan with funding from the National Institute 
on Aging (grant number NIA U01AG009740). Retrieved January 2, 2014, from 
http://hrsonline.isr.umich.edu/ 
Heeringa, S. G., & Connor, J. H. (1995). Technical Description of the Health and 
Retirement Survey Sample Design. Ann Arbor, MI. Retrieved from 
http://hrsonline.isr.umich.edu/sitedocs/userg/HRSSAMP.pdf 
Heeringa, S. G., Hurd, M., Langa, K. M., Ofstedal, M. B., Plassman, B. L., Rodgers, W. 
L., & Weir, D. R. (2009). Sample Design, Weighting and Analysis for ADAMS. Ann 
Arbor, MI. Retrieved from 
http://hrsonline.isr.umich.edu/sitedocs/userg/ADAMSSampleWeights_Jun2009.pdf 
Helmer, C., Joly, P., Letenneur, L., Commenges, D., & Dartigues, J. F. (2001). Mortality 
with dementia: Results from a French prospective community-based cohort. 
American Journal of Epidemiology, 154(7), 642–648. doi:10.1093/aje/154.7.642 
Henning-Smith, C. E., & Shippee, T. P. (2015). Expectations About Future Use Of Long-
Term Services And Supports Vary By Current Living Arrangement. Health Affairs, 
34(1), 39–47. doi:10.1377/hlthaff.2014.0556 
Herd, P., Goesling, B., & House, J. S. (2007). Socioeconomic Position and Health: The 
Differential Effects of Education versus Income on the Onset versus Progression of 
Health Problems. Journal of Health and Social Behavior, 48(3), 223–238. 
doi:10.1177/002214650704800302 
Human Fertility Database. (2015). Completed cohort fertility. Rostock, Germany. 
Retrieved from www.humanfertility.org 
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013). 
Monetary Costs of Dementia in the United States. New England Journal of 
Medicine, 368(14), 1326–1334. doi:10.1056/NEJMsa1204629 
Imai, K., & Soneji, S. (2007). On the Estimation of Disability-Free Life Expectancy. 
Journal of the American Statistical Association, 102(480), 1199–1211. 
doi:10.1198/016214507000000040 
James, B. D., Leurgans, S. E., Hebert, L. E., Scherr, P. a, Yaffe, K., & Bennett, D. a. 
(2014). Contribution of Alzheimer disease to mortality in the United States. 
Neurology, 82(12), 1045–50. doi:10.1212/WNL.0000000000000240 
171 
 
Johnson, E., Brookmeyer, R., & Ziegler-Graham, K. (2007). Modeling the Effect of 
Alzheimer’s Disease on Mortality. The International Journal of Biostatistics, 3(1). 
doi:10.2202/1557-4679.1083 
Kalyani, R. R., Saudek, C. D., Brancati, F. L., & Selvin, E. (2010). Association of 
diabetes, comorbidities, and A1C with functional disability in older adults: results 
from the National Health and Nutrition Examination Survey (NHANES), 1999-
2006. Diabetes Care, 33(5), 1055–60. doi:10.2337/dc09-1597 
Kasper, J. D., Freedman, V. A., Spillman, B. C., & Wolff, J. L. (2015). The 
Disproportionate Impact Of Dementia On Family And Unpaid Caregiving To Older 
Adults. Health Affairs, 34(10), 1642–1649. doi:10.1377/hlthaff.2015.0536 
Katz, M. J., Lipton, R. B., Hall, C. B., Zimmerman, M. E., Sanders, A. E., Verghese, J., 
… Derby, C. A. (2012). Age-specific and Sex-specific Prevalence and Incidence of 
Mild Cognitive Impairment, Dementia, and Alzheimer Dementia in Blacks and 
Whites. Alzheimer Disease & Associated Disorders, 26(4), 335–343. 
doi:10.1097/WAD.0b013e31823dbcfc 
Kemper, P., Komisar, H. L., & Alecxih, L. (2005). Long-term care over an uncertain 
future: What can current retirees expect? Inquiry, 42(4), 335–350. 
doi:10.5034/inquiryjrnl_42.4.335 
Khan, N. A., Wang, H., Anand, S., Jin, Y., Campbell, N. R., Pilote, L., & Quan, H. 
(2011). Ethnicity and sex affect diabetes incidence and outcomes. Diabetes Care, 
34(1), 96–101. doi:10.2337/dc10-0865 
Lachin, J. M. (2011). Biostatistical Methods. Biostatistical Methods: The Assessment of 
Relative Risks (2nd ed.). Hoboken, NJ, USA: Wiley. doi:10.1002/9780470317051 
Laditka, J., & Laditka, S. (2006). Effects of Diabetes on Healthy Life Expectancy: 
Shorter Lives with More Disability for Both Women and Men. In Z. Yi, E. 
Crimmins, Y. Carrière, & J.-M. Robine (Eds.), Longer Life and Healthy Aging (Vol. 
2, pp. 71–90). Springer Netherlands. doi:10.1007/1-4020-4032-6_6 
Langa, K. M., Larson, E. B., Karlawish, J. H., Cutler, D. M., Kabeto, M. U., Kim, S. Y., 
& Rosen, A. B. (2008). Trends in the prevalence and mortality of cognitive 
impairment in the United States: Is there evidence of a compression of cognitive 
morbidity? Alzheimer’s & Dementia, 4(2), 134–144. doi:10.1016/j.jalz.2008.01.001 
Langa, Plassman, B. L., Wallace, R. B., Herzog, A. R., Heeringa, S. G., Ofstedal, M. B., 
… Willis, R. J. (2005). The Aging, Demographics, and Memory Study: study design 
and methods. Neuroepidemiology, 25(4), 11. 
Lee, H.-Y., Choi, C. S., Birkenfeld, A. L., Alves, T. C., Jornayvaz, F. R., Jurczak, M. J., 
… Shulman, G. I. (2010). Targeted Expression of Catalase to Mitochondria Prevents 
Age-Associated Reductions in Mitochondrial Function and Insulin Resistance. Cell 
Metabolism, 12(6), 668–674. doi:http://dx.doi.org/10.1016/j.cmet.2010.11.004 
172 
 
Lee, J. M., Pilli, S., Gebremariam, A., Keirns, C. C., Davis, M. M., Vijan, S., … Gurney, 
J. G. (2010). Getting heavier, younger: trajectories of obesity over the life course. Int 
J Obes, 34(4), 614–623. doi:10.1038/ijo.2009.235 
Lee, P. G., Cigolle, C. T., Ha, J., Min, L., Murphy, S. L., Blaum, C. S., & Herman, W. H. 
(2013). Physical Function Limitations Among Middle-Aged and Older Adults With 
Prediabetes: One exercise prescription may not fit all. Diabetes Care, 36(10), 3076–
83. doi:10.2337/dc13-0412 
Leffondré, K., Touraine, C., Helmer, C., & Joly, P. (2013). Interval-censored time-to-
event and competing risk with death: Is the illness-death model more accurate than 
the cox model? International Journal of Epidemiology, 42(4), 1177–1186. 
doi:10.1093/ije/dyt126 
Li, N., Lee, R., & Gerland, P. (2013). Extending the Lee-carter method to model the 
rotation of age patterns of mortality decline for long-term projections. Demography, 
50(6), 2037–51. doi:10.1007/s13524-013-0232-2 
Lönnroos, E., Kyyrönen, P., Bell, J. S., van der Cammen, T. J. M., & Hartikainen, S. 
(2013). Risk of death among persons with Alzheimer’s disease: a national register-
based nested case-control study. Journal of Alzheimer’s Disease, 33(1), 157–64. 
doi:10.3233/JAD-2012-120808 
Loomis, D. (2005). Poisson regression analysis of ungrouped data. Occupational and 
Environmental Medicine, 62(5), 325–329. doi:10.1136/oem.2004.017459 
Loukine, L., Waters, C., Choi, B. C., & Ellison, J. (2012). Impact of diabetes mellitus on 
life expectancy and health-adjusted life expectancy in Canada. Population Health 
Metrics, 10(1), 7. doi:10.1186/1478-7954-10-7 
Lu, B. (2005). Propensity score matching with time-dependent covariates. Biometrics, 
61(3), 721–8. doi:10.1111/j.1541-0420.2005.00356.x 
Luo, J., Rossouw, J., Tong, E., Giovino, G. A., Lee, C. C., Chen, C., … Margolis, K. L. 
(2013). Smoking and Diabetes: Does the Increased Risk Ever Go Away? American 
Journal of Epidemiology, 178(6), 937–945. doi:10.1093/aje/kwt071 
Manton, K. G., & Ukraintseva, S. V. (2005). Decline Prevalence of Dementia in the U.S . 
Elderly Population. Advances in Gerontology, 16(73), 30–37. 
Mason, W. M., & Fienberg, S. E. (1985). Cohort Analysis in Social Research. New York, 
NY: Springer-Verlag. 
Mathers, C. D., & Robine, J. M. (1997). How good is Sullivan’s method for monitoring 
changes in population health expectancies? Journal of Epidemiology & Community 
Health, 51(1), 80–86. doi:10.1136/jech.51.1.80 
McDermott, R. A., Li, M., & Campbell, S. K. (2010). Incidence of type 2 diabetes in two 
indigenous Australian populations: a 6-year follow-up study. Medical Journal of 
Australia, 192(10), 4. 
173 
 
Meller, I., Fichter, M. M., & Schroppel, H. (1999). Mortality risk in the octo- and 
nonagenerians: longitudinal results of an epidemiological follow-up community 
study. European archives of psychiatry and clinical neuroscience, 249(4), 180–189. 
Retrieved from 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N
&AN=10449593 
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015). Prevalence of and Trends 
in Diabetes Among Adults in the United States, 1988-2012. JAMA, 314(10), 1021. 
doi:10.1001/jama.2015.10029 
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., … 
Rubino, F. (2012). Bariatric surgery versus conventional medical therapy for type 2 
diabetes. N Engl J Med, 366(17), 1577–1585. doi:10.1056/NEJMoa1200111 
Monesi, L., Baviera, M., Marzona, I., Avanzini, F., Monesi, G., Nobili, A., … Fortino, I. 
(2012). Prevalence, incidence and mortality of diagnosed diabetes: evidence from an 
Italian population based study. Diabetic Medicine, 29(3), 385–392. 
Mooney, C. Z. (1997). Monte Carlo Simulation. In Sage University Paper Series on 
Quantitative Applications in the Social Sciences. Thousand Oaks, CA: SAGE 
Publications. 
Murphy, S. L., Xu, J., & Kochanek, K. D. (2013). Deaths: Final Data for 2010 (Vol. 61). 
Hyattsville, MD: National Center for Health Statistics. 
Murray, C. J. L. (2013). The state of U.S. health, 1990-2010: burden of diseases, injuries, 
and risk factors. JAMA : the Journal of the American Medical Association, 310(6), 
591–608. doi:10.1001/jama.2013.13805 
Nagi, S. Z. (1976). An epidemiology of disability among adults in the United States. The 
Milbank Memorial Fund quarterly. Health and society, 54(4), 439–67. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/137366 
Narayan, K. M. V., Boyle, J. P., Thompson, T. J., Gregg, E. W., & Williamson, D. F. 
(2007). Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care, 30(6), 
1562–1566. doi:10.2337/dc06-2544 
Narayan, K. M. V., Boyle, J. P., Thompson, T. J., Sorensen, S. W., & Williamson, D. F. 
(2003). Lifetime risk for diabetes mellitus in the United States. JAMA : the journal 
of the American Medical Association, 290(14), 1884–90. 
doi:10.1001/jama.290.14.1884 
Narayan, K. M. V., Williams, D. E., Gregg, E. W., & Cowie, C. C. (2011). Diabetes 
Public Health. New York, NY: Oxford. 
National Health and Nutrition Examination Survey. (2006). Analytic and reporting 
guidelines. National Center for Health Statistics. Retrieved from 
http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_de
174 
 
c_2005.pdf 
National Health and Nutrition Examination Survey. (2012). Survey questionnaires, 
datasets, and related documentation. Retrieved July 1, 2013, from 
http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm 
National Health Interview Survey (1986-2004). (2009). Linked Mortality Files, mortality 
follow-up through 2006: Matching Methodology, May 2009. Hyattsville, MD: 
National Center for Health Statistics,. 
National Institute of Diabetes and Digestive and Kidney Diseases. (2011). Longitudinal 
Assessment of Bariatric Surgery (LABS). Retrieved from 
http://win.niddk.nih.gov/publications/labs.htm 
Ostbye, T., Hill, G., & Steenhuis, R. (1999). Mortality in elderly Canadians with and 
without dementia: a 5-year follow-up. Neurology, 53(3), 521–526. 
Palloni, A., & Thomas, J. R. (2013). Estimation of Covariate Effects With Current Status 
Data and Differential Mortality. Demography, 50(2), 521–544. doi:10.1007/s13524-
012-0160-6 
Pavkov, M. E., Hanson, R. L., Knowler, W. C., Bennett, P. H., Krakoff, J., & Nelson, R. 
G. (2007). Changing patterns of type 2 diabetes incidence among Pima Indians. 
Diabetes Care, 30(7), 1758–1763. doi:10.2337/dc06-2010 
Perry, G. S., Byers, T. E., Mokdad, A. H., Serdula, M. K., & Williamson, D. F. (1995). 
The Validity of Self-Reports of Past Body Weights by U.S. Adults. Epidemiology, 
6(1), 61–66. doi:10.2307/3702451 
Plassman, B. L., Langa, K. M., Fisher, G. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., 
… Wallace, R. B. (2007). Prevalence of Dementia in the United States: the Aging, 
Demographics, and Memory Study. Neuroepidemiology, 29(1), 8. 
Plassman, B. L., Langa, K. M., McCammon, R. J., Fisher, G. G., Potter, G. G., Burke, J. 
R., … Wallace, R. B. (2011). Incidence of dementia and cognitive impairment, not 
dementia in the United States. Annals of Neurology, 70(3), 418–26. 
doi:10.1002/ana.22362 
Preston, S. H., Elo, I. T., Rosenwaike, I., & Hill, M. (1996). African-American mortality 
at older ages: results of a matching study. Demography, 33(2), 193–209. 
doi:10.2307/2061872 
Preston, S. H., Heuveline, P., & Guillot, M. (2001). Demography. Oxford: Blackwell. 
Preston, S. H., & Wang, H. (2006). Sex mortality differences in the United States: The 
role of cohort smoking patterns. Demography, 43(4), 631–646. 
Raciborski, R. (2011). Right-censored Poisson regression model. Stata Journal, 11(1), 
95–105. Retrieved from http://phlib.kku.ac.th/StataJournalOnline/sj11-
1.pdf#page=103 
175 
 
RAND. (2011). Rand HRS Data Documentation, Version L. Retrieved from 
http://hrsonline.isr.umich.edu/modules/meta/rand/randhrsl/randhrsL.pdf 
Reis, J. P., Hankinson, A. L., Loria, C. M., Lewis, C. E., Powell-Wiley, T., Wei, G. S., & 
Liu, K. (2013). Duration of abdominal obesity beginning in young adulthood and 
incident diabetes through middle age: the CARDIA study. Diabetes Care, 36(5), 
1241–7. doi:10.2337/dc12-1714 
Reither, E. N., Hauser, R. M., & Yang, Y. (2009). Do birth cohorts matter? Age-period-
cohort analyses of the obesity epidemic in the United States. Soc Sci Med, 69(10), 
1439–1448. doi:10.1016/j.socscimed.2009.08.040 
Rejeski, W. J., Bray, G. A., Chen, S.-H., Clark, J. M., Evans, M., Hill, J. O., … Ip, E. H. 
(2014). Aging and Physical Function in Type 2 Diabetes: 8 Years of an Intensive 
Lifestyle Intervention. The Journals of Gerontology. Series A, Biological Sciences 
and Medical Sciences. doi:10.1093/gerona/glu083 
Rocca, W. A., Petersen, R. C., Knopman, D. S., Hebert, L. E., Evans, D. A., Hall, K. S., 
… White, L. R. (2011). Trends in the incidence and prevalence of Alzheimer’s 
disease, dementia, and cognitive impairment in the United States. Alzheimer’s & 
Dementia, 7(1), 80–93. doi:10.1016/j.jalz.2010.11.002 
Rosenbaum, P. R. (1987). Sensitivity analysis for certain permutation inferences in 
matched observational studies. Biometrika, 74(1), 13–26. Retrieved from 
http://biomet.oxfordjournals.org/content/74/1/13.short 
Rosenbaum, P. R. (2002). Observational Studies (2nd ed.). New York, NY: Springer. 
Rosenbaum, P. R. (2003). Exact Confidence Intervals for Nonconstant Effects by 
Inverting the Signed Rank Test. The American Statistician, 57(2), 132–138. 
doi:10.1198/0003130031405 
Rosenbaum, P. R. (2010). Design of Observational Studies. New York, NY: Springer. 
Rosenbaum, P. R., & Rubin, D. (1983). The central role of the propensity score in 
observational studies for causal effects. Biometrika, 70(1), 41–55. Retrieved from 
http://biomet.oxfordjournals.org/content/70/1/41.short 
Rosenbaum, P. R., & Rubin, D. B. (1985). Constructing a Control Group Using 
Multivariate Matched Sampling Methods That Incorporate the Propensity Score. The 
American Statistician, 39(1), 33–38. 
Ruitenberg, A., Ott, A., & Swieten, J. van. (2001). Incidence of dementia: does gender 
make a difference? Neurobiology of Aging, 22(June), 575–580. Retrieved from 
http://www.sciencedirect.com/science/article/pii/S0197458001002317 
Salomon, J., Mathers, C., Murray, C., & Ferguson, B. (2001). Methods for life expectancy 
and healthy life expectancy uncertainty analysis (No. 10). Retrieved from 
http://cdrwww.who.int/entity/healthinfo/paper10.pdf 
176 
 
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., 
… Bhatt, D. L. (2012). Bariatric surgery versus intensive medical therapy in obese 
patients with diabetes. N Engl J Med, 366(17), 1567–1576. 
doi:10.1056/NEJMoa1200225 
Schienkiewitz, A., Schulze, M. B., Hoffmann, K., Kroke, A., & Boeing, H. (2006). Body 
mass index history and risk of type 2 diabetes: results from the European 
Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam Study. The 
American journal of clinical nutrition, 84(2), 427–433. 
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., … 
Brancati, F. L. (2010). Glycated hemoglobin, diabetes, and cardiovascular risk in 
nondiabetic adults. N Engl J Med, 362(9), 800–811. doi:10.1056/NEJMoa0908359 
Seshadri, S., & Wolf, P. A. (2007). Lifetime risk of stroke and dementia: current 
concepts, and estimates from the Framingham Study. Lancet Neurology, 
6(December), 1106–1114. doi:10.1016/S1474-4422(07)70291-0 
Seshadri, S., Wolf, P. A., Beiser, A., Au, R., McNulty, K., White, R., & D’Agostino Sr., 
R. B. (1997). Lifetime risk of dementia and Alzheimer’s disease: the impact of 
mortality on risk estimates in the Framingham Study. Neurology, 49, 1498–1504. 
Retrieved from http://www.neurology.org/cgi/content/abstract/49/6/1498 
Sheffield, K. M., & Peek, M. K. (2011). Changes in the Prevalence of Cognitive 
Impairment Among Older Americans, 1993-2004: Overall Trends and Differences 
by Race/Ethnicity. American Journal of Epidemiology, 174(3), 274–283. 
doi:10.1093/aje/kwr074 
Silber, J. H., Lorch, S. A., Rosenbaum, P. R., Medoff-Cooper, B., Bakewell-Sachs, S., 
Millman, A., … Escobar, G. J. (2009). Time to send the preemie home? Additional 
maturity at discharge and subsequent health care costs and outcomes. Health 
Services Research, 44(2 Pt 1), 444–63. doi:10.1111/j.1475-6773.2008.00938.x 
Silber, J. H., Rosenbaum, P. R., Trudeau, M. E., Even-Shoshan, O., Zhang, X., & 
Mosher, R. E. (2001). Multivariate and Bias Reduction in the Surgical Matching 
Outcomes Study. Medical Care, 39(10), 1048–1064. 
Singer, J., & Willett, J. (1993). It’s about time: Using discrete-time survival analysis to 
study duration and the timing of events. Journal of Educational Statistics, 18(2), 
155–195. Retrieved from http://jeb.sagepub.com/content/18/2/155.short 
Spillman, B. C., & Lubitz, J. (2002). New estimates of lifetime nursing home use: Have 
patterns of use changed? Medical Care, 40(10), 965–975. 
doi:10.1097/01.MLR.0000027365.40102.7A 
Stenholm, S., Westerlund, H., Head, J., Hyde, M., Kawachi, I., Pentti, J., … Vahtera, J. 
(2014). Comorbidity and Functional Trajectories From Midlife to Old Age: The 
Health and Retirement Study. The Journals of Gerontology Series A: Biological 
Sciences and Medical Sciences, (13), 1–7. doi:10.1093/gerona/glu113 
177 
 
Stokes, A., & Mehta, N. K. (2013). Mortality and excess risk in US adults with pre-
diabetes and diabetes: a comparison of two nationally representative cohorts, 1988-
2006. Popul Health Metr, 11(1), 7. doi:10.1186/1478-7954-11-3 
Sullivan, D. F. (1971). A single index of mortality and morbidity. HSMHA health 
reports, 86(4), 347–54. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1937122&tool=pmcentr
ez&rendertype=abstract 
Sylvestre, M., Huszti, E., & Hanley, J. (2006). Do Oscar winners live longer than less 
successful peers? A reanalysis of the evidence. Annals of Internal Medicine, 145, 
361–363. Retrieved from 
http://annals.org/article.aspx?articleid=728107&issueno=5&atab=10 
The, N. S., Richardson, A. S., & Gordon-Larsen, P. (2013). Timing and duration of 
obesity in relation to diabetes: findings from an ethnically diverse, nationally 
representative sample. Diabetes Care, 36(4), 865–872. doi:10.2337/dc12-0536 
Thunander, M., Petersson, C., Jonzon, K., Fornander, J., Ossiansson, B., Torn, C., … 
Landin-Olsson, M. (2008). Incidence of type 1 and type 2 diabetes in adults and 
children in Kronoberg, Sweden. Diabetes Res Clin Pract, 82(2), 247–255. 
doi:http://dx.doi.org/10.1016/j.diabres.2008.07.022 
Tom, S. E., Hubbard, R. a, Crane, P. K., Haneuse, S. J., Bowen, J., McCormick, W. C., 
… Larson, E. B. (2015). Characterization of Dementia and Alzheimer’s Disease in 
an Older Population: Updated Incidence and Life Expectancy With and Without 
Dementia. American Journal of Public Health, 105(2), 408–413. 
doi:10.2105/AJPH.2014.301935 
Treves, T. A., & Korczyn, A. D. (2012). Modeling the Dementia Epidemic. CNS 
Neuroscience and Therapeutics, 18, 175–181. doi:10.1111/j.1755-
5949.2011.00242.x 
Tschanz, J., Corcoran, C., & Skoog, I. (2004). Dementia: The leading predictor of death 
in a defined elderly population The Cache County Study. Neurology, 62, 1156–
1162. Retrieved from http://www.neurology.org/content/62/7/1156.short 
U.S. Census Bureau. (2005). Statistical Abstract of the United States, 2004-2005. 
Retrieved from http://www.census.gov/prod/2004pubs/04statab/pop.pdf 
Vaupel, J. W. (2010). Biodemography of human ageing. Nature, 464(7288), 536–42. 
doi:10.1038/nature08984 
Vaupel, J. W., Manton, K. G., & Stallard, E. (1979). The impact of heterogeneity in 
individual frailty on the dynamics of mortality. Demography, 16(3), 439–454. 
doi:10.2307/2061224 
Venables, W. N., & Ripley, B. D. (2002). Modern Applied Statistics with S (Fourth Edi.). 
New York, NY: Springer. 
178 
 
Verbrugge, L. M., & Jette, A. M. (1994). The disablement process. Social Science & 
Medicine, 38, 1–14. doi:10.1016/0277-9536(94)90294-1 
Villarejo, A., Benito-León, J., Trincado, R., Posada, I. J., Puertas-Martín, V., Boix, R., … 
Bermejo-Pareja, F. (2011). Dementia-associated mortality at thirteen years in the 
NEDICES Cohort Study. Journal of Alzheimer’s Disease, 26(3), 543–51. 
doi:10.3233/JAD-2011-110443 
Wilson, P. W. F., Anderson, K. M., & Kannel, W. B. (1986). Epidemiology of diabetes 
mellitus in the elderly: The Framingham study. The American Journal of Medicine, 
80(5, Supplement 1), 3–9. doi:http://dx.doi.org/10.1016/0002-9343(86)90532-2 
Winkelmann, R. (2003). Econometric Analysis of Count Data (4th ed.). Berlin: Springer-
Verlag. 
Witthaus, E., Ott, A., Barendregt, J. J., Breteler, M., & Bonneux, L. (1999). Burden of 
mortality and morbidity from dementia. Alzheimer Disease and Associated 
Disorders, 13(3), 176–181. 
Wong, E., Backholer, K., Gearon, E., Harding, J., Freak-Poli, R., Stevenson, C., & 
Peeters, A. (2013). Diabetes and risk of physical disability in adults: a systematic 
review and meta-analysis. The Lancet Diabetes & Endocrinology, 1(2), 106–114. 
doi:10.1016/S2213-8587(13)70046-9 
Wong, & Gregg, E. W. (2013). Diabetes and risk of physical disability in adults: a 
systematic review and meta-analysis. The Lancet Diabetes & Endocrinology, 1(2), 
81–82. doi:10.1016/S2213-8587(13)70046-9 
Wray, L. A., Ofstedal, M. B., Langa, K. M., & Blaum, C. S. (2005). The effect of 
diabetes on disability in middle-aged and older adults. The journals of Gerontology. 
Series A, Biological Sciences and Medical Sciences, 60(9), 1206–11. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/16183964 
Yeh, H.-C., Duncan, B. B., Schmidt, M. I., Wang, N.-Y., & Brancati, F. L. (2010). 
Smoking, Smoking Cessation, and Risk for Type 2 Diabetes MellitusA Cohort 
Study. Annals of Internal Medicine, 152(1), 10–17. 
Zhao, W., Katzmarzyk, P. T., Horswell, R., Wang, Y., Li, W., Johnson, J., … Hu, G. 
(2014). Body Mass Index and the Risk of All-Cause Mortality Among Patients with 
Type 2 Diabetes. Circulation. doi:10.1161/CIRCULATIONAHA.114.009098 
Ziegler-Graham, K., Brookmeyer, R., Johnson, E., & Arrighi, H. M. (2008). Worldwide 
variation in the doubling time of Alzheimer’s disease incidence rates. Alzheimer’s & 
Dementia, 4(5), 316–323. doi:10.1016/j.jalz.2008.05.2479 
Zissimopoulos, J., Crimmins, E., & St.Clair, P. (2014). The Value of Delaying 
Alzheimer’s Disease Onset. Forum for Health Economics and Policy. 
doi:10.1515/fhep-2014-0013 
 
